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Abstract	
	
Modern	 pharmacotherapy,	 especially	 with	 regards	 to	 the	 treatment	 of	 cancer,	 has	 been	 faced	
with	 one	 major	 obstacle	 for	 many	 years:	 poor	 drug	 specificity.	 The	 use	 of	 many	 bio-
therapeutic/chemotherapeutic	 drugs	 for	 the	 treatment	 of	 cancer	 is	 largely	 dose-limited	 due	 to	
their	 highly	 toxic	 nature	 and	 largely	 unspecific	 mode	 of	 action,	 causing	 'off	 target'	 drug	
interactions,	 inadequate	 drug	 concentrations	 at	 'on	 target'	 areas	 and	 poor	 patient	 compliance	
due	 to	 the	 necessity	 to	 receive	 large	 amounts	 of	 a	 drug	 that	 hinder	 quality	 of	 life.	 Currently	
available	research	into	the	development	of	recombinant	biotherapeutic	drugs,	targeted	to	specific	
ligand	receptors,	has	presented	a	new	mode	of	drug	delivery,	which	could	potentially	avoid	these	
problems	–	drug	delivery	selective	to	the	tissue	of	choice	with	minimal	damage	to	physiologically	
normal	 cells.	 Neurotensin	 (NT)	 is	 a	 tridecapeptide	 known	 to	 exert	 a	 variety	 of	 effects	 on	 the	
human	body;	it	has	a	dual	role	as	both	a	neuromodulator	in	the	central	nervous	system	and	as	a	
local	hormone	in	the	periphery.	The	actions	of	neurotensin	are	mediated	by	specific	interactions	
with	 one	 of	 three	 neurotensin	 receptors:	 NTS1,	 NTS2	 and	 NTS3,	 all	 of	 which	 are	 known	 to	
internalise	 upon	 interaction	with	 neurotensin.	NTS1	 in	 particular	 is	 thought	 to	 play	 the	 biggest	
role	in	eliciting	the	actions	of	neurotensin	and	is	the	main	focus	of	this	study;	as	NTS1	is	known	to	
be	up	regulated	in	a	variety	of	different	cancer	types,	including	pancreatic	and	breast	tumours,	it	
could	potentially	serve	as	a	target	for	neurotensin-mediated	drug-delivery.		
	
The	data	presented	in	this	study	characterises	the	extent	of	expression	of	NTS1	in	both	polarised	
and	non-polarised	Caco-2,	and	HEK293	cell	lines.	The	uptake	and	transport	of	two	NT-conjugated	
fluorophores	(GFP	and	fluorescein)	were	compared	to	evaluate	the	affect	of	cargo	size	on	cellular	
uptake.	Investigation	into	uptake	and	transport	of	the	two	fluorophores,	elicited	by	neurotensin,	
showed	 both	 to	 be	 internalised	 in	 a	 receptor	 mediated	 fashion	 with	 the	 smaller	 of	 the	 two	
(fluorescein)	 exhibiting	 internalisation	 and	 transport	 to	 a	 greater	 extent	 than	 the	 larger	 (GFP).	
Visualisation	by	confocal	microscopy	showed	fluorophore	localisation	close	to	the	nucleus	of	the	
cell.		
	
From	a	more	general	perspective,	this	work	aims	to	elucidate	the	potential	for	neurotensin	to	
be	 employed	 to	 enhance	 the	 delivery	 of	 bio-therapeutics	 to	 treat	 'difficult'	 cancers,	 such	 as	
pancreatic	 cancer,	 which	 is	 notorious	 for	 poor	 survival	 rates	 and	 is	 known	 to	 overexpress	
receptors	 for	 neurotensin.	 If	 successful,	 neurotensin-conjugation	 of	 bio-therapeutics	 could	
improve	survival	rates	by	lowering	necessary	dosages	and	increasing	cancer	cell	specificity.	
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Chapter	1	
Introduction		
	
	
1.1:	Introduction	To	Peptide	Guided-Drug	Delivery	
	
Modern	pharmacotherapy,	especially	with	 regards	 to	 the	 treatment	of	 cancer,	has	
been	faced	with	one	major	obstacle	for	many	years:	poor	drug	specificity.	The	use	of	
many	bio-therapeutic/chemotherapeutic	drugs	for	the	treatment	of	cancer	is	largely	
dose-limited	due	to	their	highly	toxic	nature	and	 largely	unspecific	mode	of	action,	
causing	 'off	target'	drug	 interactions,	 inadequate	drug	concentrations	at	 'on	target'	
areas	and	poor	patient	compliance	due	to	the	necessity	to	receive	large	amounts	of	
a	 drug	 that	 causes	 quality	 of	 life	 dampening	 effects	 (Kimchi-Sarfaty	 et	 al.,	 2013;	
Spadiut	 et	 al.,	 2014).	 Currently	 available	 research	 into	 the	 development	 of	
recombinant	 biotherapeutic	 drugs	 has	 presented	 a	 new	 mode	 of	 drug	 delivery,	
which	could	potentially	avoid	these	problems	–	drug	delivery	selective	of	the	tissue	
of	choice	with	minimal	damage	to	physiologically	normal	cells	(Carter,	2011).	
	
Over	 a	 century	 ago,	 Paul	 Ehrlich	 introduced	 the	 idea	 of	 a	 'magic	 bullet'	 for	 the	
treatment	of	cancer.	His	discovery	of	the	specificity	of	antigen-antibody	interactions	
made	 a	 huge	 impact	 on	 chemical	 and	 biological	 research,	 but	 remained	 relatively	
unexplored	for	many	decades	from	a	pharmacological	point	of	view.	Ehrlich's	vision	
called	for	a	chemotherapeutic	selective	of	a	target	cancerous	cell,	as	an	antibody	is	
selective	 of	 its	 respective	 antigen.	 Based	on	 the	 assumption	 that	 tumours	 express	
antigens	 specific	 to	 their	 own	 constitutive	 cells,	 he	 conceived	 the	 idea	 that	
chemotherapeutics	 could	 be	 delivered	 in	 a	 specific	 manner	 once	 bound	 to	 the	
appropriate	monoclonal	antibody	(Ehrlich,	1956).	Advances	in	monoclonal	antibody	
research	allowed	the	advent	of	monoclonal	antibody	therapies	(Köhler	and	Milstein,	
1975)	which	paved	the	way	for	further	advances	in	targeted	drug	delivery	(Baldwin,	
1985),	 such	 as	 the	 employment	 of	 peptides	 and	 peptide	 receptors	 in	 place	 of	
antigens	 and	 antibodies.	 In	 theory,	 the	 use	 of	monoclonal	 antibodies	 for	 targeted	
delivery	of	chemotherapeutics	is	ideal,	but	the	seemingly	simple	principle	has	proven	
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difficult	 to	 transpose	 into	 reality	 due	 to	 their	 relatively	 large	 molecular	 mass	 of	
~150kDa	(Serafini,	1993).	
	
Peptide-based	 therapies	 have	 been	 successfully	 employed	 to	 treat	 numerous	
diseases	such	as	autoimmune	diseases,	 fibrosis	and	asthma	(Atamas,	2012;	Boulet,	
2004;	 Larché,	 2005).	 They	 are	 particularly	 successful	 candidates	 for	 therapeutic	
exploitation	due	 to	 their	 specificity,	 ease	 of	 production	 and	 importantly,	 relatively	
small	size	(Reubi,	2003).	Peptide	therapy,	as	a	broad	term	for	an	emerging	therapy,	
encompasses	 a	 large	 variety	 of	 drugs	 (including	 the	 peptides	 themselves	 acting	 as	
the	therapeutic	agent)	with	different	modes	of	action.		
	
Primary	cancerous	tissue	of	human	origin	is	known	to	overexpress	peptide	receptors	
compared	to	physiologically	normal	cells	(Reubi,	2003).	For	many	years,	researchers	
have	 been	 exploring	 the	 potential	 for	 in	 vivo	 cancer	 imaging	 via	 the	 targeting	 of	
peptide	 receptors	 for	 diagnostic	 and	 therapeutic	 purposes	 (Heppeler	 et	 al.,	 2000;	
Kwekkeboom	 et	 al.,	 2000).	 Due	 to	 the	 success	 of	 the	 first	 widely	 used	 receptor-
targeted	 radiation	 therapies	 and	 medical	 imaging	 techniques	 in	 somatostatin	
receptor	 positive	 tumours,	 other	 receptors	 have	 been	 evaluated	 as	 potential	
candidates	for	conceptually	identical	treatment	(Barbieri	et	al.,	2013;	Morgat	et	al.,	
2014).	
	
Peptides	 can	 be	 employed	 in	 a	 variety	 of	 different	manners	 to	 aid	 the	 detection,	
diagnosis	 and	 treatment	 of	 cancer.	 This	 includes	 using	 peptides	 alone	 to	 directly	
target	the	tumour;	peptides	conjugated	to	cytotoxic	agents	or	radiolabelled	peptides,	
which	will	be	discussed	in	turn	(Reubi,	2003).		
	
1.2:	Significance	of	Peptides	and	Peptide	Receptors	in	Cancer		
Due	 to	 the	 fact	 that	peptide	 receptors	 are	often	overexpressed	 in	primary	 cancer,	
focus	 has	 been	 drawn	 to	 the	 possibility	 of	 targeting	 them	 for	 the	 purposes	 of	
diagnosis	 and	 treatment.	 In	 the	 majority	 of	 cases,	 previous	 research	 has	
demonstrated	 that	 peptide	 receptor	 expression	 is	 significantly	 different	 to	 its	
corresponding	normal	tissue/tissue	of	origin.	In	terms	of	receptor	targeting,	it	can	be	
Chapter	1	 	 Introduction	
3	
done	 in	 one	 of	 two	 ways:	 binding	 sites	 for	 radioligands	 (only	 external	 cellular	
attachment	is	required	in	this	case)	or	as	a	target	to	mediate	a	functional	response;	
the	 desired	 response	 being	 ligand-bound	 receptor	 internalisation.	 Generally,	
literature	suggests	that	little	consideration	has	been	given	in	the	past	for	the	peptide	
receptor's	biological	 function;	 research	relies	on	the	presence	of	peptide	receptors	
and	the	ability	for	its	analogue	to	bind,	and	not	on	the	physiological	processes	that	
the	peptide	itself	mediates	(Reubi,	2003).		
	
Many	different	peptides/peptide	receptor	couples	are	being	 investigated	for	use	 in	
peptide	 receptor	 targeted	 therapies,	 including:	 somatostatin	 (the	 most	 widely	
studied),	 cholecystokinin/gastrin,	 substance	 P,	 bombesin	 and	 neurotensin.	
Compared	 to	 the	 other	 peptides	 listed,	 neurotensin	 specific	 therapies	 have	 been	
explored	less	(Reubi	et	al.,	2005).		
	
1.2.1:	Peptide-Based	Therapies	
Peptides	 themselves	 are	 highly	 permeable	 and	 usually	 hydrophilic	 molecules	 that	
allow	 for	 rapid	 delivery	 to	 target	 tissues	 after	 systemic	 injection.	 As	 they	 are	
physiological	 compounds,	 they	 are	 non-toxic	 compared	 to	 currently	 marketed	
chemotherapeutic	agents.	Most	peptide-conjugates	are	not	able	to	cross	the	blood-
brain	 barrier	 due	 to	 their	 size,	 to	 reach	 the	 majority	 of	 densely	 expressed	
neuropeptide	receptor	sites.	This	can	be	perceived	as	a	limitation	for	the	treatment	
of	tumours	 located	beyond	this	barrier,	but	 in	this	case,	presents	an	advantage	for	
the	treatment	of	peripheral	 tumours	 in	the	form	of	a	physical	barrier	between	the	
desired	site	of	action	and	the	site	most	likely	to	elicit	negative	side	effects.	However,	
blood-brain	 barrier	 structural	 disruption	 has	 been	 previously	 observed	 in	
undifferentiated	neural	 tumours	 such	as	glioblastomas	–	where	 the	peptide	would	
have	access	to	the	target	site	and	be	able	to	remain	there	(Haldemann	et	al.,	1995).	
	
This	approach	to	peptide	therapy	relies	on	the	particular	biological	response	elicited	
by	 activation	of	 functional	 peptide	 receptors.	 This	 requires	 the	peptide	or	 peptide	
analogue	in	question	to	be	non-toxic,	unlabelled	and	remain	at	a	therapeutic	plasma	
concentration	 for	 an	 extended	 period	 of	 time.	 The	 structural	 conformation	 of	
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peptides	makes	them	particularly	susceptible	to	cleavage	from	peptidases	present	in	
most	tissues	–	as	such,	metabolically	stable	peptide	analogues	must	be	synthesised	
prior	to	clinical	applications,	particularly	for	longer	treatment	periods.	One	example	
is	the	use	of	octreotide	–	an	octapeptide	somatostatin	analogue	with	a	much	more	
potent	 inhibitory	effect	on	 the	 secretion	of	 growth	hormone,	 glucagon	and	 insulin	
than	somatostatin	itself	(Lamberts	et	al.,	1996).		
	
A	number	of	peptides	have	been	shown	to	positively	contribute	to	the	mechanisms	
of	growth	 regulation	of	 cancerous	cells	 (Moody	et	al.,	2003),	 suggesting	 that	 long-
term	exposure	 to	appropriate	antagonists	or	 therapeutic-bound	peptide	analogues	
may	have	a	negative	 influence	on	the	growth	rate	of	tumour	cells	 in	vivo.	Previous	
research	 focussed	 on	 peptide-receptor	 expressing	 animal	 tumours	 shows	 that	
tumour	 growth	 inhibition	 is	 achieved	 with	 the	 use	 of	 corresponding	 radioactive,	
nontoxic	peptide	analogues	(Moody	et	al.,	2003;	Schally,	1988).		
	
Peptide	 therapies	 of	 this	 manner	 are	 understandably	 targeted	 towards	
neuroendocrine	tumours	 (NETs)	–	a	group	of	heterogeneous	neoplasms	originating	
from	 endocrine	 tissues	 with	 a	 shared	 ability	 to	 produce	 peptides/polypeptide	
hormones.	From	a	clinical	point	of	view,	NETs	are	 incredibly	variable:	ranging	from	
slow	 to	 fast	 growing,	 hormonally	 active	 to	 inactive	 and	 highly	 aggressive	 to	
malignant	 (Gulenchyn	 et	 al.,	 2012).	 However,	 diagnosis	 of	 these	 tumour	 types	 is	
usually	into	the	late	stages	of	tumour	growth	with	associated	metastases,	due	to	its	
slowly	 progressive	 nature	 (Yao	 et	 al.,	 2008).	 In	 advanced	 and	metastasised	 NETs,	
methods	of	treatment	such	as	surgery,	chemotherapy	and	external	radiotherapy	are	
limited.	 However,	 use	 of	 somatostatin	 analogues	 such	 as	 octreotide	 have	 been	
shown	 to	 increase	 the	 time	 taken	 for	 tumour	 progression	 as	 well	 as	 provide	
symptomatic	 relief	 from	 a	 reduction	 in	 hormone	 overproduction	 in	 placebo-
controlled	studies.		
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1.2.2:	Radio-Labelled	Peptide	Therapies	
Radio-labelled	peptide	analogues	(radioligands)	have	been	successfully	employed	for	
the	purposes	of	diagnostics	and	targeted	radiotherapy	 in	vivo	on	the	basis	of	 their	
specificity	 to	 peptide-receptor	 expressing	 tumour	 cells.	 Treatment	 of	 this	 variety	
exploits	 a	 key	 characteristic	 shared	 by	many	 G	 protein-coupled	 peptide	 receptors	
(GPCRs)	 –	 internalisation	 of	 the	 peptide/analogue-receptor	 complex	 following	
interaction	at	the	cell	membrane	(De	Jong	et	al.,	1998;	Mazella	et	al.,	1991;	Nouel	et	
al.,	 1997).	 A	 particular	 study	 of	 note,	 especially	 with	 regards	 to	 this	 work,	 is	 the	
observed	 internalisation	 of	 fluorescently	 labelled	 neurotensin	 in	 neurotensin	
receptor	1	(NTS1)	transfected	COS-7	cells	conducted	by	Vandenbulcke	et	al.,	(2000).	
Internalisation	was	able	to	be	prevented	by	hypertonic	sucrose,	potassium	depletion	
and	 cytosol	 acidification,	 demonstrating	 that	 not	 only	 is	 neurotensin	 (NT)	
internalised	in	a	receptor-mediated	fashion	via	clathrin-coated	pits,	it	is	trafficked	to	
the	 trans-golgi	 network	 through	 a	 series	 of	 endosomes	 after	 delocalisation	 from	
NTS1	 with	 acidic	 early	 endosomes	 (see	 figure	 1.1).	 The	 ability	 for	 the	 peptide	 to	
enter	 the	 cell	 and	 avoid	 degradation	 suggests	 a	 promising	 candidate	 for	 targeted	
drug	delivery.	
	
Figure.	 1.1:	 Adapted	 from	 (Vandenbulcke	 et	 al.,	 2000).	 Receptor	 mediated	 internalisation	 of	
fluorescently	 labelled	neurotensin	(Fluo-NT).	Fluo-NT	binds	to	neurotensin	receptor	1	at	the	plasma	
membrane,	where	it	 is	 internalised	via	clathrin-coated	pits.	It	 is	then	trafficked	through	early	to	late	
endosomes,	 dissociating	 from	 its	 receptor	 in	 late	 endosomes.	Neurotensin	 receptor	 1	 is	 separately	
degraded	in	lysosomes	and	Fluo-NT	arrives	at	the	trans-golgi	network.	
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The	 technique	 of	 peptide	 receptor	 scintigraphy	 in	 humans	 was	 first	 trialled	 with	
radioisotope-labelled	 somatostatin	 analogues	 to	 demonstrate	 the	 presence	 of	
somatostatin	receptor-positive	tumours	(Krenning	et	al.,	1989).	The	radioactive	label,	
conjugated	 to	 peptide	 analogues,	 can	 be	 detected	 (once	 incubated	 long	 enough	
internally	to	bind	to	peptide	receptors	expressed	by	tumours)	by	external	radiation	
detectors	 and	 analysed	 by	 medical	 experts	 (see	 figure	 1.2).	 As	 the	 radioligand	 is	
administered	by	 systemic	 injection,	 it	must	be	noted	 that	 tumours	 that	 are	poorly	
vascularised	may	 not	 be	 as	 accessible	 to	 the	 radioligand	 and	may	 not	 be	 able	 to	
collect	 in	 the	 tissue	 of	 interest	 in	 the	 same	 manner	 as	 tissues	 that	 are	 well	
vascularised.	However,	excessive	recruitment	of	vasculature	is	considered	a	hallmark	
of	cancer	and	so	would	most	 likely	be	highly	vascularised	(Hanahan	and	Weinberg,	
2011).	 It	 is	 estimated	 that	 80-90%	 of	 primary	 neuroendocrine	 tumours	 and	
metastases	can	be	imaged	and	identified	in	this	manner	(Le	Guludec	et	al.,	1996).		
	
	
	
	
	
	
	
	
	
Figure	 1.2:	 Adapted	 from	 (Baum	 and	 Kulkarni,	 2012).	 Depicts	 somatostatin	 receptor	 targeted	
scintigraphy	of	a	56	year	old	woman.	Displays	tumour	size	and	location	before	radiolabelled	peptide	
therapy,	3	months	after,	9	months	after	and	12	months	after	treatment.		
	
Peptides	have	previously	been	conjugated	to	radioactive	isotopes	for	therapeutic	
purposes	also;	they	are	reliant	on	the	same	specificity	of	peptide-to-peptide	
receptor	that	is	employed	for	medical	imaging	techniques	such	as	scintigraphy.	
Buchegger	et	al.,	2003	produced	the	first	radiolabelled	neurotensin	analogue,	called	
99mTc-NT-XI.	However,	many	variants	of	neurotensin	analogues	have	been	
synthesised	since	which	have	proven	to	be	more	successful	in	a	medical	application.	
NT-XI	used	in	their	study	was	a	hexapeptide	analogue	of	the	carboxy-terminus	of	
		Pre-therapy	 															3	Months	 	 					9	months	 															12	months	
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neurotensin,	covering	the	amino	acids	8-13	in	its	sequence.	The	modifications	made	
to	neurotensin	in	this	instance	increased	the	stability	of	the	peptide	–	for	example,	
the	link	between	residues	8	and	9	had	been	replaced	with	a	pseudolink	that	is	
resistant	to	serum	enzymes.	99mTc-NT-XI	was	created	by	connecting	the	N-terminus	
of	NT-XI	to	a	99mTc	moiety	with	an	(NαHis)Ac	group,	allowing	for	stable	labelling	of	
the	neurotensin	analogue.	The	same	technique	allowed	for	coupling	of	other	
radioisotopes.	99mTc-NT-XI	showed	a	similar	receptor	affinity	compared	to	
neurotensin	alone	and	compared	to	other	radioisotope	analogues	of	neurotensin	in	
production	at	the	time,	showed	favourable	tumour	uptake.	Unfortunately,	the	
clinical	trials	following	development	of	this	analogue	were	disappointing	but	the	
development	of	the	drug	itself	and	the	increased	stability	achieved	from	
modification	of	the	analogue	provided	a	platform	for	future	advances	(Morgat	et	al.,	
2014). 
	
1.2.3:	Peptide-Chemotherapeutic	Conjugates		
Modern	 cancer	 therapy	 usually	 involves	 highly	 intrusive	 processes;	 insertion	 of	
catheters	to	deliver	highly	toxic,	non-specific	agents	into	the	blood	to	initially	shrink	
tumours,	 surgeries	 to	 remove	 them	 and	 a	 plethora	 of	 further	 chemotherapy	 and	
radiation.	 The	 fundamental	 concept	 of	 chemotherapeutic	 agents	 is	 simple:	 to	
selectively	 kill	 cells	 that	 are	 more	 metabolically	 active	 than	 others	 (this	 generally	
applies	to	cancerous	cells,	which	have	by	definition,	metabolic	deregulation).	This	is	
the	 case	 in	 adults,	 but	 not	 in	 children	 that	 have	 a	 ubiquitously	 high	proportion	of	
quickly	 dividing	 cells	 attributing	 to	 their	 growth	 and	 development;	 extra	
considerations	must	be	made	when	treating	children.	Vast	improvements	to	patient	
survival	have	been	made	over	the	last	25	years	but	there	is	still	a	need	to	combat	the	
negative	 side	 effects	 associated	 with	 chemotherapy	 and	 radiotherapy	 (Brannon-
Peppas	and	Blanchette,	2012;	Hanahan	and	Weinberg,	2011).	Most	of	the	early	anti-
cancer	therapeutics	had	selectivity	to	cancer	cells	in	this	way,	by	inhibiting	essential	
processes	like	DNA	replication	and	cell	division	(Chabner	and	Roberts,	2005),	but	the	
critical	limitation	is	their	severe	toxicity	to	physiologically	normal	cells	(Hanahan	and	
Weinberg,	2011).	Due	to	this	highly	toxic	effect,	the	therapeutic	window	(see	figure	
1.3)	 of	 most	 chemotherapeutic	 agents	 is	 relatively	 small	 compared	 to	 other	
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pharmaceutics	(Luo	et	al.,	2009).	The	term	'therapeutic	window'	refers	to	a	range	of	
plasma	 concentrations	 of	 a	 pharmaceutic	 drug	 in	 which	 it	 has	 a	 successful	
therapeutic	effect	–	the	treatment	of	illness	with	the	intention	of	improving	health.	
A	plasma	concentration	below	this	'window'	will	result	in	no	therapeutic	effect	and	
anything	 above	 results	 in	 toxicity	 to	 the	 body	 (Das	 et	 al.,	 2011).	 As	 a	 result,	 the	
majority	of	chemotherapeutics	cannot	be	administered	 in	amounts	high	enough	to	
completely	eradicate	all	cancer	cells	present	in	the	body	–	this	is	partially	responsible	
for	 the	 occurrence	 of	 anti-cancer	 drug	 resistance	 and	 tumours	 that	 are	 therefore	
refractory	to	treatment	(Luo	et	al.,	2009).		
	
	
	
	
	
	
	
	
	
	
Figure	 1.3:	 Adapted	 from	 (Das	 et	 al.,	 2011)	 displays	 a	 representation	 of	 a	 theoretical	 therapeutic	
window	 and	 pharmacokinetic	 profile	 of	 conventional	 chemotherapeutic	 drug	 formation	 vs	 that	 of	
targeted	therapies	
	
The	technique	of	creating	carriers	for	chemotherapeutic	compounds	by	conjugating	
them	 to	 peptides	 has	 also	 been	 previously	 investigated	 for	 therapeutic	 purposes	
with	 a	 variety	 of	 peptides	 and	 neuropeptides	with	 the	 intention	 of	 internalisation	
and	subsequent	cellular	death	of	target	cancerous	cells.	Continuing	with	the	theme	
of	 somatostatin	 receptor	 targeting,	 which	 is	 certainly	 the	 most	 well	 documented	
receptor	for	peptide-targeted	therapies,	a	variety	of	differing	radiolabels	conjugated	
to	 octreotide	 have	 been	 shown	 to	 induce	 neuroendocrine	 tumour	 shrinkage	 and	
partial	 remissions.	Successful	 treatment/tumour	response	was	positively	correlated	
with	 octreotide	 uptake.	 Targeted	 treatment	 appears	 to	 differ	 from	 non-targeted	
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treatment	 with	 a	 reduced	 incidence	 of	 side	 effects	 such	 as	 nausea	 and	 vomiting	
(Kwekkeboom	et	al.,	2003).		
	
1.3:	In	Vitro	Peptide	Receptor	Expression	in	Cancerous	Tissues	vs.	Normal	Tissue	
With	 regards	 to	 non-cancerous,	 physiologically	 normal	 tissue,	 peptide	 receptor	
distribution	is	not	fully	understood;	mainly	due	to	a	lack	of	access	to	normal	human	
tissues.	 But,	 known	 locations	 are	 primarily	 the	 colon	 and	 the	 lungs	 (White	 et	 al.,	
2012).	It	 is	not	a	viable	option	to	extrapolate	data	from	animal	tissues	due	obvious	
species	 differences	 in	 physiology	 and	 biochemical	 control	 mechanisms.	 However,	
with	 reference	 to	 somatostatin	 receptors	 –	 receptor	 binding	 studies,	 mRNA	
detection	and	receptor	immunocytochemistry	has	placed	somatostatin	receptors	in	
a	 relatively	 widely	 dispersed	 pattern	 throughout	 the	 human	 body.	 Including:	 the	
pituitary,	kidney,	gut,	thyroid,	pancreas,	the	brain	and	the	immune	system	(germinal	
centres	 of	 the	 lymph	 nodes).	 Somatostatin	 receptor	 appears	 to	 be	 dispersed	 in	 a	
subtype	specific	manner	throughout	these	tissues	(Maurer	and	Reubi,	1986;	Thoss	et	
al.,	1996;	Schindler	et	al.,	1998).		
	
Reubi	and	Waser	(2003)	documented	in	a	range	of	neuroendocrine	tumours,	many	
of	 the	 tumours	 concomitantly	 expressed	 more	 than	 one	 peptide	 receptor,	
speculating	 that	 a	 cocktail	 of	 peptides	 with	 their	 respectively	 bound	 therapeutic	
agent	 could	 be	 used	 to	 target	 several	 co-expressed	 peptide	 receptors	 on	 a	 single	
tumour	for	a	more	effective	and	powerful	means	of	diagnosis	and	therapy.	The	same	
study	found	that	the	great	majority	of	investigated	tumour	types	expressed	subtype	
receptors	 for	 vasoactive	 intestinal	 peptide	 receptor	 and	 somatostatin,	 far	 more	
frequently	 than	 other	 peptide	 hormone	 receptors	 such	 as	 bombesin	 receptor	 and	
neurotensin	 receptor.	 This	 selective	 receptor	 expression	 pattern	 allows	 for	
pathobiochemical	 contrast	 between	 neuroendocrine	 tumours	 of	 differing	 origin.	
Furthermore,	allowing	for	a	much	more	refined	tumour-specific	target,	theoretically	
reducing	 any	 non-specific	 cell	 death	mediated	 by	 peptide	 receptors	 expressed	 on	
physiologically	 normal	 cells.	 Ideally,	 any	 peptide	 receptors	 expressed	 on	 the	 cell	
surface	of	 cancerous	cells	would	be	highly	overexpressed	on	 those	cancerous	cells	
and	expressed	at	minimal	levels	elsewhere	in	the	body.		
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1.4:	Pitfalls	of	Targeting	Peptide	Receptors	for	Drug	Delivery	
The	major	 limitation	 of	 peptide	 receptor	 targeted	 therapies	 is	 the	 heterogeneous	
nature	of	cancer,	and	with	it,	the	variability	of	receptor	expression	between	cells	of	
the	 same	 tumour	and	between	 individuals.	 Ideally,	 all	 of	 the	 constituent	 cells	of	 a	
tumour	would	express	the	targeted	peptide	receptor	highly	and	homogenously,	but	
this	 is	 unfortunately	 not	 likely	 to	 be	 the	 case.	 As	 variability	 of	 expression	 will	
undoubtedly	 be	 present	 in	 cells	 of	 the	 same	 tumour,	 it	 is	 expected	 that	 such	
variation	 will	 also	 be	 observed	 between	 tumours	 of	 the	 same	 classification	 in	
different	 individuals.	 Furthermore,	 studies	 using	 laboratory	 mice	 or	 cell	 lines	
cultured	 in	 vitro	 are	 not	 considered	 sufficient	 for	 determination	 of	 receptor	
expression	 in	 vivo	 in	 the	 related	 tissue	 type,	 as	 receptor	 expression	 may	 differ	
profoundly	 in	 the	 corresponding	 primary	 human	 tumour.	 For	 example,	 in	 vitro	
colonic	cancerous	cell	lines	express	certain	peptide	receptors	but	gastric	carcinomas	
in	 vivo	are	 often	 devoid	 of	 expressing	 them	 themselves	 (Reubi	et	 al.,	 1999).	With	
regards	 to	 ascertaining	 receptor	 expression	 in	 vivo	 from	 patients	 presenting	 with	
neuroendocrine	 tissues,	 sample/biopsy	 collection,	 preparation	 and	 processing	 is	
difficult	to	standardise.	For	example,	if	the	technique	is	immunostaining	(the	current	
standard	 is	 immunohistochemistry),	many	 variations	 can	affect	 the	end	 result:	 the	
delay	before	delivery	 to	a	 laboratory	 for	 receptor	expression-determining	 staining,	
sample	 processing	 (fresh/frozen),	 method	 of	 fixation,	 non-standardised	 protocols,	
antibody	 specificity	 etc.	 Inadequate	 storage	 during	 transport	 and	 excessive	
freeze/thawing	of	tissue	samples	can	 lead	to	false-negatives.	 It	must	also	be	noted	
that	there	may	be	differences	in	receptor	expression	in	different	areas	of	the	tumour,	
suggesting	multiple	biopsies	 from	different	positions	would	give	 the	most	detailed	
description	 of	 personalised	 in	 vivo	 receptor	 expression	 (Kaemmerer	 et	 al.,	 2014;	
Reubi,	2003).	In	terms	of	an	optimal	method	of	receptor	detection,	Kaemmerer	et	al,	
(2014)	 compared	 the	effectiveness	of	manual	evaluation	of	 immunohistochemistry	
to	 automated	 evaluation	 with	 software-based	 analysis	 and	 positron	 emission	
tomography	 (PET)	 and	 computerised	 tomography	 of	 in	 vivo	 tumour	 as	 a	whole	 in	
somatostatin	receptor	expressing	NETs.	The	cohort	found	there	to	be	no	significant	
difference	in	determination	of	the	relative	quantity	of	expressed	receptors.		
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Medical	 imaging	 techniques	 such	 as	 scintigraphy	 are	 limited	 by	 the	 minimum	
required	 quantity	 of	 radioactive	 peptide	 analogue	 collected	 in	 one	 area	 (by	 a	
tumour)	 to	 register	any	 tumourous	 tissue	present.	Techniques	such	as	 this	are	not	
particularly	 effective	 at	 detecting	 tumours	 smaller	 than	 1cm3.	 This	 principle	 also	
applies	 to	 radiotherapy	 –	 an	 adequate	 amount	 of	 radioligand	 is	 required	 to	
effectively	administer	a	therapeutic	dose	of	 internal	radiotherapy.	As	the	absorbed	
amount	of	radioligand	shows	huge	inter-patient	variance,	receptor	expression	in	vivo	
limits	the	therapeutic	value	of	this	method	of	treatment	(Bison	et	al.,	2014).	
	
1.5:	Neurotensin	
Neurotensin	 (NT)	 is	 a	 tridecapeptide	 (Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-
Ile-Leu)	originally	 isolated	 from	 calf	 hypothalamus	 and	 characterised	 by	 Carraway	
and	 Leeman	 (1973).	 Structurally,	 neurotensin	 is	 very	 similar	 to	 a	 related	 peptide		
neuromedin	 N.	 Both	 peptides	 have	 been	 shown	 to	 originate	 from	 a	 common	
precursor,	 differentially	 processed	 at	 dibasic	 sites	 by	 proprotein	 convertases	
(Kislauskis	et	al.,	1988).	See	figure	1.4	for	detail	of	the	peptides	structure.	
		
	
	
	
	
	
	
Figure	1.4:	The	structure	of	neurotensin	
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Neurotensin	was	named	on	the	basis	of	 its	neural	 localisation	and	the	vasodilation	
observed	after	local	administration.	Over	the	past	25	years,	there	has	been	a	steady	
interest	in	understanding	the	locality,	structure	and	function	of	NT.	Neurotensin	has	
a	dual	 role	as	both	a	neurotransmitter	and	neuromodulator	 in	 the	central	nervous	
system,	in	addition	to	acting	as	a	local	hormone	in	the	periphery	(Ferris,	2010).	In	the	
central	 nervous	 system,	 neurotensin	 acts	 as	 a	 neuromodulator	 of	 dopamine	
transmission	 and	 anterior	 pituitary	 hormone	 secretion,	 as	well	 as	 inducing	 potent	
hypothermic	and	analgesic	effects	on	the	brain	(Vincent	et	al.,	1999).	With	regards	
to	the	gastrointestinal	tract,	neurotensin	is	released	from	enteroendocrine	N	cells	in	
response	 to	 interactions	 with	 lipids	 –	 where	 it	 stimulates	 the	 release	 of	 digestive	
acids	 from	the	pancreas,	gall	bladder	and	stomach,	 facilitates	 fatty	acid	absorption	
and	regulates	small	bowel	motility	(White	et	al.,	2012).		
	
A	 large	 number	 of	 peptide	 hormones	 have	 been	 identified	 as	 growth	 factors	 in	
cancer	 (Heasley,	 2001).	 NT	 has	 been	 associated	 with	 the	 differentiation	 and	
progression	of	tumours	in	the	periphery,	where	is	has	been	documented	to	increase	
the	 size	 of	 lung	 and	 colon	 tumours	when	exposed	 to	 the	peptide	 (St-Gelais	et	 al.,	
2006).	In	dividing	human	neuroblastoma	cell	line	N1E-115,	it	has	been	documented	
that	 prolonged	 exposure	 to	NTS1	 agonists	 causes	NTS1	 to	 recycle	 back	 to	 the	 cell	
surface	to	allow	for	constant	sensitisation	(Toy-Miou-Leong	et	al.,	2004).	Literature	
also	suggests	that	cancerous	cells	have	the	ability	to	perform	autocrine	signalling,	as	
a	method	of	enhanced	self-propagation	(Carraway	and	Plona,	2006).	
	
1.6:	Neurotensin	Receptors	
The	actions	of	NT	are	mediated	by	specific	 interactions	with	neurotensin	receptors	
(NT-R)	 presented	 on	 the	 surface	 membrane	 of	 cells.	 The	 C-terminal	 region	 of	
neurotensin	 (residues	 8-13)	 is	 responsible	 for	 binding	 to	NT-R	 (Gully	 et	 al.,	 1993).	
Neurotensin	 receptors	 are	 divided	 into	 three	 subtypes:	 neurotensin	 receptor	 1	
(NTS1),	 neurotensin	 receptor	 2	 (NTS2)	 and	 neurotensin	 receptor	 3/sortilin	 (NTS3).	
NTS1	 and	 NTS2	 belong	 to	 the	 GPCR	 family	 and	 have	 a	 high	 and	 low	 affinity	 to	
neurotensin	 respectively,	 whilst	 NTS3	 has	 only	 a	 single	 transmembrane	 domain	
which	has	a	100%	homology	with	gp95/sortilin	(Wu	et	al.,	2013).	The	two	G	protein-
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coupled	 receptors	 can	 be	 differentiated	 by	 NTS2's	 specific	 sensitivity	 to	
levocarbastine	(Yamada	et	al.,	1998).		
	
	
	
	
	
	
	
	
	
	
Figure	 1.5:	 Adapted	 from	 Vincent	 et	 al.,	 (1999).	 Visualisation	 of	 rat	 NTS1	 and	 NTS2	 –	 light	 grey	
residues	 within	 the	 transmembrane	 region	 are	 indicative	 of	 invariant	 residues	 between	 the	 two	
receptor	 subtypes.	 I1,	 I2,	 I3,	 I4	 are	 intracellular	 loops	 1-4	 respectively	 and	 E1,	 E2,	 E3	 and	 E4	 are	
extracellular	loops	1-4	respectively.	E1,	13	and	14	are	regions	of	the	NTS2	receptor	that	strongly	differ	
from	NTS1	(dark	grey).	Residues	involved	in	the	binding	of	NT	are	located	on	E2	and	E4.	
	
Neurotensin	receptors	are	unstable	 in	detergent	solution,	which	creates	difficulties	
for	assessing	their	structure	–	particularly	 in	an	agonist	bound	state	(thought	to	be	
less	stable	than	an	antagonist	bound	state).	White	et	al.,	(2012)	used	conformational	
thermostabilisation	to	overcome	this	issue	and	generated	a	thermostable	mutant	of	
NTS1	 in	 the	 presence	 of	 NT	 as	 an	 agonist,	 as	 crystallisation	 of	 the	 receptor	 in	 its	
unbound	 state	 proved	 to	 be	 unsuitable	 (see	 figure	 1.6).	 The	 cartoon	 structural	
representation	 is	 displayed	 in	 figure	 1.5.	 Pharmacological	 characterisation	 of	 this	
mutant	found	the	receptor	affinity	to	be	similar	to	that	of	the	wild-type	receptor.		
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Figure	1.6:	Adapted	 from	White	et	al.,	 (2012).	Conformational	 structure	of	 thermostable	mutant	of	
NTS1	bound	to	NT.	(A)	Side	view,	(B)	extracellular	view	and	(C)	intracellular	view.	Mutations	required	
for	 thermostabilisation	are	 indicated	along	with	additional	T4	 lysozyme	that	had	been	 incorporated	
into	the	third	 intracellular	 loop.	NT	 is	coloured	 in	orange.	Thermostabilising	mutations	are	coloured	
purple,	and	the	disulphide	bond	is	coloured	yellow.	The	beta-hairpin	in	extracellular	loop	2	of	NTS1	is	
coloured	 blue.	 Each	 transmembrane	 region	 is	 coloured	 in	 green	 and	 annotated	 TM1,	 TM2	 etc.	 for	
transmembrane	region	1	and	2	respectively.		
	
The	effects	of	NT	are	primarily	 transmitted	through	 its	high	affinity	 receptor	NTS1,	
which	has	a	sub-nanomolar	affinity	of	~0.3	nM.	In	comparison,	the	lower	affinity	G	
protein-coupled	receptor	(NTS2)	has	an	affinity	of	2-4	nM	(Sarret	et	al.,	2003).	The	
signalling	 pathway	 of	 NTS1	 is	 by	 far	 the	 most	 well	 documented	 –	 including	 Ca2+	
release	 after	 inositol	 1,4,5-triphosphate	 stimulation	 (Chabry	 et	 al.,	 1994)	 and	
activation	 of	mitogen-activated	 protein	 kinases	 via	 protein	 kinase	 C,	 prompting	 its	
role	 in	cell	proliferation	(Poinot-Chazel	et	al.,	1996).	All	 three	neurotensin	receptor	
subtypes	have	been	 shown	 to	 internalise	upon	 interaction	with	NT	 (Mazella	et	al.,	
1991).	 For	 example,	 60-70%	of	 COS	 cells	 have	been	 shown	 to	 internalise	NT	upon	
interaction	with	NT	in	a	temperature	dependent	manner	(Chabry	et	al.,	1994).	
	
1.7:	Neurotensin	Internalisation	Mechanism	
All	 three	 receptor	 subtypes	 are	 known	 to	 internalise	 upon	 interaction	 with	
neurotensin,	but	NTS1	has	 thus	 far	proven	 to	be	 the	most	 functionally	 involved	 in	
the	proliferative	effects	of	neurotensin,	and	with	the	greatest	affinity	for	the	ligand	
					NT	
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(see	 figure	 1.7).	 Biochemical	 morphology	 studies	 in	 neuronal	 cell	 lines	 have	
demonstrated	 that	 the	 internalisation	 of	 NTS1	was	 time-dependent,	 temperature-
dependent	and	sensitive	to	phenylarsine	oxide	(an	endocytosis	inhibitor)	(Mazella	et	
al.,	 1991).	 Chabry	 et	 al.,	 (1993)	 observed	 the	 temperature-dependent	 nature	 of	
NTS1	internalisation	in	neurons.	The	study	documents	rapid	internalisation	at	37°C,	
but	 inhibition	 of	 internalisation	 at	 4°C.	 The	 application	 of	 the	 NTS1	 antagonist	
SR48692	virtually	 inhibits	all	NT-R	 specific	binding	 in	primary	adenocarcinoma	 (see	
figure	1.9),	suggesting	that	the	majority,	if	not	all	binding	of	neurotensin	is	specific	to	
NTS1	 or	 only	 NTS1	 is	 overexpressed	 in	 this	 cancer	 type;	 in	 turn	 suggesting	 the	
majority	 of	 NT	 internalisation	 is	 mediated	 by	 NTS1.	 Furthermore,	 Mazella	 et	 al.,	
(1991)	 compared	 the	 internalisation	 of	 NT	 at	 37°C	 and	 10°C	 in	 primary	 neuronal	
cultures	from	the	cerebral	hemispheres	of	mouse	embryos.	Their	study	documented	
the	binding	capacity	to	be	3x	higher	at	37°C	as	opposed	to	the	cooler	temperature.	
Virtually	 all	 neurotensin	 molecules	 solely	 were	 membrane	 bound	 and	 readily	
washable	 by	 hypertonic	 acid	 solution	 at	 10°C.	 Whereas,	 70%	 of	 neurotensin	 was	
detected	 internally	 in	 the	 37°C	 condition	 with	 a	 large	 proportion	 located	 in	 the	
perikarya.		
	
The	 internalisation	 of	 GPCRs	 is	 a	 phenomenon	 elicited	 by	 ligand	 stimulation.	 The	
rapid	internalisation	of	GPCRs	once	stimulated,	known	as	sequestration,	follows	the	
ligand-mediated	phosphorylation	of	the	GPCR	in	question	by	specific	GPCR	kinases.	It	
is	this	initial	phosphorylation	of	the	receptor	that	induces	sequestration	(Ferguson	et	
al.,	1995).	Receptor	phosphorylation	also	serves	to	increase	the	affinity	of	GPCRs	to	
β-arrestins,	which	in	addition	to	initiating	uncoupling	of	GPCRs	from	the	G-proteins	
themselves	 and	 preventing	 further	 stimulation,	 act	 as	 adaptor-like	 molecules	 for	
receptor	trafficking.	Β-arrestins	are	proteins	that	bind	to	GPCRs	once	phosphorylated	
and	 contribute	 to	 the	 desensitisation	 of	 the	 receptor	 by	 uncoupling	 the	 signal	
transduction	 process	 (Ferguson	 et	 al.,	 1996).	 The	 phenomenon	 of	 GPCR	
desensitisation	 is	observed	as	a	response	to	continuous	or	repeated	stimulation	by	
agonists	(Freedman	and	Lefkowitz,	1996).	There	is	considerable	evidence	suggesting	
that	 GPCRs	 internalise	 in	 a	 clathrin-mediated	 manner	 (Delom	 and	 Fessart,	 2011;	
Moore	et	al.,	1995).		
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NTS1	 is	 thought	 to	 not	 be	 recycled	 after	 ligand-mediated	 internalisation,	whereas	
NTS2	largely	 is	(Botto	et	al.,	1998;	Hermans	and	Maloteaux,	1998).	Visualisation	by	
confocal	 microscopy	 of	 NTS1	 expressing	 neurons	 incubated	 with	 fluorescently	
labelled	 NT	 demonstrated	 internalisation	 together	 with	 the	 receptor	 towards	 the	
perinuclear	 region	within	 small	 vesicles	 (Faure	 et	 al.,	 1995;	 Nouel	 et	 al.,	 1997).	 A	
similar	 internalisation	 locality	was	 observed	 by	 Vandenbulcke	et	 al.,	 (2000),	which	
monitored	the	migration	of	a	fluorescently	labelled	analogue	of	NT,	bound	to	NTS1,	
after	 internalisation	 into	 NTS1	 transfected	 COS-7	 cells.	 The	 study	 concluded	 that	
internalisation	was	mediated	 via	 clathrin	 coated-pits,	 to	 later	 accumulate	with	 the	
receptor	 in	 acidic	 early	 endosomes	where	 the	 ligand	 dissociates	 from	 its	 receptor	
due	to	the	 increased	acidity.	After	the	 loss	of	co-localisation,	neurotensin	migrated	
in	 late	 endosomes	 to	 the	 Trans-Golgi	 network,	 whilst	 NTS1	 was	 detected	 in	
lysosomes.	 Therefore,	 documenting	 a	 peptide/peptide	 receptor	 recycling	 cycle	
unique	 among	 GPCRs,	 mediating	 targeting	 of	 a	 peptide	 from	 the	 membrane,	 to	
endosomes,	to	the	Trans-Golgi	Network	(see	figure	1.1).	
	
	
	
	
	
	
	
	
Figure	1.7:	Adapted	from	(Morgat	et	al.,	2014).	Schematic	representation	of	neurotensin	receptor	
internalisation	with	its	endogenous	ligand	and	examples	of	radiopharmaceuticals	conjugated	to	its	
endogenous	ligand.	
	
Most	 of	 what	 is	 known	 about	 intracellular	 trafficking	 mechanisms	 of	 peptides	
derives	 from	 studies	 concerning	 single	 transmembrane	 domain	 receptors.	 For	
example,	 Kalgaonkar	 and	 Lönnerdal	 (2009)	 documented	 the	 receptor-mediated	
uptake	 of	 ferritin-bound	 iron	 by	 the	 human	 intestinal	 epithelial	 cell	 line,	 Caco-2.	
After	 previous	 studies	 of	 theirs	 suggested	 that	 the	 cellular	 uptake	 of	 iron	 from	
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ferritin	 (a	 relatively	 large	 iron-binding	 protein)	 was	 different	 to	 cellular	 uptake	 of	
iron	 from	 FeSO4	 –	 suggesting	 a	 different	 method	 of	 internalisation	 of	 larger	
molecules	 such	 as	 ferritin.	 They	 investigated	 the	 internalisation	 mechanism	 of	
ferritin-bound	 iron	 with	 the	 use	 of	 radiolabelled	 iron,	 determining	 that	
internalisation	 is	 in	 fact	 receptor	 mediated	 at	 physiological	 concentrations.	
Additional	macropinocytosis	was	observed	at	higher	concentrations.	
	
1.8:	Neurotensin	Receptors	in	Cancer	
Over	 20	 years	 ago,	 neurotensin	 receptors	 were	 found	 to	 be	 highly	 expressed	 on	
~75%	 of	 primary	 pancreatic	 adenocarcinomas	 (see	 figure	 1.8)	 whilst	 not	 being	
expressed	 by	 non-neoplastic	 pancreatic	 ducts	 (Reubi	 et	 al.,	 1998).	 This	 almost	
ubiquitous	expression	on	pancreatic	carcinoma	was	later	conformed	by	Ehlers	et	al.,	
(2000)	documenting	an	approximate	90%	incidence	of	NT	receptor	expression	by	RT-
PCR	 measurement	 –	 presenting	 a	 therapeutic	 target	 for	 a	 notoriously	 aggressive	
cancerous	adversary	(Oberstein	and	Olive,	2013).	NT-R	is	known	to	also	be	expressed	
in	 other	 cancer	 types	 such	 as	 sarcomas,	 gastrointestinal	 and	 prostate	 tumours	
(Carraway	and	Plona,	2006;	Reubi	et	al.,	1998;	Swift	et	al.,	2010).	A	study	by	Körner	
et	 al.,	 (2015)	 documents	 the	 expression	 of	 neurotensin	 receptors	 on	 aggressive	
primary	pancreatic	adenocarcinomas	and	metastases	as	a	novel	and	specific	marker,	
strongly	suggesting	that	radioactive	neurotensin	analogues	should	be	developed	for	
diagnosis	and	therapy	(see	figure	1.8).	
Figure	1.8:	Adapted	 from	Körner	et	al.,	 (2015).	Depicts	NT-R	expression	 in	a	biopsy	 from	a	primary	
pancreatic	carcinoma.	(A)	Shows	a	haematoxylin	and	eosin	stained	section	(B)	Shows	autoradiogram	
of	radio-labelled	NT	bound	to	NT-R.	(C)	Shows	an	autoradiogram	of	non-specific	binding	of	of	radio-
labelled	NT	to	NT-R	(in	the	presence	of	100	nM	free	neurotensin).	Bars	=1	mm.	Annotations	Tu	refers	
to	tumorous	tissue	and	P	refers	to	normal	pancreatic	tissue.		
	
The	 role	 and	 function	 of	 NT-R	 in	 cancer	 has	 come	 to	 light	 over	 the	 last	 decade,	
particularly	that	of	NTS1.	NT-R	has	been	shown	to	mediate	the	proliferative	effect	of	
A	 B	 C	
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NT	 in	 a	 variety	 of	 tumours	 (Olszewski	 and	 Hamilton,	 2009;	 Thomas	 et	 al.,	 2003;	
Vincent,	1995).	As	such,	the	use	of	neurotensin	analogues	has	been	proposed	as	an	
anti-proliferative	treatment	for	pancreatic	tumours	(Carraway	and	Plona,	2006).	The	
functionality	of	neurotensin	receptors	in	different	tumour	types	has	been	tentatively	
documented;	in	prostate	cancer,	the	receptor	is	observed	to	be	up-regulated	in	the	
absence	 of	 androgens	 as	 an	 alternative	 growth	 pathway	 (Sehgal	 et	 al.,	 1994).	
Receptor	 expression	was	 not	 observed	 in	 normal	 prostate	 epithelial	 cells	 however	
(Gugger	and	Reubi,	1999),	but	in	cell	cultures	(PC-3M	cell	line),	expression	was	found	
to	increase	in	concordance	with	tumourigenic	potential	of	the	cells.	It	has	also	been	
speculated	 that	 NTS1	 expression	 in	 this	 cancer	 type	 is	 involved	 in	 resistance	 to	
radiotherapy	(Valerie	et	al.,	2011).	This	pattern	of	receptor	expression	has	also	been	
documented	 in	 breast	 and	 lung	 cancer,	 with	 91%	 of	 invasive	 ductal	 breast	
carcinomas	(Souazé	et	al.,	2006),	60%	of	stage	1	lung	adenocarcinomas	(Alifano	et	al.,	
2010a)	and	90%	of	mesotheliomas	(Alifano	et	al.,	2010b)	testing	positively	for	NTS1	
expression.	As	such,	NT-R	positivity	was	strongly	correlated	with	decreased	survival	
rates	(Alifano	et	al.,	2010a).	
	
There	is	strong	evidence	suggesting	that	SR48692,	an	NTS1	selective	antagonist,	can	
inhibit	tumour	proliferation	by	inhibiting	the	binding	of	NT	to	NT-R	(see	figure	1.9).	
In	vitro,	SR48692	was	shown	to	inhibit	proliferation	of	lung	adenocarcinoma	(Moody	
et	 al.,	 2001).	 A	 study	 by	Moody	et	 al.,	 (2001)	 documents	 the	 use	 of	 SR48692	 and	
SR142948A	 (a	 non	 subtype-specific	 NT-R	 antagonist)	 on	 small	 cell	 lung	 cancer	 cell	
lines	NCI-H209	and	H345.	SR48692	was	 found	to	 inhibit	proliferation	and	decrease	
colony	sizes	of	both	cell	lines	in	a	concentration	dependant	manner.	The	same	study	
documents	 the	 growth	 rate	 of	 HCI-H209	 xenographs	 in	 the	 presence	 of	 10	 μg	 of	
SR48692	 compared	 to	 untreated	 –	 the	 untreated	 xenograph	 increased	 in	 volume	
from	 0mm3	 to	 ~1600mm3	 over	 a	 period	 of	 five	 weeks,	 whereas	 the	 treated	
xenograph	expanded	no	more	than	~50mm3	over	the	same	time	period.		
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 Figure	1.9:	Adapted	from	Körner	et	al.,	 (2015).	Depicts	NT-R	expression	 in	a	biopsy	 from	a	primary	
adenocarcinoma.	 (A)	 Shows	 a	 haematoxylin	 and	 eosin	 stained	 section	 (B)	 Shows	 autoradiogram	 of	
radio-labelled	NT	bound	to	NT-R.	(C)	Shows	an	autoradiogram	of	non-specific	binding	of	radio-labelled	
NT	 to	 NT-R	 (in	 the	 presence	 of	 100nM	 neurotensin).	 (D)	 Shows	 an	 autoradiogram	 of	 non-specific	
binding	of	radio-labelled	NT	to	NT-R	(in	the	presence	of	1μM	SR48692	–	confirming	the	detected	NT-R	
receptors	are	NTS1)	Bars	=1mm.	
	
1.9:	Conclusion	
Peptide	receptors	are	an	excellent	target	for	drug	delivery,	especially	with	regards	to	
cancer	 treatment	 as	 it	 presents	 an	 opportunity	 for	 eliminating	 the	 negative	 side	
effects	 associated	 with	 non-specific	 drug	 interactions.	 Compared	 to	 somatostatin,	
neurotensin	 is	 expressed	 less	 frequently	 on	 physiologically	 normal	 tissues	 and	
appears	 to	be	highly	overexpressed	on	aggressive	cancer	 types	 (such	as	pancreatic	
adenocarcinoma)	 that	 currently	 face	 poor	 survival	 rates	 and	 a	 limited	 arsenal	 of	
successful	 therapies.	The	uses	of	 radio-labelled	and	chemotherapeutic	neurotensin	
analogues	 for	 diagnostic	 and	 therapeutic	 purposes	 respectively	 have	 shown	 to	 be	
promising	 candidates	 for	 treatment	 of	 aggressive	 peripheral	 tumours	 and	
metastases.	 Especially	 as	peptide-conjugation	 significantly	 lowers	 the	dose	needed	
to	be	administered	due	to	neurotensins	nM	affinity	for	NTS1.		
	
Inhibition	 of	 NTS1	 in	 particular,	 as	 this	 is	 the	 receptor	 to	 show	 the	 greatest	
functional	 role	 in	 the	 proliferative	 effect	 of	 neurotensin,	 has	 shown	 to	 inhibit	 the	
growth	of	tumours	and	even	show	a	reduction	in	cell	counts	in	various	cell	lines.	The	
internalisation	of	larger	molecules,	such	as	ferritin,	 is	also	known	to	be	internalised	
in	 a	 receptor-mediated	 fashion,	 suggesting	 that	 it	 is	 also	 possible	 for	 larger	
chemotherapeutic	molecules	bound	to	an	appropriate	peptide	to	be	internalised	in	a	
receptor	mediated	fashion.		
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1.10:	Aims	and	Objectives	
Overall,	 the	 aim	 of	 this	 study	 is	 to	 evaluate	 the	 potential	 for	 neurotensin	 to	 be	
employed	to	specifically	deliver	molecules	(with	a	size	comparable	to	that	of	GFP)	to	
NTS1	 overexpressing	 cells.	 Differentiated	 Caco-2	 cells,	 grown	 in	 transwells,	 were	
used	 to	model	 drug	 transport	 across	 an	 intestinal	 epithelial	 barrier.	 As	 these	 cells	
were	 found	 to	 overexpress	 NTS1	 in	 this	 study	 once	 differentiated,	 they	 allow	 for	
modelling	of	NTS1	mediated	trans-epithelial	transport.	Undifferentiated	Caco-2	and	
HEK293	cells	were	used	to	represent	and	model	fluorophore-conjugated	NT	uptake	
into	 tumoral	 cells.	 As	 each	 cell	 line	 expressed	 neurotensin	 receptors	 to	 differing	
degrees	 (Caco-2	 minimally,	 HEK293	 moderately	 and	 NTS1	 transfected	 HEK293	
highly),	 this	 presented	 the	 opportunity	 to	 speculate	 how	 NTS1	 expression	 affects	
uptake	of	each	NT-bound	molecule.		
	
The	aims	of	this	study	are	to	express	in	bacteria,	purify	and	quantify	a	recombinant	
model	drug:	histidine-tagged	emerald	green	 fluorescent	protein	 (eGFP)	 conjugated	
to	NT	to	be	referred	to	hereon	as	GFP-NT.	GFP-NT	will	be	applied	to	 two	separate	
cell	 lines,	Caco-2	and	HEK293,	to	assess	 internalisation	and	transport	of	 this	model	
drug.	 GFP-NT	 will	 also	 be	 compared	 against	 another,	 smaller,	 fluorophore	
conjugated	to	NT:	fluorescein.	NT-conjugated	fluorescein	will	heron	be	referred	to	as	
F-NT.	The	effect	of	extent	of	NTS1	expression	will	 also	be	examined	by	 comparing	
uptake	 of	 both	 NT-bound	 fluorophores	 in	 NTS1	 transfected	 vs	 non-transfected	
HEK293	cells.	Exogenous	NTS1	expression	will	be	determined	 in	both	cell	 lines	and	
internalisation	 of	 NT-conjugated	 fluorophores	 will	 be	 visualised	 using	 confocal	
microscopy.	
	
This	study	focuses	on	the	potential	for	cytotoxic	drug	conjugation	to	a	neuropeptide,	
with	 the	 use	 of	 a	 model	 drug	 (green	 fluorescent	 protein)	 as	 a	 preliminary	
experimental	model.	 The	aim	 is	 to	differentially	 target	overexpression	of	 the	 focal	
neuropeptide's	 respective	 receptor	 on	 cancerous	 cells	 over	 physiologically	 normal	
cells.
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Chapter	2	
General	Methods	and	Materials	
	
	
2.1:	Materials	
	
2.1.1:	Cell	Culture	–	Cells,	Media	and	Other	Solutions	
Caco-2	 cells	were	 obtained	 from	 the	 European	 Collection	 of	 Cell	 Cultures	 (ECACC)	
and	 were	 used	 between	 passages	 60-80.	 HEK293	 cells	 were	 obtained	 from	 the	
American	Type	Culture	Collection	(ATCC®)	and	were	used	between	passages	25-40.	
Dulbeccos	Modified	 Eagles	Medium	 (DMEM)	with	 4500mg/L	 glucose,	 L-glutamine,	
sodium	 pyruvate	 and	 sodium	 bicarbonate	 was	 purchased	 from	 Sigma	 Aldrich®.	
Hank's	Balanced	Salt	 Solution	 (HBSS)	with	 sodium	bicarbonate	and	without	phenol	
red	 were	 obtained	 from	 Sigma	 Aldrich®.	 Phosphate	 buffered	 saline	 tablets	 were	
obtained	 from	Oxoid®.	0.25%	Trypsin/EDTA	solution	 (2.5g	porcine	 trypsin	and	0.2g	
EDTA	 per	 litre	 of	 HBSS)	 was	 obtained	 from	 Sigma	 Aldrich®.	 Antibiotic/antimycotic	
solution	 (penicillin,	 streptomycin	and	amphotericin),	 fetal	bovine	 serum	 (FBS)	non-
USA	origin,	dimethylsulphoxide	(DMSO),	Trypan	blue	solution	and	poly-L-lysine	(0.1%	
solution,	mw	=	70,000-15,000)	were	also	all	obtained	 from	Sigma	Aldrich®.	DMEM	
was	supplemented	with	10%	FBS	and	1%	complete	antibiotic/antimycotic	solution	to	
produce	complete	DMEM	solution.	100%	Ethanol	was	supplied	by	Fisher	Scientific®.		
	
2.1.2:	Glassware	and	Plasticware	
Clear	polystyrene	12	well	plates	(sterile,	pyrogen-free),	culture	flasks	(75	cm2,	canted	
neck	with	 vented	 caps),	 Nalgene™	 cryogenic	 tubes	 (1.5	ml),	 and	 opaque	 black	 96	
well	plates	were	supplied	by	Sarstedt®.	1,	2,	5,	10	and	25	ml	pipettes,	and	sterile	50	
ml	 falcon	 tubes	 were	 also	 supplied	 by	 Sarstedt.	 12-well	 Transwell®	 permeable	
supports	of	12	mm	diameter	and	0.4	μm	pore	size	polycarbonate	membrane	filters	
were	obtained	form	Corning	Life	Sciences®.	Haemocytometer	was	provided	by	Sigma	
Aldrich®.		
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2.1.3:	Chemicals	
Model	 drugs	 GFP-NT	 and	 GFP	 were	 synthesised	 internally	 as	 described	 in	 section	
2.21-2.2.14.	Human	Neurotensin	(>90%	purity	by	HPLC)	and	paraformaldehyde	was	
supplied	 by	 Sigma	 Aldrich®.	 SR142948	 (non-peptide	 NTS1	 and	 NTS2	 receptor	
antagonist)	 was	 obtained	 from	 Tocris	 Bioscience©.	 Triton-X	 100	 was	 supplied	 by	
Fisher	 Scientific®.	 Tris	 and	 NaCl	 were	 supplied	 by	 Melford	 Laboratories	 Ltd®.	
Protease	inhibitor	tablets	(cOmplete™	protease	inhibitor	cocktail	tablets,	EDTA-free)	
were	supplied	by	Roche	Diagnostics®,	from	which	a	25x	stock	solution	was	made	by	
adding	1	tablet	to	2	ml	of	distilled	water.	
	
2.2:	Methods	
	
2.2.1:	Production	of	the	pJB1	Plasmid	by	Mutagenesis	
pJB1	(pET	vector	containing	the	gene	for	recombinant	His-GFP)	was	synthesised	by	
mutagenesis	of	pAG3	(pET	vector	containing	the	gene	for	recombinant	His-GFP-NT)	
using	 custom	 oligonucleotide	 primers	 to	 introduce	 a	 stop	 codon	 before	 the	 gene	
coding	for	NT	in	the	plasmid.	PCR	reaction	mixture	was	set	up	as	follows	(all	reagents	
supplied	by	Novagen):	
• 1x	Buffer	for	KOD	Hot	Start	DNA	Polymerase	(concentration	as	stated	by	the	
supplier)	
• 0.2	mM	dNTPs	
• 1.5	mM	MgSO4	
• 2	μM	forward	primer	(AG6)		
• 2	μM	backward	primer	(AG7)	
• 50	ng	pAG3	
• 0.5	μl	of	IU/μl	KOD	Hot	Start	Polymerase		
• Make	up	to	50	μl	with	PCR	grade	water	
	
Reaction	mixture	was	cycled	through	optimised	PCR	programme	as	follows:	
• 30	seconds	–	90°C		
• Repeat	18	times:	
o 30s	–	95°C	
o 60s	–	60°C	
o 5	min-	68°C	
o 7	min	–	68°C	
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2.2.2:	DpnI	Digest	
The	PCR	product	(total	of	50	μl)	obtained	from	2.2.1	was	incubated	with	0.25	μl	of	
DpnI	 (20,000U/l,	New	England	Biolabs)	 and	5μl	of	10x	CutSmart	buffer	at	37°C	 for	
1hr	to	eliminate	methylated	DNA	(bacterial	DNA/pAG3)	and	ensure	only	PCR	product	
is	present	in	the	sample.	
	
2.2.3:	BamHI/NdeI	Restriction	Digest	
All	reagents	were	supplied	by	New	England	Biolabs.	Restriction	digests	were	set	up	
as	follows:	
• 1x	NEBuffer	4	
• 6	μl	pf	pAG3	(500	ng/μl)	
• 1	μl	BamHI	(20,000	U/ml)	
• 1	μl	NdeI	(20,000	U/ml)	
• Make	up	to	30	ml	with	PCR	grade	water	
	
The	reaction	mixture	was	incubated	at	37°C	for	one	hour	prior	to	being	analysed	by	
gel	electrophoresis	(see	section	2.2.4).	
	
2.2.4:	Gel	Electrophoresis	
A	Fisher	Scientific©	horizontal	electrophoresis	 tank	was	used	 for	 this	procedure.	A	
1%	agarose	gel	was	made	with	1x	TAE	buffer	(40	mM	Tris-HCl,	1	mM	EDTA	and	20	
mM	acetic	acid	at	pH	8)	and	left	to	set	in	the	tank	for	~30	mins	with	a	comb	placed	
appropriately.	Once	set,	the	gel	was	submerged	in	1x	TAE	buffer.	3	μl	of	DNA	sample	
was	 combined	 with	 3	 μl	 PCR	 grade	 water	 and	 3	 μl	 of	 DNA	 loading	 buffer	 (30%	
glycerol,	0.025%	bromophenol	blue	in	TE	buffer)	and	loaded	into	the	wells	of	the	gel.	
TE	buffer	comprised	of	10	mM	Tris-HCl	pH	7.4,	1	mM	EDTA	at	pH	8.	The	gel	was	then	
run	at	150V	until	the	dye	front	was	~80%	of	the	way	down	the	gel.	At	this	stage,	the	
gel	 was	 removed	 and	 placed	 into	 a	 separate	 plastic	 container,	 submerged	 in	 TAE	
buffer	 (just	enough	 to	cover	 the	gel)	and	5	μl	of	ethidium	bromide	 (10	mg/ml)	 for	
~30	mins.	The	gel	as	then	imaged	using	a	ChemiDoc™	MP	imaging	system	(Bio-Rad).	
	
2.2.5:	Bacterial	Transformation	for	Plasmid	Expression	
100	μl	of	XL-1	Blue	competent	E.coli	(kindly	supplied	by	Dr	Enrico	Ferrari,	University	
of	 Lincoln)	 were	 transformed	 on	 ice	 with	 either	 a	 pET	 vector	 containing	 a	 gene	
coding	 for	 recombinant	 histidine	 tagged	 GFP-NT	 (pAG3)	 or	 a	 gene	 coding	 for	
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histidine	tagged	GFP	(pJB1)	for	20	mins	 in	a	1.5	ml	eppendorf	tube.	The	Eppendorf	
tube	was	removed	and	heat	shocked	at	a	temperature	of	42°C	for	45s		on	a	heated	
block.	The	tube	was	then	replaced	on	ice	for	a	further	2	minutes.	0.5ml	of	sterile	LB	
broth	(containing	100	μg/ml	of	ampicillin)	was	then	added	to	the	tube	containing	the	
transformed	XL-1	Blue	culture	and	incubated	at	a	temperature	of	37°C	and	180	rpm	
for	 one	 hour	 to	 recover	 in	 a	 shaking	 incubator.	 Following	 recovery,	 150	 μl	 of	 the	
contents	of	 the	 tube	was	plated	onto	 LB	 agar	 (containing	100	ug/ml	of	 ampicillin)	
and	incubated	for	18hrs	at	37°C.		
	
2.2.6:	Bacterial	Culture	Expansion	
LB	agar	plates	(containing	100	ug/ml	of	ampicillin)	with	cultures	of	transformed	XL-1	
Blue	 or	 BL21	 (DE3)	 bacteria	 were	 removed	 from	 the	 37°C	 incubator	 following	
incubation	for	18hrs	as	described	in	section	2.2.5	or	2.2.8.	A	single	bacterial	colony	
was	isolated	and	used	to	inoculate	5ml	of	sterile	LB	broth	(containing	100	ug/ml	of	
ampicillin)	 in	50	ml	Falcon	 tubes.	Tubes	were	 incubated	 for	18hrs	at	37°C	and	180	
rpm	in	a	shaking	incubator.		
	
2.2.7:	Bacterial	Plasmid	Extraction	
QIAprep®	Spin	Miniprep	Kit	was	used	 for	plasmid	extraction	 (Qiagen,	UK).	Plasmid	
extraction	was	carried	out	as	stated	in	the	manufacturer’s	instructions.	The	collected	
sample	was	then	stored	at	-20°C	until	required.		
	
2.2.8:	Bacterial	Transformation	for	Protein	Expression	
100	μl	of	BL21	(DE3)	competent	E.coli	(kindly	supplied	by	Dr	Enrico	Ferrari,	University	
of	Lincoln)	were	transformed	on	ice	with	either	a	recombinant	pET	vector	containing	
a	 gene	 coding	 for	 histidine	 tagged	 GFP-NT	 (pAG3)	 or	 a	 gene	 coding	 for	 histidine	
tagged	 GFP	 (pJB1)	 for	 20	 mins	 in	 a	 1.5	 ml	 eppendorf	 tube.	 This	 procedure	 was	
carried	out	from	this	point	as	stated	in	section	2.2.5.	
	
2.2.9:	Protein	Expression	and	Induction	with	IPTG	
200	ml	of	LB	broth	was	made	up	in	2L	Erlenmeyer	flasks,	autoclaved,	left	to	cool	and	
ampicillin	was	 added	 to	 a	 final	 concentration	 of	 100	 μg/ml.	 The	 sterile	 broth	was	
then	 inoculated	 with	 a	 5	 ml	 bacterial	 culture	 as	 described	 in	 2.2.6	 and	 left	 to	
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incubate	at	37°C	at	180	rpm	until	the	optical	density	of	the	culture	was	0.4	(roughly	
2hrs).	 Culture	was	 induced	with	1	mM	 IPTG	 (Melford	 Laboratories	 Ltd)	 and	 left	 to	
incubate	at	37°C	at	180	rpm	for	a	further	8hrs.	Cultures	were	then	removed	from	the	
incubator	and	processed	prior	to	purification	as	stated	in	section	2.2.10.	
	
2.2.10:	Protein	Extraction	from	Bacterial	Cultures	
The	 original	 200	 ml	 culture	 was	 separated	 into	 4x50	ml	 samples	 in	 50	 ml	 Falcon	
tubes	and	immediately	centrifuged	at	8000g	for	10	minutes	at	4°C.	Supernatant	was	
discarded	 and	 bacterial	 pellets	 were	 resuspended	 in	 5	 ml	 of	 protein	 buffer	 with	
added	DNase	 and	protease	 inhibitors	 (50	mM	Tris,	 100	mM	NaCl,	 10	μl/ml	DNase	
and	200	μl	of	protease	inhibitor	stock	solution	(see	section	2.1.3)	at	pH	7.4).	Samples	
were	 pulse	 sonicated	 on	 ice	 for	 a	 total	 of	 5	 mins	 (5s	 on,	 5s	 off).	 Samples	 were	
centrifuged	 again	 at	 8000g	 for	 20	mins	 at	 4°C.	 Supernatant	was	 collected,	 filtered	
through	0.2	μm	pore	size	syringe	filter	and	stored	at	-80°C	until	purification	(section	
2.2.11).	
	
2.2.11:	Protein	Purification	(Immobilised	Metal	Affinity	Chromatography)	
Frozen	samples	from	section	2.2.10	were	thawed	on	ice	prior	to	purification.	100	μl	
of	 raw	 protein	 sample	was	 reserved	 for	 later	 comparison	 to	 the	 purified	 samples	
collected	 in	 this	 section.	 1	ml	 HisTrap	 HP	 columns	were	 used	 for	 purification	 (GE	
Healthcare	Life	Sciences).	 The	column	was	 initially	washed	with	5	 column	volumes	
(cv)	 of	 distilled	 water.	 Column	 was	 then	 equilibrated	 with	 5cv	 of	 protein	 buffer	
described	in	2.2.10	(minus	DNase	and	protease	inhibitors).	Protein	sample	was	then	
applied	 to	 the	column	and	washed	with	10	cv	of	protein	buffer	 containing	50	mM	
imidazole,	 collecting	 the	 flow	 through	 in	 one	 batch	 (no	 protein	 should	 have	 been	
eluted	 in	this	step).	Sample	was	then	eluted	from	the	column	with	10cv	of	protein	
buffer	containing	200	mM	imidazole	and	collected	in	1	ml	aliquots	(majority	of	the	
purified	protein	was	observed	to	be	collected	 in	the	2nd	1	ml	aliquot).	Column	was	
then	cleaned	with	10	cv	of	50	mM	imidazole	protein	buffer,	5	cv	of	distilled	water	
and	5	cv	of	20%	ethanol,	leaving	the	final	1	cv	of	20%	ethanol	in	the	column.	
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2.2.12:	Protein	Quantification	
GFP-NT	 protein	 samples	 (from	 section	 2.2.11)	 were	 quantified	 using	 a	 UV-Vis	
spectrophotometer	 and	 UV	 Probe™	 software	 (Shimadzu	 Scientific	 Instruments®).	
Protein	buffer	(see	section	2.2.10)	was	used	as	the	appropriate	blank	and	diluent	for	
samples,	 if	 dilution	 was	 required.	 Both	 sample	 and	 blank	 were	 loaded	 into	 the	
spectrophotometer	and	absorbance	was	measured	at	490	nm	(appropriate	for	eGFP).	
The	Beer-Lambert	 law	was	then	applied	to	quantify	GFP-NT	present	 in	 the	sample.	
Absorption	coefficient	of	eGFP	is	known	to	be	57,500	M-1cm-1	-	See	section	4.2.4.	F-
NT	 was	 synthesised	 and	 provided	 by	 Alta	 Biosciences©	 in	 a	 known	 amount	 and	
samples	subsequently	made	from	this	were	made	up	to	differing	concentrations	(as	
required)	 from	 this	 known	 value.	 Quantification	 of	 F-NT	was	 not	 required	 for	 this	
reason.	
	
2.2.13:	SDS-PAGE	
The	Hoefer®	 small	 format	 vertical	protein	electrophoresis	 system	was	used	 for	 this	
procedure.	1	mm	gels	were	made	as	stated	in	table	2.1.	10%	APS	was	made	on	the	
day	 of	 use.	 Resolving	 gels	 were	 made	 as	 10%	 acrylamide	 composites.	 10	 ml	 of	
resolving	gel	and	5	ml	of	stacking	gel	was	enough	to	yield	two	complete	gels.		
Table	2.1:	Composition	of	resolving	gels	(10%)	and	stacking	gels	as	recommended	by	Thermo	
Scientific®.	
	
Glass	plates	and	spacers	were	assembled	in	the	supplied	gel-casting	frame,	ensuring	
the	 contact	 between	 the	 plates	 was	 adequate	 to	 prevent	 leaks;	 this	 was	 simply	
tested	with	water	and	 removed	with	 filter	paper.	Components	of	 the	 resolving	gel	
Resolving	Gel	 Volume	required	to	make	10	ml	of	10%	resolving	
gel	
Deionised	water	 4.13	ml	
30%	Acrylamide/bisacrylamide	 3.3	ml	
1.5	M	Tris-HCl	containing	0.4%	SDS	(pH	8.8)	 2.5	ml	
10%	APS	 60	μl	
TEMED	 13	μl	
Stacking	Gel	 Volumes	required	to	make	5	ml	of	stacking	gel	
Deionised	water	 3	ml	
30%	Acrylamide/bisacrylamide	 700	μl	
0.5	M	Tris-HCl	containing	0.4%	SDS	(pH	6.8)	 1.25	ml	
10%	APS	 25	μl	
TEMED	 20	μl	
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were	combined	in	50	ml	falcon	tubes	(adding	APS	and	TEMED	last),	inserted	into	the	
apparatus	(leaving	space	for	the	resolving	gel)	and	left	to	polymerise	for	~30	mins	–	
surplus	gel	in	the	falcon	tubes	indicated	when	polymerisation	had	been	achieved.	A	
layer	of	distilled	water	was	immediately	placed	on	top	of	the	gel	line	to	prevent	any	
differences	in	gel	texture	forming	between	the	gel	exposed	to	air	and	the	main	body	
of	the	gel	as	this	could	affect	migration	of	the	samples.	Components	of	the	stacking	
gel	were	then	combined	and	added	to	the	surface	of	the	polymerised	resolving	gel	
and	 the	 comb	 was	 inserted	 after	 removal	 of	 the	 distilled	 water.	 This	 was	 left	 to	
polymerise	 for	 a	 further	 30	 mins.	 The	 set	 gel	 encased	 in	 glass	 plates	 was	 then	
transferred	 from	 the	 gel	 caster	 to	 the	 electrophoresis	 tank	 and	 submerged	 in	
running	buffer	(see	table	2.2).	
	
Buffer	 Components	
	
SDS	running	buffer	(500	ml)	
7.2	g	Glycine	
1.5	g	Tris	
5	ml	of	10%	SDS	solution	
Make	up	to	500	ml	with	deionised	water	
	
	
SDS	loading	buffer	(10	ml)	
4.8	ml	sterile	distilled	water	
1.2	ml	0.5M	Tris	pH	6.8	
1	ml	glycerol	
2	ml	10%	SDS	solution	
0.5	ml	0.1%	Bromophenol	blue	
0.5	ml	β-mercaptoetanol	
	
Coomassie	Blue	(1	L)	
250	ml	propan-2-ol	
100	ml	acetic	acid	
650	ml	deionised	water	
2	g	Coomassie	Brilliant	Blue	
	
Destain	(5	L)	
250	ml	propan-2-ol	
350	ml	acetic	acid		
Made	up	to	5	L	with	deionised	water	
Table	2.2:	Composition	of	buffers	and	imaging	reagents	used	for	SDS-PAGE	
	
10	μl	of	each	sample	was	paired	with	10	μl	of	loading	buffer	(see	table	2.2)	in	1.5	ml	
eppendorf	 tubes	 and	 heated	 to	 100°C	 for	 five	minutes	 to	 denature	 protein	 in	 the	
sample.	 Samples	 was	 left	 to	 cool	 and	 centrifuged	 at	 ~17,900g	 (13,000rpm)	 on	 a	
bench	 top	microcentrifuge	 for	60	 seconds	 to	ensure	all	 contents	of	 the	 tube	were	
collected	at	the	bottom	of	the	tube	prior	to	running	the	sample	on	the	gel.	The	comb	
was	removed	from	the	gel	(ensuring	no	air	entered	the	wells).	15	μl	of	sample	was	
loaded	into	each	well	of	the	gel.	10	μl	of	ColorPlus	prestained	protein	ladder,	broad	
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range	10-230	kDa	(NEB,	UK)	was	also	loaded	onto	the	gel	for	reference	(if	the	protein	
ladder	 differs	 from	 this,	 it	 is	 stated	 in	 the	 appropriate	 figure	 legend).	 Once	 all	
samples	were	loaded,	the	gel	was	run	at	150	V	until	the	dye	front	had	reached	the	
bottom	of	 the	gel	 (approximately	45	mins).	The	power	was	disconnected	 from	the	
tank,	 gels	 removed	 from	 the	 apparatus	 and	 separated	 from	 the	 stacking	 gel,	 and	
submerged	in	Coomassie	Blue	stain	(see	table	2)	for	30	minutes	on	a	platform	rocker.	
The	gel	was	then	rinsed	in	deionised	water	and	resubmerged	in	destain	solution	(see	
table	 2	 for	 composition)	 for	 30	 mins,	 followed	 by	 a	 second	 submersion	 in	 fresh	
destain	 until	 appropriately	 destained.	 The	 gel	 was	 then	 imaged	 in	 either	 a	
ChemiDoc™	 MP	 system	 (Bio-Rad)	 or	 digital	 camera	 (mounted	 on	 a	 light	 box)	
dependant	on	the	intensity	of	the	bands	present	on	the	gel.		
	
2.2.14:	Preparation	of	Protein	Samples	
Model	drugs	GFP-NT	and	GFP	 (as	 a	negative	 control	 to	GFP-NT)	were	produced	 in	
house	 by	 recombinant	 expression	 in	 E.coli,	 purified	 and	 quantified	 before	 being	
aliquoted	in	50μl	fractions.	The	amount	of	protein	expressed	from	each	batch	of	the	
procedure	 conducted	 was	 variable;	 hence	 the	 final	 concentrations	 of	 the	 protein	
stocks	were	variable	also	(however,	never	 less	than	50	μM).	Hence,	the	amount	of	
protein	used	 from	each	stock	was	variable	dependant	on	the	concentration.	These	
aliquots	were	stored	at	-80°C.	An	aliquot	of	each	protein	was	taken	from	the	-80°C	
freezer	and	defrosted	on	ice	to	elongate	the	thawing	process	and	protect	structural	
integrity.	 Stock	 concentrations	 of	 human	 neurotensin	 (NT)	 and	 SR142948	 were	
prepared	 from	 the	 anhydrous	 forms	 received	 from	 Sigma	 Aldrich	 and	 Tocris	
Bioscience	 respectively.	 Appropriate	 amounts	 of	 each	 stock	 solution	 were	 added	
into	HBSS	to	yield	the	desired	concentration	of	each	protein	sample.	SR142948	was	
used	 at	 a	 final	 concentration	 10x	 that	 of	 the	 concentration	 of	 conjugated	
fluorophore	sample	present	in	the	same	solution	(e.g	10x	more	SR142948	than	GFP-
NT).	NT	was	 used	 at	 a	 final	 concentration	 100x	 that	 of	 the	 protein	 present	 in	 the	
same	sample.	GFP-NT	and	GFP	concentrations	ranged	from	10	nM	-	1	μM	during	the	
proceedings	of	this	study.	NT-bound	fluorescein	(F-NT)	was	also	used	in	this	study,	as	
synthesised	and	 supplied	by	Alta	Biosciences®	 in	 lyophilised	 form.	Protein	 samples	
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containing	F-NT	were	prepared	as	replicates	 in	concentration	and	 inhibitor	content	
as	the	original	GFP-NT	samples.	
	
2.2.15:	Routine	Cell	Culture	
Note:	 all	methods	 referring	 to	 tissue	 culture	were	 performed	 in	 sterile	 conditions	
within	an	appropriate	laminar	flow	tissue	culture	hood,	sterilising	all	materials	used	
with	70%	ethanol.		Both	Caco-2	and	HEK293	cell	lines	were	routinely	cultured	in	75	
cm2	 flasks	 at	 5%	 CO2,	 95%	 relative	 humidity	 and	 37°C.	 Flasks	 were	 cultured	 until	
confluence	was	reached	(~70%	for	HEK293,	70-90%	for	Caco-2).	Both	cell	lines	were	
cultured	 in	 10-12	 ml	 of	 complete	 culture	 medium	 (DMEM)	 as	 described	 in	 2.1.1.		
During	the	time	taken	to	reach	confluence,	complete	culture	medium	was	replaced	
every	two	days.	Media	was	pre-warmed	to	37°c	before	introduction	to	the	cells.	Cell	
growth	was	regularly	monitored	by	observation	under	a	light	microscope.	Cells	were	
passaged	 by	 removing	 the	 culture	medium	 by	 aspiration,	washing	 the	 cells	 gently	
with	 PBS	 (~5	ml	 is	 sufficient	 to	 remove	 any	 dead	 cells	 and	 remaining	media)	 and	
applying	 3	ml	 of	 Trypsin/EDTA	 solution	 (See	 section	 2.1.1)	 to	 the	 cells	 for	 75	 cm2	
flask.	Flasks	were	then	incubated	at	5%	CO2,	95%	relative	humidity	and	37°C	for	~2	
mins	for	HEK293	cells	(as	they	are	a	weakly	adherent	cell	line),	and	~5	mins	for	Caco-
2.		Flasks	were	examined	using	a	light	microscope	to	evaluate	detachment	from	the	
flask.	If	the	cells	were	not	adequately	detached,	they	were	replaced	in	the	incubator	
for	 a	 further	 2-3	 mins	 and	 re-evaluated.	 Following	 detachment,	 the	 total	 flask	
volume	was	topped-up	with	complete	culture	medium	to	10	ml	and	gently	pipetted	
up	and	down	to	homogenise	the	cell	mixture.	This	dilutes	the	cells	and	deactivates	
the	 trypsin.	 1-3	 ml	 of	 Caco-2	 cells	 (dependent	 on	 when	 confluency	 was	 next	
required)	 or	 1-2	 ml	 of	 HEK293	 cell	 added	 to	 a	 new	 75	 cm2	 flask	 containing	 the	
appropriate	 amount	 of	 pre-warmed	 complete	 culture	 medium	 to	 bring	 the	 total	
volume	up	to	12	ml.		
	
2.2.16:	Cryopreservation	of	Cells	
Cells	were	cultured	to	confluence	and	detached	from	the	culture	flask	as	described	
in	section	2.2.15.	At	the	stage	where	the	cells	had	been	detached	with	trypsin/EDTA	
(see	 section	 2.1.1)	 solution	 and	 diluted	with	 complete	media,	 the	 contents	 of	 the	
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flask	 were	 transferred	 to	 a	 50	 ml	 Flacon	 tube	 and	 centrifuged	 at	 200g	 for	 five	
minutes.	The	supernatant	was	then	removed	and	the	cells	were	resuspended	in	1	ml	
of	complete	media	containing	10%	DMSO.	The	cells	were	then	added	to	sterile	1.5	
ml	Nalgene™	 cryogenic	 tubes	 (clearly	 labelled	with	 the	 date,	 cell	 line	 and	passage	
number).	 Cryovials	 were	 transferred	 to	 a	 -20°C	 freezer	 for	 one	 hour,	 followed	 by	
incubation	over	night	at	-80°C	before	addition	to	liquid	nitrogen	dewars	for	storage.	
The	freezing	procedure	was	stepped	in	this	way	to	ensure	gradual,	rather	than	fast,	
freezing.	
	
2.2.17:	Revival	of	Cells	
Note:	this	procedure	was	conducted	as	quickly	as	possible	to	ensure	maximum	cell	
survival.	All	equipment	and	reagents	required	for	this	procedure	were	prepared	prior	
to	 collection	of	 the	 cells	 from	 liquid	 nitrogen.	 Cryovials	were	 removed	 from	 liquid	
nitrogen	 and	 immediately	 placed	 in	 a	 37°C	 waterbath	 for	 5	 mins	 to	 thaw.	 Vial	
contents	 were	 transferred	 to	 a	 sterile	 15	 ml	 Falcon	 tube	 containing	 5	 ml	 of	 pre-
warmed	 complete	 media	 and	 centrifuged	 at	 200g	 for	 5	 mins	 to	 remove	 DMSO-
containing	media.	The	supernatant	was	removed	and	cells	were	resuspended	in	5	ml	
of	 culture	 media.	 This	 cell	 suspension	 was	 then	 added	 to	 a	 new	 75	 cm2	 flask	
containing	7	ml	of	pre-warmed	culture	media.	The	 flask	was	 then	 incubated	at	5%	
CO2,	95%	relative	humidity	and	37°C.		
	
2.2.18:	Counting	Cells	
Cells	were	cultured	to	confluence	and	detached	from	the	culture	flask	as	described	
in	section	2.2.15.	At	the	stage	where	the	cells	have	been	detached	with	trypsin/EDTA	
solution	and	diluted	with	complete	media,	10	μl	of	cell	suspension	was	collected	and	
combined	with	10	μl	of	Trypan	blue	solution.	10	μl	of	this	mixture	was	then	applied	
to	a	haemocytometer	and	counted	under	a	 light	microscope	(x10	magnification)	as	
follows:	 chamber	 and	 cover	 slip	 of	 the	 haemocytometer	 were	 cleaned	 with	 70%	
ethanol,	cells	were	loaded	onto	the	haemocytometer	and	live	cells	were	counted	in	
all	 four	 of	 the	 4x4	 grids	 of	 the	 haemocytometer.	 Trypan	 blue	 allowed	 for	
differentiation	between	dead	and	 live	cells	as	dead	cells	 take	up	the	blue	dye,	 live	
cells	do	not).	The	number	obtained	was	then	doubled	(to	account	for	the	trypan	blue	
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dilution)	 and	 divided	 by	 four	 to	 obtain	 the	 average	 number	 of	 cells	 per	 grid.	 This	
number	x104	is	equal	to	the	number	of	cells	per	1	ml	of	cell	suspension.	
	
2.2.19:	Culture	of	Caco-2	Cells	On	Transwells®	
Caco-2	only	were	detached	from	the	culture	flask	as	described	in	section	2.2.15	and	
counted	 as	 described	 in	 section	 2.2.18.	 Each	 well	 was	 seeded	 with	 0.5	 ml	 of	
complete	media	containing	1x105	cells	on	the	apical	side	of	the	transwell®	filter.	1.5	
ml	of	complete	media	was	added	to	the	basal	side	of	the	filter.	The	day	of	seeding	
was	considered	to	be	day	0.	Cells	were	routinely	grown	to	21-24	days,	with	media	
replaced	every	two	days.	The	media	was	replaced	as	follows:	media	on	the	basal	side	
of	 the	 transwell®	 was	 first	 aspirated	 for	 all	 12	 wells,	 followed	 by	 the	 apical	 side.	
Fresh	media	was	then	added	to	the	apical	first,	followed	by	the	basal	side.	Replacing	
the	media	in	this	manner	ensures	minimal	drying	out	of	the	cellular	monolayer.	TEER	
measurements	were	used	to	assess	cell	growth	(as	described	in	section	2.2.20).		
	
2.2.20:	Measurement	of	TEER	
Trans-Epithelial	 Electrical	 Resistance	 (TEER)	 was	 measured	 to	 monitor	 cellular	
growth	of	Caco-2	cells	 in	Transwells®.	This	was	a	non-invasive	method	 to	evaluate	
the	 confluence	 of	 the	 cells	 and	 the	 integrity	 of	 intercellular	 tight	 junctions.	 TEER	
measurement	apparatus	is	depicted	in	figure	2.1.		
	
	
	
	
	
	
	
Figure	2.1:	Apparatus	used	to	determine	TEER	and	arrangement	of	Transwell®	supports.	
	
The	 chopstick	 electrodes	were	 first	 submerged	 in	 absolute	 ethanol	 for	 30	mins	 to	
sterilise,	 and	 washed	 with	 sterile	 water	 to	 remove	 any	 residual	 ethanol.	 The	
chopsticks	were	 then	 left	 to	 air	 dry	 (care	was	 taken	 to	 not	 allow	 the	 ends	 of	 the	
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electrodes	to	touch	any	surfaces)	before	being	 inserted	into	the	media	bathing	the	
cells	in	each	well	of	the	Transwell®.	The	short	end	of	the	electrode	was	submerged	
into	the	apical	side	of	 the	filter	 (taking	care	not	to	disrupt	the	cell	monolayer)	and	
the	 longer	 end	 was	 submerged	 into	 the	 basal	 side.	 The	 electrode	 was	 held,	
submerged	 in	 the	media	 for	 a	 few	 seconds	 until	 the	 resistance	 reading	 (in	 Ωcm2)	
stabilised	 on	 a	 single	 figure.	 The	 electrode	 was	 then	 gently	 removed	 and	 the	
resistance	of	that	well	was	recorded	in	a	table.	During	initial	culture	of	Caco-2	cells	in	
this	manner,	the	TEER	of	each	Transwell®	was	measured	every	other	day	from	day	2	
to	21	 (the	 final	 reading	 indicated	cellular	 integrity	prior	 to	experimentation	on	 the	
same	day).	Daily	measurements	were	not	taken	to	limit	potential	damage	to	the	cells	
caused	by	the	process.	Experiments	were	conducted	on	day	21	on	culture,	resistance	
on	this	day	was	typically	~2000	Ω/cm2.	
	
2.2.21:	Culture	of	Cells	on	12	Well	Plates	
As	 HEK293	 cells	 are	 weakly	 adherent,	 they	 were	 grown	 on	 poly-l-lysine	 coated	
coverslips	 in	 12	well	 plates.	 Coating	 of	 the	 coverslips	 was	 performed	manually	 as	
follows:	one	coverslip	was	placed	inside	each	well	of	the	plate	and	rinsed	with	sterile	
deionised	water.	 The	water	was	 then	 aspirated	 and	 left	 to	 air	 dry.	 0.5	ml	 of	 0.1%	
poly-l-lysine	 solution	 was	 then	 added	 to	 each	 well	 and	 manually	 swirled	 for	 five	
minutes	 to	 ensure	 an	 even	 coating	 was	 achieved.	 The	 poly-l-lysine	 was	 then	
removed	and	the	coverslips	were	thoroughly	washed	with	sterile	deionised	water	(5	
times)	and	left	to	air	dry	for	at	least	3hrs.	Caco-2/HEK293	cells	were	detached	from	
their	culture	flasks	as	described	in	section	2.2.15	and	counted	as	described	in	section	
2.2.18.	1x105	cells	were	seeded	 in	each	well	 in	a	 total	volume	of	1	ml	of	complete	
media	(this	applied	to	both	Caco-2	and	HEK293).	The	plates	were	then	incubated	at	
5%	CO2,	95%	relative	humidity	and	37°C	for	48	hours	prior	to	experiments.		
	
2.2.22:	Light	Microscopy	
75	cm2	culture	flasks	containing	Caco-2	or	HEK293	cells	were	grown	as	described	in	
section	 2.2.15.	 Flasks	 were	 placed	 on	 the	 stage	 of	 a	 light	microscope	 and	 images	
were	taken	using	a	Nikon	DN100	digital	camera	control	unit	and	Nikon	Eclipse	TS100	
light	 microscope.	 Images	 were	 magnified	 using	 a	 x10	 objective	 lens.	 A	 specific	
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confluency	 of	 the	 cells	 was	 not	 required	 as	 this	 was	 purely	 for	 the	 purposes	 of	
qualitative	evaluation	of	cellular	health.		
	
2.2.23:	Transfection	Procedure	(HEK293	Only)	
Only	HEK293	 cells	 grown	 in	 12	well	 plates	were	 transfected.	 Lipofectamine®	 2000	
Transfection	 reagent	 was	 used	 for	 this	 procedure,	 supplied	 by	 Thermo	 Fisher	
Scientific.	 The	 NTS1	 containing	 plasmid	 (pcDNA3.1-NTS1,	 from	 cDNA.org)	 was	
supplied	 by	 Dr	 Alan	 Goddard	 and	 quantified	 using	 the	 NanoDrop	 2000	 (Thermo	
Scientific).	This	procedure	was	optimised	as	described	in	section	3.2.2	–	resulting	in	
the	use	of	4	μl	of	Lipofectamine	per	well	of	cells.	1	μg	of	DNA	was	used	per	well	of	
cells.	The	procedure	was	conducted	as	 follows	and	 is	sufficient	 to	transfect	one	12	
well	plate	of	cells:	~12	μl	(dependant	on	amount	needed	for	12	μg	of	DNA)	of	DNA	
was	pipetted	into	240	μl	of	serum	and	antibiotic/antifungal	solution-free	DMEM.	The	
mixture	was	homogenised	by	vortexing.	48	μl	of	Lipofectamine	was	 then	added	to	
the	DNA/DMEM	mixture	and	 left	 to	 incubate	at	 room	 temperature	 for	60	mins	 to	
form	DNA-containing	liposomes.	This	mixture	totalled	300	μl	in	volume.	The	media	in	
each	well	of	the	plate	was	replaced	with	reduced	serum	media	(5%	FBS)	and	25	μl	of	
the	transfection	mixture	was	then	pipetted	into	each	well	of	the	plate.	The	plate	was	
then	incubated	at	5%	CO2,	95%	relative	humidity	and	37°C	for	24	hrs	before	use	in	
experiments.		
	
2.2.24:	Immunostaining	of	Transwells®	(Caco-2	Only)	
Caco-2	cells	were	grown	for	21	days	as	described	in	section	2.2.19	and	evaluated	for	
monolayer	 integrity	 as	 described	 in	 section	 2.2.6.	 The	 contents	 of	 each	well	were	
then	aspirated,	followed	by	two	washes	with	PBS.	The	cell	monolayer	(on	the	apical	
side	of	the	Transwell®	filter)	was	then	fixed	with	200	μl	of	4%	paraformaldehyde	in	
PBS	for	30	mins	at	room	temperature.	After	30	mins	of	fixation,	the	monolayer	was	
washed	3	times	with	PBS	and	incubated	for	one	hour	with	0.5	ml	of	1%	bovine	serum	
albumin	(BSA)	at	room	temperature	as	a	non-specific	binding	blocking	step.	A	1:5000	
dilution	of	the	primary	antibody	(Rabbit	Anti-Human	NTS1)	was	prepared	in	1%	BSA	
in	PBS	as	recommended	by	the	supplier	(Thermo	Scientific).	Optimisation	of	primary	
antibody	 dilution	 was	 carried	 out	 and	 1:5000	 was	 found	 to	 be	 sufficient.	 After	
incubation	with	blocking	solution,	the	contents	of	the	well	were	aspirated	and	each	
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monolayer	was	 incubated	with	300	μl	of	primary	antibody	solution	for	one	hour	at	
room	temperature.	Primary	antibody	solution	was	omitted	for	the	negative	controls	
and	 replaced	 with	 antibody	 diluent	 solution.	 Each	 monolayer	 was	 then	 washed	
thoroughly	with	PBS	3	 times,	and	 incubated	 for	one	hour	with	0.5	ml	of	goat	anti-
rabbit	 AlexaFluor®488	 at	 a	 dilution	 of	 1:800	 in	 1%	 BSA	 in	 PBS.	 The	 secondary	
antibody	 solution	was	 then	 removed	 and	 each	monolayer	was	washed	 thoroughly	
with	PBS	five	times.	The	filters	from	each	Transwell®	(containing	the	immunostained	
cellular	monolayer)	was	then	excised	from	the	attached	plastic	insert	with	a	scalpel	
and	mounted	on	a	glass	slide,	taking	care	to	mount	the	membrane	as	flat	as	possible,	
monolayer	 side	 facing	 up.	 The	 monolayer	 was	 then	 covered	 with	 two	 drops	 of	
Fluoroshield™	with	DAPI	mounting	medium	and	covered	with	glass	cover	slips.	The	
slides	were	then	left	to	dry	overnight	and	assessed	by	confocal	microscopy.	
	
2.2.25:	Immunostaining	of	12	Well	Plates	
Caco-2	and	HEK293	cells	were	grown	until	~70%	confluency	as	described	in	section	
2.2.21.	The	contents	of	each	well	were	then	aspirated,	followed	by	two	washes	with	
PBS.	The	cell	monolayer	was	then	fixed	with	0.5	ml	of	4%	paraformaldehyde	in	PBS	
for	 30	 minutes	 at	 room	 temperature.	 After	 30	 minutes	 of	 fixation,	 the	 well	 was	
washed	3	times	with	PBS	and	incubated	for	one	hour	with	0.5	ml	of	1%	bovine	serum	
albumin	(BSA)	at	room	temperature	as	a	non-specific	binding	blocking	step.	A	1:5000	
dilution	of	the	primary	antibody	(Rabbit	Anti-Human	NTS1)	was	prepared	in	1%	BSA	
in	PBS	as	recommended	by	the	supplier	(Thermo	Scientific).	Optimisation	of	primary	
antibody	 dilution	 was	 carried	 out	 and	 1:5000	 was	 found	 to	 be	 sufficient.	 After	
incubation	with	blocking	solution,	the	contents	of	the	well	were	aspirated	and	each	
well	was	 incubated	with	0.5	ml	of	primary	antibody	solution	 for	one	hour	at	 room	
temperature.	Primary	antibody	 solution	was	omitted	 for	 the	negative	controls	and	
replaced	with	antibody	diluent	solution.	Each	well	was	then	washed	thoroughly	with	
PBS	 3	 times,	 and	 incubated	 for	 one	 hour	 with	 0.5	 ml	 of	 goat	 anti-rabbit	
AlexaFluor®488	 at	 a	 dilution	 of	 1:800	 in	 1%	 BSA	 in	 PBS.	 The	 secondary	 antibody	
solution	was	 then	 removed	and	each	monolayer	was	washed	 thoroughly	with	PBS	
five	 times.	 The	 coverslip	 from	 each	 well	 was	 then	 removed	 from	 the	 well	 with	 a	
scalpel	 and	 placed	 on	 a	 glass	 slide,	 cell-covered	 side	 facing	 up.	 The	 coverslip	was	
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then	 coated	 with	 two	 drops	 of	 Fluoroshield™	 with	 DAPI	 mounting	 medium	 and	
topped	with	a	square	glass	cover	slip.	The	slides	were	then	left	to	dry	overnight	and	
imaged	by	confocal	microscopy.	
	
2.2.26:	Confocal	Microscopy	
The	Leica	TCS	SP8	confocal	microscope	was	used	for	qualitative	assessment	of	NTS1	
expression	 in	 HEK293	 cells,	 transfected	 HEK293	 cells	 and	 Caco-2	 cells.	 Pre-
programmed	 settings	 in	 the	 LAS-AF	 programme	 for	 DAPI	 (at	 gain	 600)	 and	
AlexaFluor®488	(at	gain	750)	were	used	to	detect	fluorescence	of	both	components	
of	the	immunostain.	DAPI	stains	for	nucleic	acids	and	so	showed	the	position	of	the	
nucleus	and	AlexaFluor®488	indicated	the	presence	of	human-NTS1	receptors	on	the	
cell	 membrane.	 The	 gain	 of	 the	 lasers	 was	 kept	 constant	 for	 DAPI	 and	
AlexaFluor®488	in	all	immunostained	sections	imaged	by	confocal	microscopy	in	this	
study	 unless	 stated	 otherwise	 in	 the	 accompanying	 figure	 legend.	 The	 Z	 stack	
function	was	used	to	obtain	any	3D	images	displayed	in	this	study	
	
2.2.27:	Evaluation	of	Cellular	Growth	in	Transwells®	
Transwells®	 were	 seeded	 as	 described	 in	 section	 2.2.19	 with	 Caco-2	 cells.	 TEER	
readings	(see	section	2.2.20)	were	taken	every	two	days	for	the	full	duration	of	their	
growth	 (21	 days)	 and	 plotted	 on	 a	 line	 graph	 to	 assess	 their	 growth	 rate.	 TEER	
measurements	 were	 taken	 prior	 to	 any	 experimentation	 with	 the	 Transwell®	 to	
ensure	 structural	 integrity	of	 the	 cell	monolayer.	 TEER	was	measured	 immediately	
after	being	taken	out	of	the	 incubator	 (as	 incubation	periods	at	room	temperature	
affect	the	TEER	reading).	This	continuity	allowed	for	reliable	comparison	of	data	to	
track	the	growth	of	the	cells	and	integrity	of	intercellular	tight	junctions.			
	
2.2.28:	Evaluation	of	Cellular	Growth	in	12	Well	Plates	
Cells	were	 grown	 in	 12-well	 plates	 as	 described	 in	 section	 2.2.21.	 Caco-2,	 HEK293	
and	transfected	HEK293	were	assessed	 in	this	procedure.	Transfected	HEK293	cells	
were	transfected	24	hrs	before	this	procedure.	48	hrs	after	seeding,	growth	media	
was	removed	and	cells	were	washed	and	detached	from	the	coverslips	in	each	well	
with	 200	μl	 of	 trypsin,	 incubated	 at	 5%	CO2,	 95%	 relative	 humidity	 and	 37°C	 until	
detached	(2	mins	for	HEK293/5	mins	Caco-2).	Each	well	was	then	topped	up	to	1	ml	
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by	 adding	 800	μl	 of	 complete	media.	 This	mixture	was	 not	 centrifuged	 to	 remove	
trypsin	as	the	centrifugation	process	may	have	compromised	cellular	integrity.	10	μl	
of	each	cell	line	(transfected	and	non-transfected	for	HEK293)	was	then	mixed	with	
10	μl	of	trypan	blue	and	counted	using	a	haemocytometer	(see	section	2.2.18).	The	
number	of	viable	cells	was	compared	against	the	number	of	dead	cells	to	assess	cell	
viability	after	48	hours	of	growth.	
	
2.2.29:	Protein	Transport	Studies	in	Transwells®	
TEER	 was	 measured	 in	 each	 well	 prior	 to	 experimentation	 to	 ensure	 structural	
integrity	of	the	cell	monolayer,	this	was	typically	~2000	Ω/cm2	(see	section	2.2.20).	If	
the	resistance	measured	in	any	of	the	wells	were	significantly	different,	that	well	was	
not	used	for	experimentation.	Each	well	of	the	transwell®	was	then	incubated	at	5%	
CO2,	 95%	 relative	 humidity	 and	 37°C	 in	 pre-warmed	 HBSS	 for	 at	 least	 30	mins	 to	
acclimatise	 to	 the	 change	 in	 media.	 Samples	 of	 GFP-NT	 of	 GFP	 (with	 or	 without	
inhibitors	 NT	 and	 SR142948)	 as	 described	 in	 section	 2.2.14,	 were	 prepared	 at	
variable	concentrations	in	HBSS.	Contents	of	the	wells	were	gently	aspirated	and	0.5	
ml	of	an	appropriate	protein	sample	was	then	applied	to	the	apical	side	of	the	cell	
monolayer	and	1.5	ml	of	fresh	HBSS	was	added	to	the	basal	side.	A	100	μl	sample	of	
HBSS	from	the	basal	side	of	the	transwell®	was	taken	immediately	after	introduction	
of	the	protein	samples	(to	the	apical	side)	as	a	measure	of	protein	transport	through	
the	monolayer	at	time	0	mins.	This	was	done	to	ensure	there	were	no	 leaks	 in	the	
polycarbonate	 filter	 or	 cellular	 monolayer	 affecting	 the	 data	 obtained.	 100	 μl	 of	
fresh	HBSS	was	then	added	to	the	basal	side	to	replace	that	taken	for	the	previous	
sample.	100	μl	samples	were	then	taken	every	30	mins	for	three	hours,	replacing	the	
volume	 of	 sample	 taken	 with	 fresh	 HBSS	 each	 time.	 Between	 samples,	 the	
Transwell®	was	returned	to	the	incubator	each	time	and	covered	with	aluminium	foil	
to	protect	the	fluorescent	protein	samples	from	light.	Care	was	taken	to	ensure	the	
external	 environment	 was	 as	 dark	 as	 possible.	 Each	 sample	 was	 loaded	 into	 an	
appropriate	 well	 of	 a	 black	 96	 well	 plate	 and	 stored	 in	 the	 dark	 at	 4°C	 between	
sampling	times.	After	three	hours,	the	plate	was	read	for	fluorescence	(Fluorescein	-
ex:	490	nm,	em:	525	nm/GFP	–	ex:	488	nm,	em:	509	nm)	using	the	Tecan	Infinite®	Pro	
200	microplate	reader	at	gain	100.	
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2.2.30:	Protein	Uptake	Studies	in	Transwells®	
TEER	 was	 measured	 in	 each	 well	 prior	 to	 experimentation	 to	 ensure	 structural	
integrity	of	the	cell	monolayer,	this	was	typically	~2000	Ω/cm2	(see	section	2.2.20).	If	
the	resistance	measured	in	any	of	the	wells	were	significantly	different,	that	well	was	
not	used	for	experimentation.	Each	well	of	the	transwell®	was	then	incubated	at	5%	
CO2,	 95%	 relative	 humidity	 and	 37°C	 in	 pre-warmed	 HBSS	 for	 at	 least	 30	mins	 to	
acclimatise	 to	 the	 change	 in	 media.	 Samples	 of	 GFP-NT	 of	 GFP	 (with	 or	 without	
inhibitors	 NT	 and	 SR142948)	 as	 described	 in	 section	 2.2.14,	 were	 prepared	 at	
variable	concentrations	in	HBSS.	The	HBSS	was	then	gently	aspirated	from	the	wells	
(both	apical	and	basal	sides)	and	0.5	ml	of	an	appropriate	protein	sample	(GFP-NT)	
etc.	in	HBSS)	was	then	applied	to	the	apical	side	of	the	cell	monolayer	and	1.5	ml	of	
fresh	HBSS	was	added	to	the	basal	side.	One	filter	of	each	protein	sample	condition	
tested	was	 immediately	 transferred	 to	 a	 fresh	 12	well	 plate	 (to	 represent	 cellular	
uptake	at	time	0)	and	the	remaining	wells	in	the	original	transwell®	were	covered	in	
aluminium	 foil	 and	 replaced	 in	 the	 incubator.	 The	 samples	 transferred	were	 then	
aspirated	of	previous	contents	and	washed	3	times	by	swirling	with	cold	(4°C)	PBS.	
The	 temperature	 of	 the	 PBS	 halted	 any	 cellular	 transport	 of	 the	 protein	 sample.	
200μl	of	0.1%	Triton-X	100	in	protein	buffer	(200	mM	Tris,	50	mM	NaCl	with	200	μl	
of	 25x	 complete	 protease	 inhibitor	 stock	 solution	 (see	 section	 2.1.3))	 was	 then	
added	to	the	apical	side	of	the	cell	monolayer	(to	permeabilise	the	cells)	and	left	to	
incubate	at	room	temperature	for	30	minutes	(taking	care	to	not	expose	samples	to	
light).	 After	 incubation,	 the	 contents	 of	 each	well	 were	 pipetted	 up	 and	 down	 to	
detach	cells	from	the	filter	and	homogenise	contents,	before	being	transferred	to	a	
1.5	ml	eppendorf	and	stored	at	4°C	in	the	dark	until	required	for	quantification.	This	
was	repeated	 for	each	protein	sample	condition	every	30	minutes	 for	2.5	hours	 to	
represent	 protein	 uptake	 at	 times:	 0.5,	 1,	 1.5,	 2	 and	 2.5	 hrs.	 Care	 was	 taken	 to	
ensure	the	external	environment	was	as	dark	as	possible.	Once	all	samples	had	been	
collected,	 samples	 were	 centrifuged	 at	 17,900g	 (13,000	 rpm)	 in	 a	 bench	 top	
centrifuge	to	extrude	cellular	debris.	The	supernatant	(100	μl)	was	then	loaded	into	
appropriate	wells	of	a	black	96	well	plate	and	read	for	fluorescence	(Fluorescein	-ex:	
490	nm,	em:	525	nm/GFP	–	ex:	488	nm,	em:	509	nm)	using	the	Tecan	Infinite®	Pro	
200	microplate	reader	at	gain	100.	
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2.2.31:	Protein	Uptake	Studies	in	12	Well	Plates	
Cells	were	seeded	 in	 the	12	well	plate	as	described	 in	section	2.2.21.	After	48	hrs,	
the	contents	of	the	wells	were	aspirated	and	the	wells	were	incubated	with	1	ml	of	
pre-warmed	HBSS	to	acclimatise	to	new	media	and	remove	any	dead	cells.	Note:	the	
previous	step	was	required	to	be	performed	gently	with	HEK293	cells,	as	they	are	a	
weakly	adherent	cell	 line.	Samples	of	GFP-NT	or	GFP	(with	or	without	inhibitors	NT	
and	 SR142948)	 as	 described	 in	 section	 2.2.14,	 were	 prepared	 at	 variable	
concentrations	in	HBSS.	1	ml	of	the	appropriate	protein	sample	was	added	to	each	of	
the	wells	and	incubated	at	5%	CO2,	95%	relative	humidity	and	37°C	for	1	hr,	taking	
care	to	protect	the	plate	from	light.	Following	incubation,	contents	of	the	wells	were	
aspirated	 and	 the	wells	were	washed	with	 cold	 (4°C)	 PBS	 3	 times.	 Each	wash	was	
performed	for	five	minutes	whilst	being	gently	rocked	to	ensure	complete	coverage	
of	the	cells.	After	washing	the	cells,	they	were	incubated	with	200	μl	of	0.1%	Triton-X	
100	 in	 protein	 buffer	 (200	 mM	 Tris,	 50	 mM	 NaCl	 with	 200	 μl	 of	 25x	 complete	
protease	 inhibitor	 stock	 solution)	 for	 30	 mins	 at	 room	 temperature	 whilst	 being	
protected	from	light.	Following	this,	the	contents	of	the	well	were	pipetted	up	and	
down	 to	 ensure	 detachment	 of	 the	 cells	 from	 the	 wells	 and	 homogenise	 the	
contents	of	the	well.	Each	sample	was	then	transferred	to	a	1.5	ml	eppendorf	tube	
and	 centrifuged	at	 17,900g	 (13,000rpm)	 for	 5	miNs	 to	 extrude	 cellular	 debris.	 The	
supernatant	(100	μl)	was	then	loaded	into	appropriate	wells	of	a	black	96	well	plate	
and	read	for	fluorescence	(Fluorescein	-ex:	490	nm,	em:	525	nm/GFP	–	ex:	488	nm,	
em:	509	nm)	using	the	Tecan	Infinite®	Pro	200	microplate	reader	at	gain	100.	
	
2.2.32:	Statistical	Analysis	
Statistical	analysis	was	performed	using	GraphPad	Prism©	software.	The	parametric	
unpaired	Student's	 t-test	was	used	 to	determine	 the	significance	of	NT-conjugated	
fluorophore	 uptake	 into	 cells	 under	 different	 conditions	 (e.g	 inhibited	 by	 free	
NT/SR142948	 or	 non-inhibited)	 compared	 to	 uptake	 of	 unconjugated	 fluorophore.	
Statistical	 analysis	 was	 performed	 for	 uptake	 of	 conjugated	 fluorophore	 for	 NTS1	
non-transfected/transfected	 HEK293	 and	 undifferentiated/differentiated	 Caco-2	
cells.	Welsh's	correction	was	applied	to	each	test,	as	the	SD	for	each	data	point	was	
not	identical.	See	section	5	for	graphical	representation	of	the	data	sets	used	for	this.
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Chapter	3	
Characterisation	of	Cell	Lines	
	
3.1:	Introduction	
	
3.1.1:	Caco-2	Cell	Line	
The	production	of	model	mucosal	membranes	is	widely	employed	to	predict	mucosal	
absorption	of	drugs	 intended	for	oral	delivery	 (Antunes	et	al.,	2013).	One	such	cell	
line	used	for	this	purpose	is	Caco-2.	The	Caco-2	cell	line,	derived	from	a	moderately	
differentiated	human	colon	carcinoma,	has	been	widely	used	over	the	last	couple	of	
decades	as	a	model	of	the	intestinal	barrier	(Sambuy	et	al.,	2005).	When	grown	on	
polycarbonate	 or	 nitrocellulose	 filters,	 Caco-2	 cells	 undergo	 differentiation	 into	
enterocyte-like	 membrane	 monolayers,	 expressing	 several	 morphological	 and	
functional	 characteristics	 of	 the	 mature	 enterocyte.	 Morphological	 assessment	 of	
the	differentiation	of	Caco-2	monolayers	confirms	an	 increase	 in	cellular	height	 (of	
~500%),	 decrease	 in	 cell	 width	 (of	 ~50%)	 and	 presence	 of	 microvilli	 (Pinto	 et	 al.,	
1983).	 Past	 research	 into	 the	 use	 of	 differentiated	 (sometimes	 referred	 to	 as	
'polarised')	 Caco-2	 monolayers	 concludes	 that	 the	 use	 of	 such	 monolayers	 as	 a	
model	transport	system	to	mimic	the	small	intestinal	epithelium	is	valid	(Hidalgo	et	
al.,	1989;	Pinto	et	al.,	1983).		
	
3.1.2:	HEK293	Cell	Line	
The	 HEK293	 cell	 line	 was	 created	 following	 transformation	 of	 human	 embryonic	
kidney	(HEK)	cells	following	exposure	to	fragments	of	adenovirus	type	5	(Ad5)	DNA	
by	Graham	 et	 al.,	 (1977),	 and	 numbered	 due	 to	 Graham's	 habit	 of	 numbering	 his	
experiments.	 The	 cells	 were	 extracted	 from	 an	 embryo	 legally	 terminated	 in	 the	
Netherlands.	Viral	transformation	resulted	in	incorporation	~4.5	kb	of	viral	DNA	into	
chromosome	19	of	 the	cell	 line	 (Louis	et	al.,	1997).	This	allows	 for	hijacking	of	 the	
cells	 internal	 control	 mechanisms	 and	 counteraction	 of	 apoptosis	 and	 created	 an	
effective	tool	for	recombinant	protein	production	(Lin	et	al.,	2014).	The	HEK293T	cell	
line	used	in	this	study	(referred	to	here-on	as	'HEK293')	is	a	derivative	of	the	original	
HEK293	 cell	 line,	 which	 is	 the	 transformation	 product	 of	 HEK293	with	 the	 large	 T	
antigen	 of	 the	 SV40	 virus.	 The	 HEK293T	 variant	 is	 documented	 to	 have	 a	 higher	
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transfection	efficiency	than	the	original,	hence	the	reason	for	their	use	in	this	study.	
Graham	et	al.,	 (1977)	documented	 the	pre-cursor	 transformation	of	HEK	cells	with	
adenoviral	 DNA	 to	 be	 difficult,	 suggesting	 that	 the	 cell	 line	may	 not	 be	 of	 kidney	
origin	at	all.	Although	the	name	of	the	cell	line	suggests	the	origin	of	the	cell	line	as	
kidney,	 Shaw	 et	 al.,	 (2002),	 (a	 post-doc	 of	 Grahams')	 have	 provided	 evidence	
suggesting	 that	 all	 variants	 of	 the	 HEK293	 cell	 line	 show	 similar	 characteristics	 to	
immature	 neuronal	 cell	 lines.	 As	 such,	 it	 was	 speculated	 that	 the	 adenovirus	
preferentially	 transform	 into	 cells	 of	 neuronal	 lineage,	 which	 would	 have	 been	
abundance	in	embryonic	tissue.		
	
3.1.3:	Transfection	
Eukaryotic	cells	are	able	to	take	up	exogenous	DNA	under	certain	conditions.	There	
are	 many	 methods	 of	 inducing	 this	 phenomenon	 for	 scientific	 gain,	 known	 as	
transfection,	 including:	 the	 calcium	 phosphate	 method,	 electroporation,	 liposome	
fusion,	microinjection	 and	with	 the	 use	 of	 retroviruses	 (Kim	 and	 Eberwine,	 2010).	
However,	chemical	methods	of	transfection	have	been	documented	to	elicit	toxicity	
to	 certain	 cell	 types.	 Transfection	 is	 a	 procedure	 that	 inserts	 foreign	 nucleic	 acids	
into	a	host	cell	–	this	DNA	can	exist	in	one	of	two	forms,	stably	or	transiently.	Stable	
transfections	incorporate	the	foreign	DNA	into	the	hosts	own	DNA	and	is	expressed	
sustainably,	 whereas	 transient	 transfection	 deliver	 foreign	 DNA	 to	 the	 nucleus	
without	incorporating	itself	into	host	DNA	(Kim	and	Eberwine,	2010).		
	
Lipofectamine	is	a	cationic	lipid,	synthesised	by	Felgner	et	al.,	(1987),	which	is	known	
to	spontaneously	interact	with	DNA	and	form	liposomes,	fuse	with	mammalian	cell	
lines	and	 facilitate	 the	delivery	of	DNA	to	 the	host	cell.	Non-viral	delivery	systems,	
such	as	lipofectamine,	have	been	shown	to	have	an	advantage	over	viral	methods	as	
they	are	non-immunogenic,	easy	to	produce	and	not	oncogenic	(Zhang	et	al.,	2010).	
However,	 they	 do	 not	 have	 as	 great	 a	 transfection	 efficiency.	 The	 method	 of	
endocytosis	with	 lipofectamine	 is	 not	 completely	 understood,	 however,	 Cui	 et	 al.,	
(2012)	have	documented	a	correlation	between	clathrin-dependant	endocytosis	and	
transfection	efficiency	in	HEp-2	cells.	
	
Chapter	3	 	 Characterisation	of	Cell	Lines	
41	
3.1.4:	Methods	of	Determining	Cell	Viability	
There	 is	 a	 diverse	 array	 of	 methods	 for	 determining	 cellular	 viability,	 which	 is	
variable	 between	 studies.	Understandably,	 this	 can	 influence	 the	 interpretation	 of	
experimental	results	from	paper	to	paper.	Commonly	used	methods	of	determining	
cellular	 viability	 include	 colorimetric	 assays	 such	 as	 the	 MTS/MTT	 assays,	 Alamar	
Blue	assay,	 LDH	assay,	and	crystal	 violet	assay	 (Vega-Avila	and	Pugsley,	2011).	The	
term	viability	can	refer	to	variety	of	terms	such	as	cell	survival,	cellular	integrity	and	
cytotoxicity;	 it	 is	 the	 interpretation	 of	 what	 constitutes	 viable,	 and	 the	 choice	 of	
assay	used	that	causes	these	differences	(Cook	and	Mitchell,	1989).	Trypan	Blue	is	a	
diazo	 dye	 commonly	 used	 to	 selectively	 colour	 dead	 cells,	 as	 the	 dye	 cannot	
penetrate	 intact	cell	membranes.	One	 limitation	associated	with	the	method	 is	the	
need	 to	 perform	 any	 cell	 count	 including	 the	 dye	 immediately	 as	 cells	 may	 non-
selectively	intake	the	blue-stain	after	~5	minutes	(Altman	et	al.,	1993).		
	
3.2:	Results	
	
3.2.1:	Light	Microscopy	of	Caco-2	and	HEK293		
	
Figure	 3.1	 depicts	 the	 morphology	 of	 HEK293	 and	 Caco-2	 cells	 respectively.	 The	
images	 were	 taken	 using	 the	 Nikon	 DN100	 digital	 camera	 control	 unit	 and	 Nikon	
Eclipse	 TS100	 light	 microscope	 (see	 section	 2.2.22).	 Images	 were	 taken	 at	 x40	
magnification.	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.1:	A	–	HEK293	cells	at	a	confluency	of	40-50%.	B	–	image	of	undifferentiated	Caco-2	cells	at	a	
confluency	of	~70%.	These	images	were	taken	at	a	40x	magnification.	
	
	
	
A	 B	
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3.2.2:	Optimisation	of	Transfection	of	HEK293	
Figures	3.2-3.4	show	confocal	microscope	images	detailing	NTS1	expression	
following	transfection	of	HEK293	cells	with	an	NTS1	containing	plasmid	(with	the	
intention	of	producing	NTS1	overexpressing	HEK293	cells)	using	differing	
concentrations	of	lipofectamine	to	perform	the	transfection.	This	was	done	to	
optimise	the	procedure	and	result	in	the	highest	level	of	NTS1	expresison	possible.	
The	amount	of	plasmid	remained	constant	at	1μg	per	well	(see	section	2.2.23	for	
further	details).		
	
	
	
	
	
	
	
	
	
Figure	 3.2:	 Qualitative	 evaluation	 of	 NTS1	 expression	 in	 transfected	 HEK293	 with	 2	 μl	 of	
Lipofectamine	 per	 well	 (left)	 with	 negative	 control	 (right).	 Blue	 staining	 represents	 nucleic	 acids	
(stained	by	DAPI)	and	green	staining	represents	NTS1.	The	white	bar	represents	50	μm.	
	
	
	
	
	
	
	
	
	
Figure	 3.3:	 Qualitative	 evaluation	 of	 NTS1	 expression	 in	 transfected	 HEK293	 with	 3	 μl	 of	
Lipofectamine	 per	 well	 (left)	 with	 negative	 control	 (right).	 Blue	 staining	 represents	 nucleic	 acids	
(stained	by	DAPI)	and	green	staining	represents	NTS1.	The	white	bar	represents	50	μm.	
	
	
	
	
	
	
	
	
	
	
Figure	3.4:	Confocal	images	of	NTS1	expression	in	transfected	HEK293	with	4	μl	of	Lipofectamine	per	
well	 (left)	with	negative	control	 (right).	Blue	staining	 represents	nucleic	acids	 (stained	by	DAPI)	and	
green	staining	represents	NTS1.	The	white	line	is	representative	of	50	μm.	
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Figures	3.2-3.4	above	are	images	of	transfected	HEK293	cells	with	differing	amounts	
of	 lipofectamine	used	for	the	transfection	procedure,	coupled	with	their	respective	
negative	 controls.	 Immunofluorescence	 staining	 of	 NTS1	 was	 carried	 out	 as	
described	 in	 section	 2.2.25.	 Images	 were	 taken	 using	 confocal	 microscopy	 as	
described	 in	 section	 2.2.26.	 	 Figure	 3.4	 (representing	 a	 transfection	 protocol	
including	4	μl	of	lipofectamine	per	well)	shows	the	highest	level	of	NTS1	expression.	
As	 such	 this	 volume	 of	 lipofectamine	 was	 used	 for	 the	 transfection	 procedure	
described	in	section	2.2.23	henceforth.		
	
3.2.3:	Evaluation	of	NTS1	Expression	in	Caco-2	and	HEK293	by	Immunostaining	
	
Figures	3.5	and	3.6	depict	NTS1	expression	on	polarised	(grown	on	a	transwell®	filter	
for	 21	 days)	 Caco-2	 cells,	 non-permeabilised	 and	 permeabilised	 before	
immunofluorescence	 (section	 2.2.24)	 respectively	 to	 display	 the	 locality	 of	 the	
receptor.	 Permeabilisation	 of	 the	 cellular	 membrane	 disrupts	 its	 integrity	 and	
therefore	 any	membrane	 proteins	 present.	NTS1	 is	 strongly	 detected	 in	 figure	 3.5	
(non-permeabilised)	 and	 not	 figure	 3.6	 (permeabilised).	 Some	 fluorescence	 is	
noticeable	 located	 around	 the	 nucleus	 of	 cells	 in	 figure	 3.6.	 Negative	 controls	
confirm	that	fluorescence	on	the	test	samples	was	not	due	to	non-specific	staining.	
Images	were	taken	using	confocal	microscopy	as	described	in	section	2.2.26.			
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.5:	Confocal	images	of	NTS1	expression	in	non-permeabilised	polarised	Caco-2	cells	(left)	with	
negative	control	(right).	Blue	staining	represents	nucleic	acids	(stained	by	DAPI)	and	green		represents	
NTS1.	The	white	bar	is	representative	of	50	μm.	
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Figure	 3.6:	 Confocal	 images	 of	 NTS1	 expression	 in	 permeabilised	 polarised	 Caco-2	 cells	 (left)	 with	
negative	control	(right).	Samples	were	permeabilised	with	0.1%	Triton	X	100	in	PBS.	Gain	of	the	laser	
detecting	DAPI	was	reduced	in	this	image	compared	to	other	confocal	images	displayed	in	order	make	
fluorescence	of	AlexaFluor®488	clearer.	Blue	staining	represents	nucleic	acids	 (stained	by	DAPI)	and	
green	staining	represents	NTS1.	The	white	bar	is	representative	of	50	μm.	
	
Figure	3.7	depicts	NTS1	expression	on	non-polarised	Caco-2	cells	grown	as	described	
in	section	2.2.21.	NTS1	 immunostaining	was	performed	as	stated	 in	section	2.2.25.	
Images	 were	 taken	 using	 confocal	 microscopy	 as	 described	 in	 section	 2.2.26.	
Suggested	by	a	lack	of	fluorescence,	NTS1	is	not	expressed	in	undifferentiated	Caco-
2	cells.		
	
		
	
	
	
	
	
	
	
	
	
	
	
Figure	3.7:	 Confocal	 images	of	NTS1	expression	 in	undifferentiated	Caco-2	 cells	 (left)	with	negative	
control	(right).	Blue	staining	represents	nucleic	acids	(stained	by	DAPI)	and	green	staining	represents	
NTS1.	The	white	bar	is	representative	of	50	μm.	
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Figure	 3.8:	 Qualitative	 evaluation	 of	 NTS1	 expression	 in	 untransfected	 HEK293	 cells	 (left)	 with	
negative	 control	 (right).	 Blue	 staining	 represents	 nucleic	 acids	 (stained	by	DAPI)	 and	 green	 staining	
represents	NTS1.	The	white	bar	is	representative	of	50	μm.		
	
Figure	 3.8	 depicts	 NTS1	 expression	 on	 non-transfected	 HEK293	 cells	 grown	 as	
described	 in	 section	 2.2.21.	 Images	 were	 taken	 using	 confocal	 microscopy	 as	
described	 in	 section	 2.2.26.	 HEK293	 are	 shown	 to	 express	 NTS1	 as	 suggested	 by	
observable	fluorescence	in	figure	3.8.	Negative	controls	confirm	that	fluorescence	on	
the	test	samples	was	not	due	to	non-specific	staining.	
	
3.2.4:	TEER	Profile	of	Caco-2	Cells	Grown	in	Transwells®	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.9:	 TEER	profile	of	Caco-2	 cells,	 grown	 for	 a	 total	of	24	days	 in	Transwells®.	 Error	bars	 are	
representative	of	±SD.	Data	points	plotted	are	representative	of	n=12.		
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Figure	3.9	shows	the	TEER	(Ω/cm2)	of	Caco-2	cells	grown	in	Transwells®	for	a	total	of	
24	 days	 (see	 section	 2.2.19).	 TEER	 was	 recorded	 (as	 described	 in	 section	 2.2.27)	
every	two	days	from	seeding.	Each	value	plotted	is	the	mean	of	12	wells.	Error	bars	
plotted	 are	 representative	 of	 one	 standard	 deviation.	 An	 almost	 linear	 increase	 in	
TEER	is	observable,	followed	by	a	plateau	of	resistance	at	day	21.		
	
3.2.5:	Evaluation	of	Cellular	Growth	in	12	Well	Plates	
	
Figure	3.10:	Displays	cellular	growth	over	48	hours	when	grown	in	12	well	plates	(see	
section	 2.2.28).	 Cells	were	 counted	 and	 healthy	 cells	were	 identified	 using	 Trypan	
blue	as	described	in	section	2.2.18.	Data	is	representative	of	N=4	wells	per	cell	line.	
Each	 well	 was	 counted	 three	 times	 and	 averaged.	 Error	 bars	 are	 equal	 to	 one	
standard	deviation.	Wells	were	seeded	at	10x104	cells	per	cm3.		
	
																									
Figure	3.10:	Cellular	growth	of	Caco-2,	HEK293	and	HEK293	transfected	with	NTS1	when	grown	in	12	
well	plates	for	48	hours.	Black	bars	represent	the	total	number	of	cells	(n=3)	and	grey	bars	represent	
the	total	number	of	viable	cells	(n=3).	Error	bars	are	representative	of	±	SD.	
	
Figure	3.11:	Displays	%	cellular	viability	of	each	cell	line	after	48	hours	when	grown	
in	 12	 well	 plates	 (see	 section	 2.2.21).	 Cells	 were	 counted	 and	 healthy	 cells	 were	
identified	using	Trypan	Blue	as	described	in	section	2.2.18.	Data	is	representative	of	
Ca
co
-2
HE
K2
93
Tr
an
sfe
cte
d H
EK
29
3
0
20
40
60
80
100
Cell Line
N
um
be
r o
f c
el
ls
 p
er
 m
l (
x1
04
)
Total
Viable
Chapter	3	 	 Characterisation	of	Cell	Lines	
47	
N=4	wells	per	cell	line.	Each	well	was	counted	three	times	and	averaged	for	that	well.	
Caco-2	=	92.07%,	HEK293	=	95.91%,	Transfected	HEK293	=	99.02%.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.11:	%	cellular	viability	of	Caco-2,	HEK293	and	HEK293	transfected	with	NTS1	when	grown	in	
12	well	plates	for	48	hours.	The	data	displayed	in	each	bar	is	representative	of	n=4.	
	
3.3:	Discussion	
3.3.1:	Caco-2	Cells	
NTS1	is	documented	to	be	expressed	in	foetal	colonic	epithelial	cells,	but	not	mature,	
differentiated	 enterocytes	 in	 physiologically	 normal	 conditions.	 Expression	 in	 the	
gastrointestinal	 system	 is	 thought	 to	be	 localised	 to	 the	distal	 small	 intestine,	with	
little	 or	 no	 expression	 in	 the	 healthy	 colon	 (NTS1	 is	 transiently	 expressed	 during	
colon	 development,	 however).	 Expression	 is	 known	 to	 be	 unregulated	 in	 a	
progressive	 manner	 during	 neoplastic	 transformation	 of	 colonic	 adenocarcinomas	
(Evers	et	al.,	1993;	Gui	et	al.,	2008).	A	comparison	of	figures	3.5	and	3.7	indicates	a	
clear	 absence	 of	NTS1	 expression	 in	 undifferentiated	 Caco-2	 cells	 compared	 to	 an	
almost	 homogenously	 high	 level	 of	 expression	 in	 differentiated	 cells.	 The	
differentiation	process	 itself	 following	 a	progressively	neoplastic	 transformation	or	
NTS1	having	a	direct	role	in	the	differentiation	process	of	Caco-2	cells	could	explain	
this.	However,	no	previous	research	has	been	done	into	NTS1	expression	in	Caco-2	
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cells	 during	 the	 differentiation	 process.	 As	 Caco-2	 cells	 are	 sourced	 from	 a	
moderately	 differentiated	 adenocarcinoma	 as	 opposed	 to	 a	 poorly	 differentiated	
one,	undifferentiated	Caco-2	cells	might	be	exhibiting	 similar	 characteristics	 to	 the	
healthy	colon	with	regards	to	NTS1	expression.	The	comparison	of	internalisation	of	
NT-bound	 fluorophores	 between	 undifferentiated	 and	 differentiated	 Caco-2	 cells	
(later	described	in	chapters	5	and	6)	will	therefore	serve	as	an	experimental	model	
for	 internalization	 of	 NT	 in	 invasive	 adenocarcinoma/other	 NTS1	 expressing	
cancerous	cells	vs	physiologically	normal	cells.		
	
Gui	et	al.,	 (2008)	found	NTS1	expression	to	be	predominantly	 localised	in	the	basal	
cells	 of	 the	 crypts,	 known	 to	 contain	 the	 self-renewing	 epithelial	 stem	 cell	
populations	and	rapidly	dividing	cells,	compared	to	superficial	colonic	epithelial	cells.	
However,	 they	also	noted	 there	 to	be	 low	 levels	of	NTS1	mRNA	present	 in	around	
40%	of	normal	colonic	mucosa	samples	examined.	This	supports	the	idea	that	NTS1	
plays	 a	 role	 in	 cellular	 propagation	 and	 division,	 as	 well	 as	 its	 role	 as	 a	 hormone	
receptor	 in	 the	 gut.	 Interestingly,	 although	 undifferentiated	 Caco-2	 cells	 showed	
next	 to	 no	 expression	 of	 NTS1,	 cells	 that	 were	 visually	 determined	 to	 be	 in	 the	
process	of	cellular	division	appeared	to	up	regulate	expression	of	the	receptor	(see	
figure	3.12).	This	applied	to	both	undifferentiated	Caco-2	cells	and	HEK293	cells.	The	
image	of	the	dividing	Caco-2	cell	in	figure	3.12	is	an	enlargement	of	the	dividing	cell	
visible	in	figure	3.7.	
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Figure	3.12:	Shows	Caco-2	cells	(left)	and	HEK293	cells	(right)	in	the	progress	of	cellular	division.	NTS1	
is	 noticeably	 up	 regulated	 compared	 to	 cells	 in	 interphase	 (Figures	 3.7	 and	 3.8	 respectively).	 This	
further	supports	the	idea	that	NTS1	is	involved	in	cellular	division	and	propagation.	
	
Expression	 levels	 of	 differentiation	 markers	 such	 as	 the	 GLUT-5	 transporter	 and	
sucrose-isomaltase	 have	 been	 shown	 to	 increase	 in	 later	 passages	 of	 Caco-2s	
compared	 to	 earlier	 ones	 (Sambuy	 et	 al.,	 2005).	 Due	 to	 observable	 shifts	 in	
phenotype,	 it	 is	 safe	 to	 assume	 that	 the	 passage	 number	 may	 also	 affect	 NTS1	
expression	in	both	differentiated	and	undifferentiated	Caco-2	cells.	As	such,	further	
studies	 into	 how	 the	 passage	 number	 of	 Caco-2s	 affects	 NTS1	 expression	 is	
recommend.	As	this	study	has	continuously	utilised	and	assessed	NTS1	expression	in	
Caco-2	cells	of	passage	60-80,	it	should	be	representative	of	that	range	of	passages	
only	until	the	effect	of	passage	number	on	NTS1	expression	has	been	determined.	
		
The	 most	 obvious	 limitation	 in	 this	 study	 is	 the	 lack	 of	 quantification	 of	 NTS1	
expression	(in	both	Caco-2	and	HEK293).	All	confocal	images	in	the	results	section	of	
this	 chapter	 are	 representative	 of	 replicate	 slides	 and	 multiple	 fields	 of	 view,	
however,	 a	 lack	 of	 quantification	 presents	 a	 inability	 to	 definitively	 compare	
expression	 levels	 between	 both	 cell	 lines	 and	 undifferentiated	 vs	 differentiated	
conditions	 for	Caco-2	 cells.	 Therefore,	 it	 is	 recommended	 that	NTS1	expression	be	
quantified	 by	 RT-PCR,	 flow	 cytometry	 or	 by	 employing	 software	 for	 the	
quantification	of	NTS1	expression	obtained	by	immunofluorescence.			
	
Several	 studies	 have	 suggested	 that	 the	 passage	 number	 of	 the	 cell	 line	 also	
increases	 the	 proliferation	 rate	 and	 elicits	 higher	 TEER	 readings	 in	 later	 passages	
(Briske-Anderson	 et	 al.,	 1997;	 Lu	 et	 al.,	 1996).	 However,	 Anderle	 et	 al.,	 (2003)	
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evaluated	changes	 in	 transport	properties	of	Caco-2	 from	earlier	 to	 later	passages,	
including	transcellular	(mannitol),	paracellular	(hydrocortisone)	and	carrier-mediated	
(dipeptide)	methods.	All	of	which	were	shown	to	be	unchanged	in	earlier	compared	
to	 later	passages.	The	cells	used	 for	 this	 study	 fell	 in	between	the	 ranges	 for	early	
and	 late	 passaged	 cells	 stated	 from	 the	 describe	 studies,	 35-47	 and	 82-95	
respectively.		
	
The	density	of	 cell	 seeding	has	also	been	put	under	 scrutiny	 in	previous	 studies.	A	
common	problem	with	the	production	of	monolayers	when	grown	on	polycarbonate	
filters	is	a	tendency	to	form	multilayers.	This	tendency	is	also	dependent	on	the	cell	
line	used.	Tavelin	et	al.,	(2002)	speculates	that	this	is	due	to	high	seeding	densities.	
Their	study	suggests	that	any	seeding	density	above	0.6x104		cells/cm2	will	require	a	
washout	of	cells	 three	hours	after	seeding	to	avoid	this	problem.	However,	Caco-2	
cells	were	seeded	at	a	density	of	2x105	cells/cm2	for	this	study,	without	washing	after	
three	 hours,	 and	 no	 multilayer	 formation	 was	 observed	 as	 determined	 by	 a	
combination	of	 confocal	microscopy	and	 light	microscopy	 (see	 figure	3.13).	Higher	
seeding	densities,	such	as	that	used	in	this	study,	decrease	the	time	taken	for	cells	to	
reach	 confluency	 and	 thus	 allow	 for	 the	 development	 of	 tight	 junctions	 and	
maturation	of	the	monolayer	to	proceed	for	longer	(Ranaldi	et	al.,	2003).	
	
	
	
	
	
	
	
	
Figure	 3.13:	 Confocal	 image	 taken	 of	 cell	 nuclei	 only	 (as	 stained	 by	 DAPI).	 This	 figure	 shows	 the	
relatively	flat	arrangement	of	cells	with	no	overlapping.	This	image	is	coloured	in	relation	to	depth	so	
areas	with	the	same	colour	are	the	same	height	above	the	polycarbonate	membrane.	Relatively	few	
cell	nuclei	appear	to	be	positioned	above		
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Caco-2	 cells	 follow	 a	 well-documented,	 time-dependent	 pattern	 of	 differentiation	
into	expressing	the	morphological	characteristics	of	mature	enterocytes.	Expression	
of	 these	characteristics	happens	 through	 three	phases	of	monolayer	development;	
homogeneously	 undifferentiated	 (days	 0-3),	 heterogeneously	 polarized	 and	
differentiated	 (days	 3-20)	 and	 homogeneously	 polarized	 and	 differentiated	 (days	
21+).	 Plateaus	 in	 TEER	 readings	 are	 documented	 to	 occur	 at	 21	 days	 (as	 seen	 in	
figure	3.9),	in	concordance	with	the	generally	accepted	21	days	of	culture	for	Caco-2	
monolayers	 before	 experiments;	 but	 this	 does	 not	 affirm	maximum	homogeneous	
expression	of	NTS1	at	 day	21	of	 culture	 (Vachon	et	al.,	 1996).	 Bravo	et	al.,	 (2004)	
evaluated	 expression	 of	 the	 PepT1	 transporter	 in	 polarized	 Caco-2s,	 achieving	
maximum	expression	at	day	25	of	culture.	It	is	recommended	that	NTS1	expression	
be	evaluated	at	different	time	periods	of	monolayer	culture	as	further	work	as	it	has	
not	been	previously	evaluated.		
	
3.3.2:	HEK293	Cells	
HEK293	 cells	 were	 included	 in	 this	 study	 to	 provide	 a	 model	 for	 GFP-NT	
internalisation	that	does	not	mimic	the	intestinal	membrane	like	Caco-2.	To	instead	
mimic	internalisation	of	GFP-NT	in	NTS1	overexpressing	solid-state	tumours.	HEK293	
cells	 are	 known	 to	 exhibit	 some	 neuronal	 characteristics	 (as	 described	 in	 section	
2.1.2),	 including	 the	 expression	 of	 neuroreceptors	 like	 NTS1	 (Thomas	 and	 Smart,	
2005).		
	
As	expression	of	NTS1	was	transient	 in	HEK293	cells,	transfections	were	performed	
the	day	before	and	not	stored	past	the	day	of	experimentation.	Transfection	of	NTS1	
using	the	lipofectamine	method	appears	to	have	been	successful	(see	figure	3.4),	but	
has	 not	 yielded	 homogeneous	 expression	 throughout	 observed	 immunostained	
sections.	This	may	be	due	to	the	need	for	 further	optimization,	 the	plasmid	vector	
used	not	being	highly	efficient	or	the	method	of	transfection	itself.	The	293T	variant	
of	 HEK293	 used	 for	 this	 study	 enables	 the	 amplification	 of	 plasmid	 vectors	
containing	 the	 SV40	 ori	 (Lin	 et	 al.,	 2014)	 as	 previously	 described	 to	 increase	
transfection	efficiency	–	the	plasmid	vector	used	for	this	study	did	not	contain	this.	
However,	 cationic	 lipids	 such	 as	 lipofectamine	 have	 generally	 yielded	 the	 highest	
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transfection	 efficiencies	 of	 all	 the	 chemical-based	methods	 of	 transfection	 (de	 los	
Milagros	Bassani	Molinas	et	al.,	2014).		
	
	Like	Caco-2	cells,	the	passage	number	is	known	to	affect	the	functionality	of	HEK293	
cells.	 Lower	 passages	 of	 cells	 (<30)	 have	 been	 documented	 to	 have	 greater	
transfection	 efficiencies	 for	 DNA	 and	 RNA	 (Elbashir	 et	 al.,	 2002).	 The	 passage	
number	 of	 HEK293	 ranged	 from	 25-40	 for	 this	 study	 –	 during	 which	 time	 the	
morphology	and	growth	rate	was	observed	to	be	consistent	with	 that	described	 in	
related	literature.	Figure	3.10	shows	the	growth	rate	of	HEK293	to	be	almost	double	
that	of	undifferentiated	Caco-2,	with	a	 reduction	 in	growth	rate	when	transfected.	
This	 is	 to	 be	 expected	 as	 recombinant	 protein	 production	 of	 NTS1	 will	 increase	
cellular	demand	and	as	a	result,	decrease	growth	rate.	The	influence	of	growth	rate	
on	internalisation	of	GFP-NT	between	the	cell	lines	will	be	discussed	in	chapter	5.		
	
3.4:	Conclusion	
Expression	 of	 NTS1	 on	 differentiated	 Caco-2,	 undifferentiated	 Caco-2,	 wild	 type	
HEK293	and	transfected	HEK293	was	qualitatively	assessed	along	with	optimization	
of	 the	 transfection	procedure.	4μl	of	 lipofectamine	with	1μg	of	DNA	was	 found	 to	
have	the	greatest	transfection	efficiency	 in	reduced	serum	media.	NTS1	expression	
was	 found	 to	change	 from	not	present	 to	highly	present	during	 the	differentiation	
process	of	Caco-2	cells.	As	such,	undifferentiated	and	differentiated	Caco-2s	can	be	
used	as	a	model	for	the	comparison	of	GFP-NT	internalization	in	the	healthy	colon	vs	
NTS1	 expressing	 adenocarcinoma.	 Similarly,	 the	 comparison	 of	 internalisation	 of	
HEK293	and	transfected	HEK293	can	be	used	to	compare	internalisation	of	GFP-NT	in	
cells	moderately	expressing	vs	highly	expressing	NTS1.	However,	the	methods	used	
for	evaluation	of	NTS1	expression	are	purely	qualitative	in	this	instance	and	further	
quantitative	 evaluation	 is	 recommended	 for	 definitive	 comparison	 of	 how	 NTS1	
expression	 influences	 internalization	 and	 transport	 of	 NT-bound	 fluorophores.
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Chapter	4	
Production	of	Neurotensin-Conjugated	GFP	
	
4.1:	Introduction	
	
4.1.1:	Recombinant	Therapeutics	
The	production	of	recombinant	proteins	has	been	 increasingly	utilised	as	a	tool	 for	
molecular	biologists	 as	 a	 result	 in	demand	 for	 commercially	 available	 recombinant	
biotherapeutics.	The	technique	is	employed	in	a	variety	of	areas	for	the	production	
of	 large	 amounts	 of	 recombinant	 proteins	 from	 genetically	 manipulated	 bacteria,	
yeast,	mammalian	cells,	plants	and	transgenic	animals	(Palomares	et	al.,	2004).	For	
example,	 Goeddel	 et	 al.,	 (1979)	 produced	 one	 of	 the	 first	 human	 recombinant	
proteins,	 insulin,	 by	 DNA	 manipulation	 in	 the	 bacterium	 Escherichia	 coli	 (E.coli),	
where	it	was	originally	synthesised	separately	as	A	and	B	chains.	Later,	the	process	
was	 modified	 to	 produce	 proinsulin	 to	 be	 later	 modified	 by	 enzymatic	 cleavage	
(Johnson,	 1983).	 As	 diabetes	 is	 one	 of	 the	 most	 prevalent	 diseases	 to	 date,	 the	
production	of	 insulin	maintains	a	 large	 influence	on	the	pharmaceutical	 today.	The	
production	 of	 recombinant	 proteins	 also	 expands	 into	 the	 production	 of	
bioinsecticides,	diagnostic	kits	and	enzymes	for	numerous	applications	(Palomares	et	
al.,	2004).		
	
There	 are	 over	 200	 recombinant	 biotherapeutics	 approved	 for	 human	 use	 on	 the	
market	 today,	with	over	30%	of	 those	produced	using	E.coli	 (Ferrer-Miralles	et	al.,	
2009).	
	
4.1.2:	Plasmid-Based	Systems		
Plasmids	are	extrachromosomal	 cytoplasmic	DNA	elements	with	 the	ability	 to	 self-
replicate,	found	in	eukaryotes	and	prokaryotes.	They	have	been	utilised	as	vehicles	
for	 recombinant	 genes	 since	 the	 advent	 of	 genetic	 engineering,	 and	 have	 been	 a	
favoured	 method	 of	 expression	 in	 prokaryotes	 due	 the	 ease	 of	 genetically	
manipulating	plasmids	(Margaritis	and	Bassi,	1991).		
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The	 number	 of	 plasmid	 copies	 held	 within	 each	 prokaryotic	 cell	 is	 variable,	
dependant	on	the	prokaryote,	the	plasmid	in	question	and	the	size	of	the	protein	to	
be	 expressed.	 As	 such,	 the	 number	 of	 copies	 for	 the	 plasmid	 within	 the	 cell	
determines	the	metabolic	load	on	the	host.	As	cellular	resources	must	be	utilised	for	
recombinant	protein	expression	(not	just	cellular	replication)	the	greater	the	number	
of	plasmids,	the	greater	the	metabolic	load.	The	load	also	increases	with	the	size	of	
the	 insert,	expression	rate,	protein	yield,	temperature	of	expression	and	toxicity	of	
the	 expressed	 protein	 toward	 the	 host	 (Corchero	 and	 Villaverde,	 1998;	 Summers,	
1998).	 Increased	 metabolic	 load	 results	 in	 a	 decrease	 in	 growth-rate	 of	 plasmid	
containing	 cells.	 The	 main	 contributing	 factors	 for	 decreases	 in	 efficiency	 of	
recombinant	protein	expression	lie	with	plasmid	loss	from	host	cells	and	the	toxicity	
of	the	recombinant	protein.	Generally,	this	is	caused	by	poor	dispersion	of	plasmids	
during	division	to	daughter	cells,	resulting	in	plasmid-free	cells.	However,	production	
of	 plasmid-free	 daughter	 cells	 is	 unlikely	 with	 high	 plasmid	 copy	 numbers.	 As	
previously	mentioned,	 plasmid-containing	 cells	 experience	 an	 increased	metabolic	
load;	the	emergence	of	plasmid-free	prokaryotes	will	therefore	exhibit	an	increased	
growth-rate	and	begin	to	overtake	the	culture	(Paulsson	and	Ehrenberg,	2001).	
	
Various	 natural	 mechanisms	 exist	 to	 ensure	 plasmid	 survival	 in	 cell	 populations,	
which	have	been	incorporated	into	recombinant	plasmids	to	increase	their	stability.	
These	 mechanisms	 prevent	 plasmid	 instability	 if	 they	 present	 an	 advantage	 over	
plasmid-free	cells,	such	as	the	introduction	of	antibiotic	resistance	genes	to	cultures	
grown	with	that	particular	antibiotic	(Baneyx,	1999).		
	
4.1.3:	The	pET	Expression	System	
The	pET	expression	system	 is	 commonly	used	 for	 recombinant	protein	production,	
based	on	the	T7	RNA	polymerase	 (Studier,	1991).	This	system	relies	upon	an	E.coli	
host	 that	 contains	 a	 copy	 of	 the	 gene	 encoding	 for	 the	 RNA	 polymerase	 of	
bacteriophage	 T7,	 which	 is	 regulated	 by	 an	 isopropyl	 β-D-1-thiogalactopyranoside	
(IPTG)	inducible	promoter.	An	example	is	lacUV5	–	the	construct	is	incorporated	into	
the	 bacterial	 chromosome	 at	 the	 DE3	 locus	 (Reznikoff,	 1992).	 The	 locality	 of	 this	
construct	is	what	gives	rise	to	the	name	of	competent	E.coli	strain	commonly	used	in	
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conjunction	with	the	pET	system:	BL21	(DE3).	In	the	absence	of	IPTG,	transcription	of	
this	 promoter	 region	 (located	 in	 the	bacterial	 chromosome)	 is	 inhibited	by	 the	 lac	
repressor	Lacl,	inhibiting	synthesis	of	T7	RNA	polymerase.	Upon	addition	of	IPTG	and	
following	subsequent	transcription	of	T7	RNA	polymerase,	the	T7	promoter	located	
in	 the	pET	expression	 system	 is	 able	 to	become	active	and	enable	 transcription	of	
the	recombinant	gene	of	 interest,	downstream	(see	figure	4.1).	The	pET	expression	
system	is	commercially	available	from	Novagen.		
	
Due	to	the	diversity	of	recombinant	proteins,	no	specific	promoter	system	can	suit	
all	recombinant	proteins	or	bacterial	strains	used	for	protein	expression.	Optimally,	
the	 chosen	 system	 should	 demonstrate	minimal	 faults	 in	 expression,	 high	 protein	
yield	and	be	sensitive	to	inducer	concentration	(Brautaset	et	al.,	2009).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.1:	 Taken	 from	 Overton,	 (2013).	 The	 pET	 system	 control	 mechanism.	 Diagrammatical	
representation	 of	 the	 activation	 of	 the	 lacUV5	at	 the	DE3	 locus	 of	 the	 bacterial	 chromosome,	 and	
subsequent	activation	of	the	T7	promoter	region	in	the	pET	system.	
	
	
4.1.4:	Green	Fluorescent	Protein	
Green	fluorescent	protein	(GFP)	was	originally	cloned	from	the	jellyfish	species	
Aequorea	victoria.	The	fluorophore	absorbs	blue	light	and	emits	fluorescence	as	
green	light	–	hence	its	name.	It	is	a	popular	tool	for	molecular	biologists	due	its	
stable	nature	and	independence	from	substrates	and	cofactors	(Cody	et	al.,	1993).	
The	fluorophore	retains	fluorescence	when	fused	to	other	proteins	or	peptides	on	
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both	the	N	and	C	terminus,	making	it	an	attractive	tool	for	intracellular	targeting	as	a	
fluorescent	tag	(Leffel	et	al.,	1997).	With	regards	to	the	stability	of	the	protein,	it	has	
been	shown	to	maintain	fluorescence	even	after	incubation	with	strongly	denaturing	
agents	such	as	urea	and	sodium	dodecyl	sulphate	(SDS).	GFP	has	also	been	
documented	to	continue	to	exert	fluorescence	for	5hrs	when	continuously	exposed	
to	UV	light	irradiation,	with	fluorescence	lasting	6	days	when	stored	at	4°c	and	4	
days	when	stored	at	room	temperature	(Liu	et	al.,	1999).	Mutants	of	GFP	have	been	
made	and	employed	as	a	fluorophore	since	the	original	discovery	of	GFP,	for	the	
purpose	of	enhanced	fluorescence.	For	example,	emerald	GFP	or	eGFP	produced	by	
Clontech	(the	variant	used	in	this	study)	has	an	increased	level	fluorescence	and	
decreased	susceptibility	to	photo	bleaching	compared	to	GFP	due	to	two	amino	acid	
substitutions.	This	shifts	the	emission	wavelength	from	green	(509	nm)	to	yellowish	
green	(525	nm),	with	an	excitation	wavelength	of	488	nm	(Cubitt	et	al.,	1995).	
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4.2:	Results	
4.2.1:	Analysis	of	pAG3	by	Restriction	Digest	
Figure	4.2	displays	the	success	of	bacterial	plasmid	transformation	and	subsequent	
plasmid	extraction	of	pAG3	as	described	 in	 sections	2.2.5-2.2.7.	The	pAG3	plasmid	
contains	a	recombinant	DNA	insert	coding	for	GFP-NT.	Gels	were	made	as	stated	in	
section	 2.2.4.	 A	 combination	 of	 the	 restriction	 enzymes	 BamHI	 and	 NdeI	 were	
incubated	with	the	extraction	samples	as	follows:	BamHI	and	NdeI	(2),	BamHI	alone	
(3)	 and	without	 restriction	enzymes	 (4)	 (see	 section	2.2.3).	 The	 restriction	enzyme	
sites	are	displayed	in	figure	4.3.	Lane	2	contains	bands	corresponding	to	the	size	of	
the	 insert	 (~0.75	 kb)	 and	 the	 plasmid	 vector	 (3.3	 kb).	 Lane	 3	 contains	 a	 band	
corresponding	 to	 the	 size	 of	 the	 plasmid	 cut	 at	 one	 site,	 and	 therefore	 linear	 in	
shape.	Lane	4	contains	a	band	corresponding	to	the	uncut	size	of	the	plasmid	vector	
plus	 insert.	 The	 lack	 of	 other	 bands	 on	 the	 gel	 eliminates	 the	 possibility	 of	
contamination.	 The	 sequence	 of	 the	 insert	 was	 confirmed	 as	 correct	 by	 genetic	
sequencing.	
	
	
	
	
	
	
Figure	4.2:	DNA	electrophoresis	of	pAG3	Expression	by	restriction	digest.	Lane	1	contains	DNA	ladder,	
annotated	to	the	left	of	this	figure.	Lane	2	contains	a	restriction	digest	of	pAG3	with	both	BamHI	and	
NdeI.	 Lane	 3	 contains	 a	 restriction	 digest	 of	 pAG3	 with	 BamHI	 and	 lane	 4	 shows	 the	 undigested	
plasmid.	A	total	volume	of	10	μl	was	run	in	each	lane	(including	the	ladder),	the	composition	of	which	
is	stated	in	section	2.2.3.	
	
	
	
	
	
	
	
	
Figure	4.3:	pET17b	expression/cloning	regions.	The	red	boxes	indicate	the	positions	of	NdeI	(left)	and	
BamHI	(right)	restriction	sites.	
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4.2.2	Quikchange	of	pAG3	to	Insert	a	Stop	Codon	
	
Quikchange	mutagenesis	was	conducted	(as	described	in	section	2.2.1)	to	insert	a	
stop	codon	before	the	coding	sequence	for	NT.	pAG3	was	produced	as	described	in	
section	2.2.5-2.2.7).	The	product	of	this	procedure	is	referred	to	as	pJB1.	An	
optimised	protocol	has	been	produced	and	is	listed	in	section	2.2.1.	pJB1	underwent	
a	DpnI	restriction	digest	to	remove	the	methylated	template	DNA	before	bacterial	
transformation	of	the	Quikchange	product	(see	section	2.2.2).	
	
	
	
	
	
	
	
	
	
Figure	4.4:	Schematic	representation	of	the	pAG3	and	pJB1	plasmids.	AG6	and	AG7	represent	the	
sense	and	antisense	primers	used	for	quikchange	mutagenesis	respectively	(see	table	3).	
	
Table	4.1:	Sequences	of	the	sense	and	antisense	primers	used	for	quikchange	mutagenesis	of	pAG3.	
The	antisense	codon	is	coloured	black	with	areas	corresponding	to	the	genes	coding	for	GFP	and	NT	in	
green	and	yellow	respectively.	
	
The	His-tagged	GFP-NT	coding	portion	of	the	plasmid	was	fully	sequenced,	
confirming	the	correct	introduction	of	a	stop	codon	(TAA)	before	the	NT	coding	
region	(see	figure	4.5).	
Figure	4.5:	Chromatogram	of	 sequenced	pJB1	displaying	 the	 inserted	stop	codon	 from	mutagenesis	
(indicated	by	the	red	box).	GFP	and	NT	encoding	regions	are	located	to	the	left	and	right	of	the	stop	
codon	 respectively.	 4Peaks	 software	 was	 used	 to	 visualise	 the	 sequence.	 Samples	 of	 pJB1	 were	
sequenced	by	Source	Biosciences	(Nottingham)	using	the	Sanger	sequencing	method.	
	
Primer	 Sequence	
AG6	(sense)	 AGGACGAGCTGTACAAGTAAgaactgtatgaaaacaaacc	
AG7	(antisense)	 ggtttgttttcatacagttcTTACTTGTACAGCTCGTCC	
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4.2.3:	Optimisation	of	Protein	Expression	
	
Figures	 4.6	 and	 4.7	 detail	 quantified	 protein	 expression	 over	 time	 after	 induction	
with	 1	 mM	 IPTG	 (see	 sections	 2.2.8-2.2.10).	 GFP-NT	 expressed	 from	 the	 pAG3	
plasmid	and	GFP	was	expressed	from	the	pJB1	plasmid.	Samples	were	quantified	as	
cell	lysates	(filtered	but	not	purified)	as	detailed	in	section	2.2.10.	Expression	at	37°C	
yields	 higher	 concentrations	 of	 both	 proteins	 quicker	 compared	 to	 20°C.	 Greatest	
concentration	of	protein	produced	at	both	temperatures	(~40-50	uM),	regardless	of	
the	 time	 taken	 to	 do	 so,	 was	 similar	 for	 both	 temperatures.	 Maximum	 protein	
expression	 took	 longer	at	20°C	but	yielded	 the	highest	 concentration	of	protein	at	
16hrs.	Whereas,	protein	expression	declined	at	16hrs	in	the	37°C	condition.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.6:	Quantified	 protein	 expression	 in	 BL21	 (DE3)	 (as	 described	 in	 2.2.12)	 over	 time	 at	 37°C,	
quantified	by	UV-Vis	spectrophotometry	measured	at	an	excitation	490	nm.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.7:	Quantified	 protein	 expression	 in	 BL21	 (DE3)	 (as	 described	 in	 2.2.12)	 over	 time	 at	 20°C,	
quantified	by	UV-Vis	spectrophotometry	at	an	excitation	wavelength	of	490	nm.	
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Figures	4.8	and	4.9	show	images	of	SDS-PAGE	ran	to	visualise	relative	expression	
amounts	of	target	protein	produced	at	each	optimisation	condition.	The	gels	vary	in	
stain	intensities	slightly	from	one	another	-	this	is	due	to	the	amount	of	time	spent	in	
Coomassie	Blue	stain.	Gels	representative	of	the	37	°c	expression	series	spent	longer	
in	the	stain,	therefore	display	a	deeper	blue	colouration.	As	these	gels	are	only	used	
for	comparison	against	the	samples	in	the	same	gel	and	expression	temperature,	this	
is	not	an	issue.		
Figure	4.8:	SDS-PAGE	gels	of	GFP-NT	(left)	and	GFP	(right)	samples	 taken	at	stated	time	 intervals	of	
expression.	 10	 μl	 of	 sample	 (that	 had	 been	 lysed,	 centrifuged,	 resuspended	 in	 protein	 buffer	 and	
filtered)	was	combined	with	10	μl	of	loading	buffer	(see	section	2.2.13),	15μl	of	this	was	run	in	each	
well	 of	 the	 gel.	 The	 ladder	 used	 for	 this	 gel	 was	 the	 SeeBlue®	 Plus2	 protein	 standard	 (Life	
Technologies).	The	gels	above	are	representative	of	the	expression	documented	in	figure	4.6.	
Figure	4.9:	SDS-PAGE	gels	of	GFP-NT	(left)	and	GFP	(right)	samples	 taken	at	stated	time	 intervals	of	
expression.	 10	 μl	 of	 sample	 (that	 had	 been	 lysed,	 centrifuged,	 resuspended	 in	 protein	 buffer	 and	
filtered)	was	combined	with	10	μl	of	loading	buffer	(see	section	2.2.13),	15	μl	of	this	was	run	in	each	
well	 of	 the	 gel.	 	 The	 ladder	 used	 for	 this	 gel	 was	 the	 SeeBlue®	 Plus2	 protein	 standard	 (Life	
Technologies).	The	gels	above	are	representative	of	the	expression	documented	in	figure	4.7.	
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4.2.4:	Quantitative	Analysis	of	GFP-NT/GFP	Purification		
Protein	samples	were	prepared	from	bacterial	cultures	after	IPTG	induction	of	
transformed	(with	either	pAG3	or	pJB1)	BL21	E.coli.	Metal	affinity	chromatography	
was	used	to	purify	the	samples	using	1	ml	nickel	affinity	HisTrap	HP	columns	as	
described	in	section	2.2.11.	With	200	mM	imidazole,	the	second	collected	elution	(in	
a	series	of	10	1	ml	samples)	was	visibly	determined	to	contain	the	highest	
concentration	of	eluted	protein	(see	figure	4.10)	and	was	selected	to	be	aliquoted	
and	stored.	An	aliquot	was	reserved	for	quantification	of	the	sample.	Care	was	taken	
to	avoid	air	bubbles	entering	the	purification	columns	including	filtering	and	
degassing	of	the	protein	buffers	and	other	wash	solutions	with	the	use	of	a	Merck	
Millipore™	chemical	duty	pump	and	filtration	system.		
	
	
	
	
	
	
Figure	4.10:	First	five	1	ml	samples	eluted	from	the	HisTrap	column	with	200	mM	imidazole		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.11:	UV-Vis	 spectrophotometry	of	GFP-NT	and	GFP	at	a	dilution	of	1	 in	20.	Peak	at	490	nm	
represents	eGFP	present	in	both	samples.	
	
Figure	 4.11	 shows	 the	 data	 obtained	 from	 quantification	 of	 GFP-NT	 (green	 curve)	
and	GFP	(black	curve)	as	described	in	2.2.12.	This	graph	is	representative	of	multiple	
quantifications	of	protein	expression	from	pAG3	(GFP-NT)	and	pJB1	(GFP).	The	Beer-
Lambert	Law	was	used	to	quantify	protein	present	in	each	sample	(see	equation	4.1).	
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The	absorption	coefficient	for	eGFP	(specific	GFP	variant	used	in	this	study)	is	24,995	
M-1cm-1	 at	 280	nm,	 57,500M-1cm-1	 at	 490	nm	and	 the	 path	 length	 of	 light	 is	 1cm.	
Extinction	 coefficients	 were	 calculated	 using	 ProtParam	 (this	 resource	 can	 be	
accessed	 here:	 http://web.expasy.org/protparam/)	 and	 the	 known	 amino	 acid	
sequence	of	eGFP.		
	
	
	
	
Equation	4.1:	Beer-Lambert	 Law	equation.	A	=	absorbance	at	 a	 specific	wavelength.	 ε	=	 absorption	
coefficient	of	eGFP	at	490	nm.	c	=	concentration	of	protein.	l	=	path	length	of	light.	
	
Calculation	 of	 protein	 concentration	 of	 each	 sample	 was	 performed	 using	 the	
equation	in	figure	4.6.	Known	values	were:	absorption	coefficient	of	eGFP	at	490	nm,	
path	length	of	light	and	the	absorbance	of	the	sample	at	490	nm.	The	equation	was	
rearranged	to	determine	the	unknown	value	(concentration)	and	corrected	for	any	
dilutions.	 Using	 the	 absorption	 coefficient	 of	 eGFP	 at	 280	 nm,	 the	 purity	 of	 the	
samples	in	figure	4.11	was	calculated	by	comparing	the	amount	of	eGFP	to	the	total	
amount	of	protein	in	the	sample	(using	equation	4.1	and	absorbance	values	at	280	
and	490	nm)	to	be	64.5%	and	67.8%	respectively.	These	values	are	likely	to	be	lower	
than	the	actual	purity	of	 the	samples	as	small	 concentrations	of	 imidazole	and	are	
present	 in	 the	 protein	 samples.	 As	 imidazole	 absorbs	 light	 at	 280	 nm,	 it	 will	 be	
forming	 the	 false	 blank	 plateau	 observable	 at	 ~260	 nm	 seen	 in	 figure	 4.11.	 The	
protein	samples	run	on	the	SDS-PAGE	gels	in	figures	4.12	and	4.13	indicate	that	the	
samples	are	at	a	much	higher	purity.		
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4.2.5:	Qualitative	Analysis	of	GFP-NT/GFP	Purification	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.12:	 SDS-PAGE	 to	 display	 purity	 of	 purified	 His-GFP-NT.	 Each	 well	 contains	 10	 μl	 of	 each	
respective	 sample.	 This	 Image	 is	 representative	 of	multiple	 purifications	 of	His-GFP-NT.	 The,	 broad	
range	11-245	kDa	colour	pre-stained	protein	standard	was	used	for	reference	in	this	gel	(New	England	
Biolabs).	
	
Figures	4.12	and	4.13	show	the	qualitative	success	of	protein	purification	from	BL21	
E.coli	 as	described	 in	2.2.11.	Wells	 2-5	 contain	 samples	 from	 the	 first	 four	protein	
elution	 aliquots	 with	 200mM	 imidazole.	 The	 lack	 of	 bands	 other	 than	 that	
corresponding	 to	 the	 size	 of	 GFP-NT	 confirms	 the	 purity	 of	 the	 elution	 product.	
Elution	fraction	in	well	3	represents	the	aliquot	with	the	greatest	amount	of	protein	
eluted.	This	aliquot	was	 later	quantified	and	used	 in	 future	experiments.	Wells	6-8	
represent	wash	fractions	prior	to	addition	of	the	protein	sample,	confirming	that	no	
protein	was	present	 in	the	column	before	use.	Well	9	represents	the	100ul	sample	
taken	 from	 the	 bacterial	 lysis	 product	 described	 in	 section	 2.2.10.	 The	 bands	
corresponding	to	the	size	of	GFP-NT	are	labelled	with	red	boxes.	
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Figure	4.13:	Displays	purified	samples	of	His-GFP	following	expression	over	time	at	37°C.	10	μl	of	each	
sample	(that	had	been	purified)	was	combined	with	10μl	of	loading	buffer	(see	section	2.2.13),	15	μl	
of	 this	was	run	 in	each	well	of	 the	gel.	The	 ladder	used	 for	 this	gel	was	 the	SeeBlue®	Plus2	protein	
standard	 (Life	 Technologies).	 The	 presence	 of	 only	 one	 band	 corresponding	 to	 the	 size	 of	 GFP	
indicates	purity	of	the	samples	qualitatively.	
	
4.3:	Discussion	
Although	 the	 pET	 system	 is	 a	 popular	 vector	 of	 choice	 for	 recombinant	 protein	
expression,	 it	 is	 associated	 with	 several	 drawbacks.	 For	 example,	 the	 levels	 of	 T7	
RNA	 polymerase	 generated	within	 the	 bacterial	 cell	may	 be	 higher	 than	 required,	
leading	 to	excessive	expression	of	 the	 recombinant	 gene	of	 interest.	As	previously	
mentioned,	 this	 could	 lead	 to	 a	 decrease	 in	 cellular	 growth,	 or	 potentially	 reach	
protein	concentrations	that	are	toxic	to	the	cell.	For	this	reason,	and	for	the	interest	
of	obtaining	protein	samples	as	efficiently	as	possible,	optimisation	of	the	expression	
procedure	 was	 carried	 out	 (as	 documented	 in	 4.2.3).	 Leaky	 control	 in	 gene	
expression,	perhaps	due	to	bacterial	RNA	polymerase,	has	also	been	observed	in	this	
vector	–	allowing	for	low	levels	of	gene	expression	in	the	absence	of	IPTG	(Overton,	
2014).	 This	 was	 observed	 during	 protein	 expression	 of	 both	 small	 bacterial	
expansion	 cultures	 and	 large	 batch	 protein	 production	 cultures,	 which	 can	 be	 a	
problem	if	the	recombinant	protein	 in	question	 is	toxic	to	the	cells.	Some	research	
speculates	 that	 eGFP	 is	 toxic	 to	 living	 cells,	 which	 could	 explain	 the	 decrease	 in	
protein	 quantified	 after	 sample	 collection	 at	 16hrs	 from	 the	 37°C	 expression	
condition.	 However,	 the	 only	 documented	 GFP-induced	 cell	 death	 in	 living	 cells	
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comes	from	constant	intense	excitation	of	the	fluorophore	over	long	periods	of	time,	
which	is	speculated	to	produce	free	radicals	(Liu	et	al.,	1999).	As	protein	expression	
was	performed	in	a	relatively	dark	environment,	this	 is	unlikely	to	be	the	case.	The	
decrease	in	protein	expression	observed	at	the	37°C	seen	at	16hrs	is	likely	to	be	the	
result	of	cell	lysis	during	culture	due	to	a	build	up	of	toxic	by-products	of	growth	or	
excessive	 intracellular	 demand	 due	 to	 previously	 high	 throughputs	 of	 protein	
production	 (Shiloach	 and	 Fass,	 2005).	 The	 doubling	 time	 of	 E.coli	 in	 LB	 broth	 has	
been	 extensively	 documented	 at	 20	 minutes	 during	 the	 steady-state/exponential	
growth	 phase,	 which	 lasts	 until	 an	 optical	 density	 of	 around	 0.3	 (but	 is	 slightly	
variable	between	strains	of	E.coli).	After	this	time,	a	decrease	in	growth	rate	and	cell	
size	 is	 observed	 (Sezonov	 et	 al.,	 2007).	 Recombinant	 protein	 production	 can	 be	
induced	at	either	a	high	or	low	biomass	phase	of	growth,	to	either	induce	production	
when	cells	are	naturally	slowing	in	growth	or	be	produced	concurrently	with	growth.	
Both	 methods	 have	 found	 success,	 but	 inducing	 at	 a	 high	 biomass	 when	 the	
expressed	protein	 is	 toxic	 to	 cells	will	 limit	any	growth	 inhibition	caused	 (Overton,	
2014).	IPTG	addition	was	synchronised	with	the	end	of	the	exponential	growth	phase	
in	this	study	(see	section	2.2.9).	To	minimise	any	loss	in	protein	before	purification,	
sample	processing	(section	2.2.10)	was	conducted	immediately	after	collection	from	
the	original	culture	volume.	If	whole	culture	samples	were	frozen	immediately	after	
collection,	 a	 visually	 noticeable	 amount	 of	 cells	 had	 lysed	 during	 the	 freeze-thaw	
process,	releasing	protein	into	the	supernatant,	which	would	ultimately	be	discarded	
(see	figure	4.14).	
	
	
	
	
	
	
	
	
Figure	 4.14:	 Comparison	 of	 supernatant	 colour	 after	 centrifugation	 of	 bacterial	 culture	 sample	
immediately	after	collection	(left)	or	after	a	freeze-thaw	cycle	(right).	Both	samples	were	expressed	at	
20°C.	
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The	 concept	 of	 immobilised	 metal	 affinity	 chromatography	 (IMAC)	 was	 first	
developed	by	Porath	(1975)	and	is	based	on	the	affinity	of	transition	metal	ions	(Zn2+,	
Cu2+	and	Ni2+)	towards	histidine,	cysteine	and	tryptophan.	A	HisTrap	HP	column	(GE	
Healthcare)	was	employed	for	this	study,	based	on	the	affinity	of	Ni2+	to	the	histidine	
residues	 recombinantly	 expressed	 with	 GFP-NT	 and	 GFP.	 Imidazole	 acts	 by	
competing	 for	binding	sites	 in	the	column	and	displacing	His-GFP-NT.	Compared	to	
other	methods	of	protein	purification,	(such	as	size	exclusion	chromatography,	high	
performance	 liquid	 chromatography	 and	 ultracentrifugation)	 IMAC	 compares	 well	
with	 biospecific	 affinity	 chromatography	 with	 respect	 to	 separation	 efficiency	 but	
without	 the	 limitation	 of	 degradation	 of	 antibodies	 or	 enzymes	 present	 in	 the	
column.	Metal	ions	are	much	more	likely	to	withstand	the	wear	and	tear	of	repeated	
use	 (Porath,	 1992).	 Coupled	 with	 the	 ease	 of	 bioengineering	 Histidine	 tags	 into	
recombinant	DNA,	this	makes	IMAC	an	ideal	candidate	for	protein	purification	of	His-
GFP-NT.		
	
To	ensure	100%	purity	of	the	protein	sample,	gel	filtration	chromatography	could	be	
utilised	after	 initial	purification	by	metal	affinity	chromatography.	This	 is	a	 form	of	
partition	 chromatography	 used	 to	 separate	molecules	 of	 different	molecular	 sizes	
(O’Fágáin	et	al.,	2011).	
	
With	regards	to	protein	structural	 integrity	post-expression	–	compared	to	the	vast	
array	 of	 proteins	 that	 have	 been	 produced	 by	 recombinant	 expression,	 eGFP	 is	
relatively	 stable	 (as	 described	 in	 4.1.4).	 However,	 to	 ensure	 protein	 structural	
integrity	 -	 protein	 samples	 (1	ml)	once	purified	were	 separated	 into	50	ul	 aliquots	
and	 only	 thawed	 once	 on	 ice	 (when	 required	 for	 experiments)	 per	 aliquot,	 then	
discarded.		
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4.4:	Conclusion	
Generally,	 the	 pET	 system	 for	 recombinant	 expression	 worked	 very	 well	 for	
expression	of	the	model	drug	His-tagged	GFP-NT	and	for	His-tagged	GFP	(created	for	
the	purposes	of	acting	as	a	negative	control	in	future	experiments).	No	issues	were	
encountered	during	the	protein	expression,	purification	and	quantification	procures	
that	have	not	already	been	discussed.	Expression	for	8hrs	and	37°c	was	found	to	be	
optimal	 and	 therefore	 employed	 for	 expression	 of	 all	 His-tagged	 GFP-NT	 and	 His-
tagged	GFP	 samples	used	 in	 this	 study.	 Purification	was	 assessed	qualitatively	 and	
shown	 to	 be	 acceptable	 for	 further	 use.	 Considerations	 for	 the	 future	 use	 of	 the	
recombinant	 proteins	 in	 this	 study	were	made	 and	 enforced	 strictly	 to	 ensure	 no	
unnecessary	degradation	to	the	protein	was	incurred	as	discussed	in	section	4.3.	
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Chapter	5	
Internalisation	of	Neurotensin-Conjugated	Fluorophores	
	
5.1:	Introduction		
	
5.1.1:	Variability	in	Receptor	Mediated	Endocytosis	
Endocytosis,	 a	 mechanism	 common	 to	 all	 cells	 in	 the	 human	 body,	 internalises	
molecules	 for	 retention	within	an	endosomal	 scaffold	and	delivery	 to	 specific	 sub-
cellular	 organelles.	 Internalisation	mechanisms	 and	 the	 constructs	 associated	with	
them	(such	as	clathrin	and	caveolin)	are	specific	to	certain	molecules	and	cell	types;	
hence,	 researchers	have	been	presented	the	opportunity	 to	bioengineer	molecular	
complexes	 for	 targeted	 delivery.	 One	 such	 target	 is	 membrane	 specific	 peptide	
receptors	 such	 as	 NTS1.	 The	 majority	 of	 targeted	 delivery	 systems	 aim	 to	 avoid	
lysosomal	 trafficking	 of	 the	 attached	 therapeutic	 molecule	 and	 subsequent	
enzymatic	degradation	(Bareford	and	Swaan,	2007).		
	
Most	 of	 what	 is	 currently	 understood	 about	 internalisation	 of	 trafficked	 ligand-
receptor	 complexes	 originates	 from	 studies	 focused	 on	 receptors	 with	 single	
transmembrane	 domains,	 such	 as	 the	 internalisation	 of	 transferrin	 via	 clathrin-
coated	pits.	Following	internalisation	of	many	different	ligand-receptors	complexes,	
dissociation	of	ligand	from	receptor	appears	to	be	common	in	early	endosomes	due	
to	 their	 slightly	acidic	nature	–	 from	this	point,	variability	 in	whether	 the	 ligand	or	
receptor	is	degraded	or	recycled	back	to	the	cell	surface	is	evident	(Pearse,	1982).		
	
In	most	 cell	 types,	 receptor-mediated	peptide	 internalisation	 results	 in	 fusion	with	
lysosomes	and	degradation	 (Backer	et	al.,	 1990).	However,	 internalisation	of	NT	 is	
thought	 to	 follow	 a	 different	 route.	 Vandenbulcke	 et	 al.,	 (2000)	 investigated	 the	
method	 of	 internalisation	 of	 fluorescently	 labelled	 NT	 (Fluo-NT)	 in	 COS-7	 cells	
transfected	 with	 NTS1;	 the	 team	 demonstrated,	 by	 methods	 of	 inhibition	
(hypertonic	 sucrose,	 potassium	 depletion	 and	 cytosol	 acidification)	 that	 NT	
internalisation	is	mediated	by	clathrin	coated	pits	(see	Figure	1.1).	Within	30	minutes,	
NT-NTS1	 complexes	 accumulated	 within	 early	 endosomes,	 characterised	 by	
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positively	staining	with	Acridine	Orange	and	for	rab	5A.	Between	30	and	45	minutes,	
NT	was	shown	to	have	delocalised	 from	 its	 receptor	and	was	 later	 identified	 to	be	
present	 in	 the	 non-acidic	 juxtanuclear	 compartment	 of	 the	 trans-golgi	 network	
(TGN).	This	suggested	recruitment	of	the	peptide	from	late	endosomes.	The	receptor	
itself	 was	 determined	 to	 be	 trafficked	 to	 Lamp-1	 positive	 lysosomes,	 suggesting	
degradation	(see	figure	5.1).		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.1	taken	from	(Vandenbulcke	et	al.,	2000)	shows	the	localisation	of	fluorescently	labelled	NT	
during	internalisation	over	time	in	transfected	COS-7	cells.	(A)	The	majority	of	NT	localised	at	the	cell	
membrane	after	5	minutes	(B)	After	hypertonic	acid	stripping	of	NT	after	5	minutes	of	incubation	with	
NT	(C)	Localisation	after	20	minutes	of	incubation	with	Fluo-NT	in	endosome-like	particles	within	the	
cytoplasm.	(D)	Localisation	after	45	minutes	clustered	near	the	nucleus.	
	
The	 trafficking	 of	 GPCRs	 through	 endosomes	 is	 critical	 in	 determining	 cellular	
response	 to	 external	 agonists.	 Ligand-stimulated	 receptor	 endocytosis	 generally	
depletes	GPCRs	from	the	membrane	in	an	attempt	to	prevent	overstimulation	of	the	
cell	 from	the	ligand	(as	previously	mentioned	in	section	1.7)	–	this	can	be	reversed	
by	 receptor	 recycling	 and	 receptor	 dephosphorylation	 following	 internalisation	
(Ferguson,	2001;	Garland	et	al.,	1996).	NTS1	has	been	shown	to	exhibit	high	affinity	
interactions	with	β-arrestins	during	receptor	endocytosis	(Oakley	et	al.,	2000),	which	
has	 been	 shown	 to	 be	 important	 for	 NTS1	 internalisation	 in	 many	 cell	 types.	
However,	 the	 subject	 of	 whether	 NTS1	 is	 recycled	 back	 to	 the	 cell	 surface	 or	
degraded	is	a	controversial	subject	(Law	et	al.,	2012).	This	characteristic	appears	to	
10μm	
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be	 dependant	 on	 the	 cell	 type	 as	 NTS1	 is	 recycled	 in	 human	 neuroblastoma	 cells	
CHP212	(Toy-Miou-Leong	et	al.,	2004)	but	degraded	in	COS-7	cells	(Vandenbulcke	et	
al.,	2000).	Little	is	known	about	NT	internalisation	in	Caco-2	and	HEK293,	although,	
Neuropeptide	Y	(also	a	neuropeptide)	is	thought	to	be	internalised	into	HEK293	in	a	
similar	manner	 to	 NT	 is	 COS-7	 (Pheng	 et	 al.,	 2003).	 Other	 GPCRs	 such	 as	 the	 β2-
adernergic	 receptor,	 neurokinin	 1	 receptor	 and	 gastrin-releasing	 peptide	 receptor	
are	all	recycled	following	ligand-induced	internalisation	(Grady	et	al.,	1996;	Tarasova	
et	al.,	1997;	Zastrow	and	Kobilka,	1992).	
	
Studies	 into	 the	 internalisation	 of	 NT	 in	 cells	 of	 neuronal	 lineage,	 endogenously	
expressing	 NTS1,	 show	 that	 the	 ligand	 is	 internalised	 with	 the	 receptor	 and	
subsequently	 trafficked	from	the	perikarya	and	dendrites	 to	 the	perinuclear	region	
within	vesicular	organelle-like	structures.	 Interestingly,	NT	was	only	observed	to	be	
internalised	 with	 incubations	 at	 37°c,	 as	 opposed	 to	 being	 almost	 completely	
membrane-bound	 with	 incubations	 at	 4°c.	 Suggesting	 that	 the	 receptor-mediated	
internalisation	of	NT	is	temperature	dependant	(Nouel	et	al.,	1997).		
	
5.1.2:	Clathrin-Mediated	Endocytosis		
Of	 all	 methods	 of	 endocytosis,	 clathrin-mediated	 is	 by	 far	 the	 most	 extensively	
studied.	 Other	 mechanisms	 of	 endocytosis	 include	 caveolin-mediated,	
macropinocytosis	 and	 phagocytosis.	 Many	 clathrin-dependant	 endocytosis	 events	
mediate	the	transport	of	large	molecules	needed	for	essential	cell	maintenance	such	
as	 lipoproteins,	 iron-saturated	 transferrin	 and	 an	 array	 of	 growth	 factors	 (Conner	
and	Schmid,	2003).	The	process	of	internalisation	is	a	multi-step	mechanism,	starting	
with	the	formation	of	clathrin-coated	vesicles,	which	requires	the	cooperative	efforts	
of	 more	 than	 50	 different	 proteins.	 The	 formation	 of	 vesicles	 begins	 with	 the	
recruitment	 of	 clathrin,	 adaptor	 proteins	 and	 endocytic	 accessory	 proteins	 to	 the	
plasma	 membrane,	 where	 it	 forms	 lattices	 of	 clathrin	 around	 the	 internalised	
portions	of	membrane	ranging	in	diameter	from	10	to	~500	nm.	Clathrin	forms	a	cag-
like	 spherical	 structure	 once	 vesicle	 formation	 is	 complete.	 Adaptor	 proteins	
mediate	 clathrin	 binding	 to	 transmembrane	 receptors	 shortly	 after	 ligand	 binding	
(and	 required	 conformational	 changes	 to	 the	 transmembrane	 receptor	 induced	by	
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ligand	 binding).	 The	 cage-like	 clathrin	 structure	 is	 later	 disassembled	 by	 accessory	
proteins	once	internalisation	of	extracellular	cargo	has	been	achieved,	releasing	the	
contained	vesicle	into	the	cell	for	continued	intracellular	trafficking	(Heuser,	1980).	
	
Clathrin-mediated	membrane	vesicle	formation	is	not	limited	to	the	cell	membrane	–	
it	can	also	occur	in	the	TGN,	contributing	to	the	transport	of	cargo	from	the	TGN	to	
endosomes,	 as	 well	 as	 transporting	 cargo	 from	 the	 cell	 membrane	 to	 the	 TGN	
(Robinson,	2004).		
	
5.1.3:	How	Do	Modifications	To	The	Peptide	Affect	Internalisation?	
As	GPCRs	 are	 a	 popular	 target	 for	 therapeutic	 purposes,	 it	 is	 beneficial	 to	modify	
their	respective	peptides	or	 ligands	to	better	avoid	degradation	prior	to	delivery	to	
its	receptor.	This	applies	to	the	production	if	peptide	analogues	that	have	previously	
been	 described	 to	 be	 modified	 to	 withstand	 degradation	 by	 in	 vivo	 pH	 and	
temperature	changes.	Chemical	modifications	such	as	PEGylation	and	lipidation	are	
employed	 to	 prolong	 the	 half-lives	 of	 peptides	 and	 have	 been	 shown	 to	 confer	
additional	benefits.	For	example,	modification	of	pancreatic	polypeptides	has	shown	
to	enhance	the	preference	of	 the	polypeptides	to	certain	receptors	over	others.	 In	
this	 case,	 lipidation	 of	 the	 polypeptide	 encourages	 arrestin	 recruitment	 and	
internalisation,	whereas	PEGylation	encourages	the	complete	opposite	(Mäde	et	al.,	
2014).	This	observation	suggests	that	selective	modifications	to	peptides	may	make	
them	preferentially	 select	 certain	 receptor	 sub-types	 if	 it	 is	 a	 ligand	 to	more	 than	
one	receptor.		
	
Jia	et	al.,	(2015)	investigated	the	rates	of	internalisation	of	NT	conjugated	to	a	large	
molecule	(DOTA),	used	for	radiotherapy.	The	study	found	that	the	use	of	a	spacer	(β-
Alanine)	 between	 NT	 and	 the	 large	 molecule	 increase	 internalisation	 rates	 of	 NT	
analogues	mediated	 by	 NTS1	 compared	 to	 conjugation	 of	 the	molecule	without	 a	
spacer.	This	reflects	the	work	of	Antunes	et	al.,	(2007)	that	documents	the	effect	of	
spacers	between	somatostatin	analogues	and	radiolabelled	DOTA.	The	study	found	
that	 the	 introduction	 of	 a	 β-Alanine	 spacer	 did	 not	 affect	 hydrophilicity	 (although	
other	spacers	did	increase	this),	whilst	maintaining	the	peptide	analogue's	structural	
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modifications	 and	 slightly	 decreasing	 the	 affinity	 of	 the	 analogue	 to	 its	 receptors.	
The	 main	 benefit	 of	 introducing	 of	 spacers	 was	 the	 noticeable	 increase	 in	
internalisation	rate;	somatostatin-DOTA	uptake	went	from	0.48%	IA/g	in	four	hours	
to	4.17%	IA/g	in	pancreatic	tumour	cells.		
	
5.1.4:	Small	Molecule	Fluorophores	
Fluorescent	compounds	based	on	synthetic	small	molecules	are	useful	tools	for	the	
visualisation	of	events	 inside	 living	cells.	Since	 the	discovery	of	quinine	sulphate	 in	
1845,	and	the	realisation	that	the	molecule	emitted	blue	fluorescence	when	exposed	
to	UV	light,	fluorescent	molecules	have	been	continually	modified	and	improved	for	
use	 as	 labelling	 agents	 and	 biosensors	 (Terai	 and	 Nagano,	 2013).	 Fluorescein	 has	
become	 the	 ubiquitous	 small-molecule	 fluorophore	 for	 countless	 scientific	 and	
industrial	 applications,	 including	 being	 the	 first	 label	 for	 immunofluorescence	
microscopy	 (Coons	 and	Kaplan,	 1950).	 The	 florescent	 properties	 of	 fluorescein	 are	
formed	from	an	equilibrium	of	the	'open',	fluorescent	form	of	the	structure	and	the	
'closed'	non-fluorescent	structure	–	an	equilibrium	that	can	be	modulated	with	the	
use	of	blocking	groups	to	preserve	its	open	structure	(Tian	et	al.,	2012).	Fluorescein	
(F)	is	one	of	the	most	commonly	used	fluorescent	probes,	with	a	large	fluorescence	
quantum	 yield	 and	 high	 photostability,	 it	 has	 proven	 to	 be	 an	 effective	 tool.	
Derivatives	of	 fluorescein	exist	 that	are	 lipophilic	 in	nature,	but	 fluorescein	 itself	 is	
hydrophilic	and	can	exist	 in	many	 forms	 in	aqueous	 solution:	occurring	 in	cationic,	
neutral,	anionic	and	dianionic	forms,	making	its	fluorescent	properties	pH	dependent	
(Sjöback	et	al.,	1995).	
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5.2:	Results	
5.2.1:	Converting	Fluorescence	Readings	Into	Concentrations	
Calibration	 curves	 were	 made	 with	 serial	 dilutions	 of	 solutions	 of	 known	
concentrations	 for	 both	 F-NT	 and	 GFP-NT,	 originally	 quantified	 by	 UV-Vis	
spectrophotometry	as	described	 in	section	4.2.4.	The	 fluorescence	of	each	dilution	
was	 read	 with	 the	 Tecan	 Infinite	 Microplate	 reader	 at	 an	 excitation	 wavelength	
appropriate	for	the	fluorophore	in	question	(see	figure	5.2).	Calibration	curves	were	
produced	in	triplicate	and	the	graph	plotted	(figure	5.2)	shows	the	average	of	those.	
The	 number	 of	 cells	 estimated	 to	 be	 present	 in	 each	 test	 well	 after	 48	 hours	 of	
growth	in	a	12	well	plate	(see	Figure	3.10)	was	lysed	in	lysis	buffer,	removed	of	any	
cellular	 debris	 by	 centrifugation,	 and	 used	 as	 the	 diluent	 for	 each	 fluorophore	
dilution	 to	 ensure	 that	 cellular	 auto-fluorescence	did	 not	 affect	 the	 data	 collected	
from	each	experiment.		
	
Figure	 5.2:	 Calibration	 curve	 for	 the	 quantification	 of	 GFP-NT	 protein	 samples	 collected	 from	
undifferentiated	Caco-2	cells.		
	
The	calibration	curve	shown	is	made	from	a	serial	dilution	of	GFP-NT.	This	curve	has	
been	 constructed	 to	 exclude	 autofluorescence	 from	 experimental	 samples	 by	
including	 the	 intracellular	 contents	 of	 an	 appropriate	 number	 of	 undifferentiated	
Caco-2	 cells.	 Calibration	 curves	 had	 also	 been	made	 from	 serial	 dilutions	 of	 F-NT.	
Calibrations	 for	 each	 respective	 cell	 line	were	made	using	 intracellular	 contents	of	
HEK293	cells,	undifferentiated	Caco-2	cells	and	differentiated	Caco-2	cells	 for	both	
GFP-NT	 and	 F-NT.	 The	 appropriate	 calibration	 curve	 was	 used	 for	 converting	
fluorescence	 intensity	 into	 fluorophore	 concentration	 for	 each	 cell	 line	 and	
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fluorophore	 used	 in	 each	 assay	 to	 ensure	 the	 most	 accurate	 acquisition	 of	
quantitative	uptake	or	transport	of	GFP-NT/F-NT	into	or	through	cells.	
	
5.2.2:	Fluorophore	Internalisation	into	Undifferentiated	Caco-2	
See	section	2.2.31	for	the	full	description	of	methods	employed	in	this	section.	
Undifferentiated	Caco-2	cells,	grown	for	48	hours	(detailed	in	2.2.21)	were	incubated	
with	solutions	of	NT-conjugated	fluorophores	(GFP-NT	or	F-NT)	containing	either	NT-
fluorophore	alone,	NT-fluorophore	with	a	100x	excess	of	free	NT,	NT-fluorophore	
with	a	10x	excess	of	SR142948	or	fluorophore	alone.	This	was	done	to	compare	
internalisation	of	NT-fluorophore	in	receptor	uninhibited	and	receptor	inhibited	
conditions.	Free	NT	competitively	inhibits	all	NT	receptors,	and	SR142948	selectively	
inhibits	NTS1	and	NTS2.	All	solutions	were	made	in	HBSS.		
	
Figure	5.3	shows	GFP-NT	and	F-NT	internalisation	into	undifferentiated	Caco-2	cells,	
which	have	been	previously	characterised	to	minimally	express	NTS1.	The	extent	of	
internalisation	seen	for	each	condition	is	comparable	to	uptake	of	fluorophore	alone,	
and	therefore	due	to	non-specific	transport.	Figure	5.4	provides	a	visual	comparison	
of	GFP-NT	(A)	and	F-NT	(B)	internalisation	into	undifferentiated	Caco-2	cells.	The	
images	show	minimal	amounts	of	both	GFP-NT	and	F-NT	within	the	cells.	
	
Figure	5.3:	Quantification	of	internalised	GFP-NT	(left)	or	F-NT	(right)	in	undifferentiated	Caco-2	cells.	
The	samples	applied	to	each	well	(as	annotated	in	this	figure)	are	as	follows:	(GFP-NT/F-NT)	=	20	nM	
GFP-NT	in	HBSS,	(GFP-NT	+	Free	NT/F-NT	+	Free	NT)	=	20	nM	GFP-NT/F-NT	+	2μM	free	NT,	(GFP-NT	+	
2R142948)	 =	 20	 nM	 GFP-NT/F-NT	 +	 200	 nM	 SR142948,	 (GFP/F)	 =	 20	 nM	 GFP/F.	 Error	 bars	 are	
representative	of	±SD	and	each	data	point	is	the	mean	of	n=3.	
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Figure	5.4:	(A)	GFP-NT	internalisation	in	undifferentiated	Caco-2	after	incubation	for	1hr	with	20	nM	
GFP-NT.	(B)	F-NT	internalisation	in	undifferentiated	Caco-2	after	incubation	for	1hr	with	20	nM	F-NT.	
The	white	bar	is	representative	of	50	μm.	
	
5.2.3:	GFP-NT	Internalisation	into	HEK293	
See	section	2.2.31	for	the	full	description	of	methods	employed	in	this	section.	
HEK293	cells,	grown	for	48	hours	(detailed	in	2.2.21)	were	incubated	with	solutions	
of	GFP-NT	containing	either	GFP-NT	alone,	GFP-NT	with	a	100x	excess	of	free	NT,	
GFP-NT	with	a	10x	excess	of	SR142948	or	GFP	alone.	This	was	done	to	compare	
internalisation	of	GFP-NT	in	receptor	uninhibited	and	receptor	inhibited	conditions.	
This	was	assessed	in	both	non-transfected	and	transfected	HEK293	cells.	Free	NT	
competitively	inhibits	all	NT	receptors,	and	SR142948	selectively	inhibits	NTS1	and	
NTS2.	All	solutions	were	made	in	HBSS.	
	
	Figure	5.5	shows	GFP-NT	internalisation	to	be	receptor	mediated	as	uptake	is	
greatly	reduced	in	conditions	containing	competitive	inhibitors	of	NT-receptors	(free	
NT	and	SR142948).	The	maximum	uptake	of	GFP-NT	alone	is	also	greater	in	
transfected	HEK293	cells	compared	to	non-transfected	cells,	suggesting	uptake	
correlates	with	relative	NTS1	expression	(as	transfected	HEK293	express	higher	
levels	of	NTS1).	Table	5.1	states	the	p	values	of	each	data	point	in	figure	5.5	when	
compared	to	the	others	in	the	same	figure	by	(Student's	T-test)	to	determine	any	
significant	differences	in	internalisation	of	each	fluorophore.	This	table	is	separated	
into	transfected	and	non-transfected	cells.	
	
	
	
		A	 		B	
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Figure	 5.5:	 Quantification	 of	 internalised	 GFP-NT	 in	 non-transfected	 (left)	 and	 transfected	 (right)	
HEK293	cells.	The	samples	applied	to	each	well	(as	annotated	in	this	figure)	are	as	follows:	(GFP-NT)	=	
20	nM	GFP-NT,	(GFP-NT	+	Free	NT)	=	20	nM	GFP-NT	+	2	μM	free	NT,	(GFP-NT	+	SR142948)	=	20	nM	
GFP-NT	+	200	nM	SR142948,	(GFP)	=	20	nM	GFP.	Error	bars	are	representative	of	±SD	and	each	data	
point	is	the	mean	of	n=3.	Data	sets	were	analysed	using	an	unpaired	t-test	and	P-values	are	stated	in	
table	5.1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	 5.1:	 Statistical	 significance	 of	 internalisation	 in	 each	 condition	 shown	 in	 Figure	 5.5	 as	
determined	by	an	unpaired	Students	t-test	with	Welsh's	correction.	All	P	values	are	two-tailed.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Non-transfected	 P	value	
GFP-NT	vs	GFP-NT	+	Free	NT	 0.1039 (ns)	
GFP-NT	vs	GFP-NT	+	SR142948	 0.0.1353 (ns)	
GFP-NT	vs	GFP	 0.1760 (ns)	
Transfected	 P	value	
GFP-NT	vs	GFP-NT	+	Free	NT	 0.0066 (**)	
GFP-NT	vs	GFP-NT	+	SR142948	 0.0044 (**)	
GFP-NT	vs	GFP	 0.0009 (***)	
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Figure	5.6	provides	a	visual	comparison	of	GFP-NT	(A)	and	GFP-NT	with	a	100x	excess	
of	NT	 (B)	 internalisation	 into	 transfected	HEK293	cells.	Relatively	 large	amounts	of	
GFP-NT	 are	 observable	 in	 areas	 localised	 around	 the	 nucleus	 in	 (A),	 compared	 to	
minimal	amounts	seen	 in	(B),	confirming	 inhibition	of	uptake	with	the	 introduction	
of	 an	 excess	 of	 NT	 and	 transport	 being	 mediated	 via	 neurotensin	 receptors.	 The	
separated	 channels	 of	 (A),	 seen	 as	 DAPI	 (C)	 and	GFP-NT	 (D)	 show	main	 bodies	 of	
fluorescence	originating	from	regions	surrounding	the	nucleus	of	the	cell.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.6:	Confocal	microscope	images	of	transfected	HEK293	after	(A)	incubation	with	20	nM	GFP-
NT	 	 for	 1hr	 and	 (B)	 incubation	 with	 20	 nM	 GFP-NT	 and	 2	 μM	 NT	 for	 1	 hr.	 (C)	 and	 (D)	 shows	 a	
breakdown	 of	 image	 (A)	 to	 show	 the	 locality	 of	 the	 fluorophore	 within	 the	 cell.	 The	 white	 bar	 is	
representative	of	50	μm.	
	
5.2.4:	F-NT	Internalisation	into	HEK293	
See	section	2.2.31	for	the	full	description	of	methods	employed	in	this	section.	
HEK293	cells,	grown	for	48	hours	(detailed	in	2.2.21)	were	incubated	with	solutions	
of	F-NT	containing	either	F-NT	alone,	F-NT	with	a	100x	excess	of	free	NT,	F-NT	with	a	
10x	excess	of	SR142948	or	F	alone.	This	was	done	to	compare	internalisation	of	F-NT	
in	receptor	uninhibited	and	receptor	inhibited	conditions.	This	was	assessed	in	both	
non-transfected	and	transfected	HEK293	cells	(refer	to	section	2.2.23	for	the	
A	
C	 D	
B	
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transfection	process).	Free	NT	competitively	inhibits	all	NT	receptors,	and	SR142948	
selectively	inhibits	NTS1	and	NTS2.	All	solutions	were	made	in	HBSS.	
	
Figure	5.7	shows	F-NT	internalisation	to	also	be	receptor	mediated	as	uptake	is	
greatly	reduced	in	conditions	containing	competitive	inhibitors	of	NT-receptors	(free	
NT	and	SR142948).	Similarly	to	GFP-NT	uptake,	maximum	uptake	of	F-NT	alone	is	
also	greater	in	transfected	HEK293	cells	compared	to	non-transfected	cells,	
suggesting	that	uptake	correlates	with	relative	NTS1	expression	(as	transfected	
HEK293	express	higher	levels	of	NTS1).	Maximum	uptake	is	also	greater	with	F-NT	
compared	to	GFP-NT	in	the	same	condition	and	cell	transfection	status	(non-
transfected	or	transfected).	Table	5.2	states	the	p	values	of	each	data	point	in	figure	
5.7	when	compared	to	the	others	in	the	same	figure	by	(Student's	T-test)	to	
determine	any	significant	differences	in	internalisation	of	each	fluorophore.	This	
table	is	separated	into	transfected	and	non-transfected	cells.	
	
Figure	 5.7:	 Quantification	 of	 internalised	 F-NT	 in	 non-transfected	 (left)	 transfected	 HEK293	 cells	
(right).	The	samples	applied	to	each	well	(as	annotated	in	this	figure)	are	as	follows:	(F-NT)	=	20nMF-
NT,	 (F-NT	 +	 Free	 NT)	 =	 20	 nM	 F-NT	 +	 2	 μM	 free	 NT,	 (F-NT	 +	 SR142948)	 =	 20	 nM	 F-NT	 +	 200	 nM	
SR142948,	(F)	=	20	nM	F.	Error	bars	are	representative	of	±SD	and	each	data	point	is	the	mean	of	n=3.	
Data	sets	were	analysed	using	an	unpaired	t-test	and	P-values	are	stated	in	table	5.2.	
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Table	 5.2:	 Statistical	 significance	 of	 internalisation	 in	 each	 condition	 shown	 in	 figure	 5.7	 as	
determined	by	an	unpaired	Student's	t-test	with	Welsh's	correction.	All	P	values	are	two-tailed.	
	
	
Figure	5.8	provides	a	visual	comparison	of	F-NT	(A)	and	F-NT	with	a	100x	excess	of	
NT	(B)	internalisation	into	transfected	HEK293	cells.	Relatively	large	amounts	of	F-NT	
are	observable	in	areas	localised	in	'C'	shapes	around	the	nucleus	in	(A),	compared	to	
a	smaller	in	(B).	Uptake	inhibition	was	achieved	with	the	introduction	of	an	excess	of	
NT,	 suggesting	 transport	 is	 mediated	 via	 neurotensin	 receptors.	 The	 separated	
channels	of	(A),	representing	as	nucleic	acids	stained	by	DAPI	(C)	and	F-NT	(D)	show	
main	bodies	of	fluorescence	originating	from	regions	surrounding	the	nucleus	of	the	
cell	with	scattering	of	fluorescence	observable	throughout	the	cell	cytoplasm.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Non-transfected	 P	value	
F-NT	vs	F-NT	+	Free	NT	 0.0011	(**)	
F-NT	vs	F-NT	+	SR142948	 0.0017	(**)	
F-NT	vs	F	 0.0012	(**)	
Transfected	 P	value	
F-NT	vs	F-NT	+	Free	NT	 0.0031	(**)	
F-NT	vs	F-NT	+	SR142948	 0.0007	(***)	
GFP-NT	vs	F	 0.0001	(***)	
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Figure	5.8:	Confocal	microscope	images	of	transfected	HEK293	after	(A)	incubation	with	20	nM	F-NT	
for	1hr	and	(B)	incubation	with	20	nM	F-NT	and	2	μM	NT	for	1	hr.	(C)	and	(D)	shows	a	breakdown	of	
image	(A)	to	show	the	locality	of	the	fluorophore	within	the	cell.	The	white	bar	is	representative	of	50	
μm.	
	
5.3:	Discussion	
Delivery	of	chemotherapeutic	agents	to	overcome	drug	resistance	is	a	major	topic	of	
interest	and	is	currently	being	investigated	for	the	potential	to	improve	drug	delivery	
of	 chemotherapeutics.	 For	 example	 Fan	 et	 al.,	 (2015)	 recently	 investigated	 the	
influence	 of	 conjugating	 doxorubicin	 (DOX)	 to	 epidermal	 growth	 factor	 (EGF)	 for	
targeted	 delivery	 to	 EGF	 over-expressing	 tumours.	 Their	 study	 consisted	 of	
internalisation	 assays	 of	 EGF-DOX	 against	 internalisation	 of	 free	 DOX,	 and	
internalisation	 of	 EGF-DOX	 under	 inhibitory	 conditions,	 concluding	 that	 EGF-DOX	
uptake	 is	 far	 greater	 than	 uptake	 of	 DOX	 alone,	 which	 was	 documented	 to	 be	
receptor	 mediated.	 Uptake	 of	 NT-bound	 fluorophores	 in	 this	 study	 followed	 the	
same	pattern	 in	correlation	with	 relative	 intensity	of	NTS1	expression	 (see	chapter	
3):	 transfected	 HEK293	 cells	 internalised	 the	 most	 NT-bound	 fluorophores	 (see	
figures	5.5	and	5.7)	and	are	also	the	cell	line	which	appear	to	express	the	most	NTS1	
A	 B	
C	 D	
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(see	 figure	 3.4).	 Whereas,	 undifferentiated	 Caco-2	 cells	 were	 characterised	 to	
express	NTS1	very	minimally,	if	at	all	(see	figure	3.7)	–	these	cells	did	not	show	any	
difference	in	cellular	uptake	of	GFP-NT	or	F-NT	compared	to	the	fluorophore	alone	
or	in	the	documented	inhibited	conditions	(see	figure	5.3).		
	
Referring	to	figures	5.5	and	5.7,	the	maximum	uptake	of	GFP-NT	appears	to	be	lower	
than	the	maximum	uptake	of	F-NT	in	both	non-transfected	and	transfected	HEK293.	
This	 could	 be	 attributable	 to	 the	 size	 of	 the	 fluorophore	 affecting	 the	 extent	 of	
uptake.	 It	 is	 estimated	 that	 about	 2500	 clathrin-coated	 vesicles	 leave	 the	 plasma	
membrane	of	cultured	fibroblast	cells	every	minute.	Extracellular	fluid	is	trapped	in	
each	clathrin-coated	vesicle	once	internalised,	bringing	molecules	in	the	surrounding	
area	with	it	(Liu	et	al.,	2001).	It	is	possible	that	the	greater	extent	of	uptake	seen	for	
F-NT	could	be	attributable	to	its	small	size,	allowing	for	more	molecules	to	become	
trapped	during	 the	 internalisation	process.	Although	 they	can	enter	 the	cell	 slowly	
by	 other	 non-specific	 means,	 clathrin-mediated	 endocytosis	 of	 receptor-ligand	
complexes	is	thought	to	be	a	rapid	and	more	efficient	method	of	gaining	entry	into	
the	host	cell	in	most	cases.	Whilst	receptor	complexes	can	be	internalised	in	just	10	
seconds,	a	select	few	can	take	several	hours,	such	as	the	α-2-bungaratoxin	receptor	
(August,	2013;	Weigel	et	al.,	2013).	Little	is	known	about	the	specific	internalisation	
dynamics	of	neurotensin	in	the	cell-lines	used	in	this	study,	and	as	endocytotic	rates	
can	be	variable,	no	conclusions	can	be	drawn	from	the	data	presented	in	the	study	
about	how	the	size	of	the	molecule	affects	internalisation	rate.	For	further	study,	it	is	
suggested	that	more	frequent	samples	be	taken	between	time	0	minutes	and	time	
30	minutes	to	evaluate	the	dynamics	of	initial	uptake	when	the	rate	is	greatest.	One	
possible	means	of	further	elucidating	any	possible	relationship	between	fluorophore	
size	and	transport	 in	this	model	would	be	to	employ	other	quantitative	techniques	
such	as	flow	cytometry.	
	
One	 topic	 that	 this	 chapter	 aimed	 to	 address	 is	whether	 the	 size	 of	 the	molecule	
conjugated	 to	 NT	 inhibits	 its	 internalisation.	 This	 would	 elucidate	 whether	 larger	
chemotherapeutic/biotherapeutic	 molecules	 have	 the	 potential	 to	 be	 delivered	 in	
this	way.	GFP	has	a	relatively	large	structure	of	~27kDa	(Niwa	et	al.,	1996)	making	it	
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larger	in	size	or		comparable	to	the	size	of	most	commonly	used	chemotherapeutics.	
Fluorescein	is	much	smaller	at	~330	Da	(Tian	et	al.,	2012).	Data	displayed	in	figures	
5.5	 (GFP-NT)	 and	 5.7	 (F-NT)	 determined	 that	 size	 does	 affect	 internalisation,	 but	
does	 not	 inhibit	 it.	 Quantified	 values	 for	 GFP-NT	 uptake	 were	 found	 to	 be	 ~50%	
lower	than	that	of	F-NT.	Comparing	the	values	obtained	for	uptake	of	GFP-NT	vs	F-
NT	 in	 non-transfected	 HEK293,	 uptake	 of	 GFP-NT	was	 not	 found	 to	 be	 significant	
compared	 to	 the	 fluorophore	 alone	 (p=0.1760).	 Whereas,	 uptake	 of	 F-NT	 was	
significant	 compared	 to	 uptake	 of	 the	 fluorophore	 alone	 (p=0.0012).	 This	 may	
suggest	that	a	larger	cargo	is	internalised	less	efficiently	in	cells	that	only	moderately	
express	NTS1.	Although,	other	factors	such	as	stability	of	the	fluorophore	in	the	cell	
cannot	be	ruled	out.	Either	fluorophore	may	be	more	structurally	integral	within	the	
cell	 compared	 to	 the	 other,	 affecting	 the	 fluorescence	 reading.	 This	 idea	 could	 be	
extrapolated	 to	 hypothesise	 that	 physiologically	 normal	 tissues,	 that	 only	
moderately	 expresses	NTS1,	 such	 as	 cells	within	 the	 gastrointestinal	 tract	 and	 the	
brain	 (Zhao	 and	 Pothoulakis,	 2006),	 would	 uptake	 minimal	 amounts	 of	 NT-
conjugates	 compared	 to	 NTS1	 overexpressing	 tumours	 during	 peptide	 receptor	
targeted	bio-therapeutic	treatments.		
	
Confocal	images	of	HEK293	cells	following	1hr	incubation	with	20	nM	GFP-NT	(figure	
5.6)	and	F-NT	(figure	5.8)	show	the	localisation	of	the	fluorophore	within	the	cell.	In	
concordance	 with	 the	 quantified	 amount	 of	 GFP-NT	 and	 F-NT	 within	 the	 cell	 (as	
described	in	figures	5.5	and	5.7	respectively),	the	visible	amount	GFP-NT	in	HEK293	
appears	 to	 be	 less	 than	 that	 observed	 from	 F-NT.	 In	 terms	 of	 the	 locality	 of	 each	
fluorophore,	 the	majority	 of	 both	 appear	 to	 be	 localised	 in	 areas	 surrounding	 the	
nucleus	 of	 the	 cell.	 However,	 neither	 fluorophore	 appears	 to	 be	 surrounding	 the	
nucleus	as	tightly	as	that	documented	by	Vandenbulcke	et	al.,	(2000),	see	figure	5.1.	
This	may	be	due	to	break-down	of	NT	following	internalisation	as	the	peptide	is	very	
susceptible	to	enzymatic	degradation	by	peptidases	(Lamberts	et	al.,	1996).	As	GFP	is	
relatively	stable	and	resistant	to	slight	changes	 in	pH	(Liu	et	al.,	1999),	 it	may	have	
avoided	degradation	itself	and	begun	to	diffuse	throughout	the	cell,	if	not	continuing	
its	 set	 internalisation	 route	 with	 intact	 NT.	 As	 both	 fluorophores	 appear	 to	
congregate	around	the	nucleus	of	the	cell,	this	suggests	that	internalisation	of	NT	in	
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transfected	 HEK293	 follows	 a	 similar	 (if	 not	 the	 same)	 route	 of	 uptake	 as	 that	
documented	 in	 COS-7	 cells	 by	 Vandenbulcke	 et	 al.,	 (2000).	 Further	 investigation	
would	 be	 needed	 to	 ascertain	 the	 exact	 internalisation	 mechanism	 of	 NT	 into	
transfected	HEK293	cells,	but	the	data	presented	in	this	study,	with	HEK293	acting	as	
a	model	 for	NTS1	overexpressing	 solid-state	 tumours,	 suggests	 that	 conjugation	of	
bio-therapeutics	 to	NT	 for	 targeted	 delivery	 has	 potential	 for	 success.	 The	 data	 in	
this	 chapter	 was	 obtained	 flowing	 incubations	 with	 20	 nM	 solutions	 of	 NT-
conjugates,	 and	 was	 able	 to	 elicit	 an	 observable	 response	 at	 this	 relatively	 small	
concentration.	 When	 this	 is	 brought	 into	 context	 with	 relative	 amounts	 of	
chemotherapeutic	 vs	 NT-conjugate	 needed	 to	 elicit	 a	 therapeutic	 effect,	 the	
difference	is	very	clear.	For	example,	for	the	treatment	of	metastatic	breast	cancer,	
40-60	mg/m2	of	doxorubicin	 is	administered	 intravenously	and	 is	known	to	cause	a	
variety	of	adverse	side	effects,	such	as	hair	loss,	skin	reactions	and	diarrhoea	(Ai	et	
al.,	2013;	Misset	et	al.,	1999).	This	amount	could	be	greatly	decreased	if	conjugated	
to	a	high	affinity	peptide	such	as	neurotensin.	The	concentration	of	neurotensin	 in	
peripheral	plasma	is	dependent	on	levels	of	fat	ingestion,	but	rises	to	no	more	than	
30	 pM	 concentrations	 in	 the	 blood	 (Theodorsson-Norheim	 and	 Rosell,	 1983).	
Theoretically,	 the	 targeted-delivery	 of	 therapies	 will	 have	 the	 ability	 to	 reach	 a	
therapeutic	effect	with	a	lower	dose.	Hopefully,	this	will	reduce	adverse	side	effects	
seen	with	chemotherapeutic	therapies	(Majumdar	and	Siahaan,	2012).		
	
A	limitation	of	this	study	is	the	lack	of	differentiation	between	NT	receptor	subtypes	
and	 therefore	 how	each	one	 influences	 internalisation	 in	 Caco-2	 and	HEK293.	 The	
antagonist	 SR142948,	which	 is	 selective	 of	 both	 NTS1	 and	 NTS2,	 was	 used	 in	 this	
study.	 To	 differentiate	 further,	 the	 NTS1	 specific	 agonist,	 SR48692	 could	 be	 used.	
Therefore	 the	 data	 obtained	 is	 representative	 of	 the	 inhibition	 of	 these	 receptor	
subtypes,	 and	 not	 NTS3	 inhibition.	 However,	 the	 majority	 of	 data	 concerning	
neurotensin	internalisation	in	multiple	cell	lines	and	tissues	types	suggests	that	NTS1	
is	 responsible	 for	 the	 vast	 majority	 of	 NT	 uptake.	 This	 is	 shown	 by	 neurotensin	
binding/uptake	 being	 almost	 completely	 inhibited	 by	 the	 NTS1	 specific	 antagonist	
SR48692	(Körner	et	al.,	2015;	Moody	et	al.,	2001).	However,	this	may	not	be	the	case	
for	 the	 cell	 lines	 used	 in	 this	 study.	 Further	 experimentation	would	 be	 needed	 to	
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determine	whether	NTS1	 is	 responsible	 for	 the	 internalisation	 documented	 in	 this	
study,	and	to	also	characterise	NTS2	and	NTS3	expression.	
	
5.4:	Conclusion	
A	relationship	between	the	size	of	the	molecule	conjugated	to	NT	and	the	amount	
internalised	was	 suggested	with	 the	data	presented	 in	 this	 chapter.	 Internalisation	
was	 shown	 to	 be	 receptor	 mediated,	 due	 to	 its	 inhibition	 with	 an	 excess	 of	 free	
neurotensin	or	SR142948	 (as	competitive	 inhibitors)	and	qualitatively	correlated	to	
relative	expression	of	NTS1.	However,	no	differentiation	was	made	between	which	
neurotensin	 receptor	 subtype	 was	 responsible	 for	 uptake	 of	 the	 conjugated	
fluorophores.	 It	 is	 also	 unable	 to	 compare	 quantitative	 values	 for	 internalisation	
against	values	for	NTS1	expression	as	this	was	assessed	qualitatively	(see	chapter	3).	
As	 a	 response	 is	 observed	 in	 concentrations	 as	 small	 as	 20	 nM,	 peptide-targeted	
delivery	 has	 been	 shown	 to	 be	 a	 promising	 candidate	 for	 the	 delivery	 of	
chemotherapeutics	to	NT	receptor	overexpressing	tumours.	Further	work	is	needed	
to	elucidate	whether	NT	is	degraded	within	the	cell	following	internalisation	and	the	
precise	mechanism	of	uptake.	
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Chapter	6	
Internalisation	and	Transport	of	NT-Conjugated	Fluorophores	in	
Polarised	Caco-2	Monolayers	
	
6.1:	Introduction	
The	use	of	 intestinal	epithelial	 cells	 such	as	Caco-2	has	 increased	drastically	 in	 the	
field	of	pharmaceutical	 science	over	 the	 last	 20	 years.	A	 large	proportion	of	 these	
studies	 include	 cultivation	 as	monolayers	 on	 permeable	 filters	 for	 studies	 into	 the	
transport,	permeability	or	absorption	of	drugs	(Artursson	et	al.,	2012).	Generally,	the	
aim	of	cultivating	these	monolayers	 is	 to	determine	the	bioavailability	of	new	drug	
compounds,	 investigate	 the	 mechanism	 of	 drug	 uptake	 or	 transport	 across	 the	
epithelium	(passive	or	active)	identifying	any	relevant	carriers	that	may	be	involved.	
For	example,	P-glycoprotein,	an	ATP	binding	cassette	transporter	responsible	for	the	
efflux	of	xenobiotics	and	drugs,	is	known	to	be	localised	on	the	apical	side	of	several	
barrier	epithelia	 including:	 the	 intestinal	epithelia,	brain	endothelial	cells	and	renal	
epithelial	cells	(Endres	et	al.,	2006).		
	
The	transport	of	drugs	across	the	epithelium	of	the	intestine	can	occur	in	one	of	four	
ways,	 two	 passive	 and	 two	 active:	 passive	 transcellular/paracellular	 routes	 and	
active	 carrier	 mediated/transcytosis	 (see	 figure	 6.1).	 However,	 there	 are	 other	
factors	 that	 need	 to	 be	 considered	 that	 influence	 the	 transport	 of	 drugs	 through	
epithelial	 membranes;	 P-glycoprotein	 has	 been	 related	 to	 the	 occurrence	 of	
multidrug	resistance	in	a	variety	of	CNS	diseases	and	cancer	(Hoosain	et	al.,	2015).	It	
is	thought	to	be	a	contributing	factor	to	drug	resistance	in	cancer	by	expelling	drugs	
in	 the	 opposite	 direction	 to	 which	 they	 are	 absorbed	 (Augustijns	 et	 al.,	 1993).	
Polarised	Caco-2	monolayers	are	known	to	apically	express	P-glycoprotein	(Anderle	
et	al.,	1998;	Pang,	2003)	and	are	useful	 for	 investigating	this	phenomenon.	Studies	
have	 found	 that	conjugation	of	chemotherapeutic	agents	 to	peptides	 for	 receptor-
mediated	delivery	 can	overcome	drug	 resistance	 induced	 in	 this	manner	 (Ai	et	al.,	
2013).	
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Figure	 6.1:	 Adapted	 from	Artursson	 et	 al.,	 (2012).	 Documents	 the	 four	 routes	 of	 drug	 transport	 in	
intestinal	epithelial	monolayers	
	
	
The	 active	 transcytosis	 route	 of	 transport	 from	 the	 apical	 to	 basal	 side	 of	 the	
monolayer	has	proven	to	be	the	least	attractive	route	of	transport	in	terms	of	drug	
delivery,	due	to	its	small	capacity.	However,	more	potent	drugs,	such	as	high	affinity	
peptides,	are	transported	much	more	efficiently	through	their	respective	receptors.	
Transport	 via	 receptor-mediated	 internalisation	 can	 occur	 in	 proteolytic	 enzyme-
containing	vesicles,	as	a	result,	exogenous	proteins	can	be	degraded	during	transport	
(Heyman	et	al.,	1982).		
	
One	of	the	principal	limiting	factors	of	the	design	and	development	of	peptide-based	
therapies	 is	poor	transport	of	the	drug	across	the	intestinal	mucosa.	Shimizu	et	al.,	
(1997)	 suggested	 that	 the	 transcytosis	 of	 peptides	 into	 Caco-2	 monolayers	 is	
dependent	on	the	hydrophobic	properties	of	the	peptide	itself	and	susceptibility	to	
brush-border	 and	 intracellular	 peptidases.	 Furthermore,	 differences	 in	 transport	
activity,	 permeability	 and	 TEER	 readings	 of	 Caco-2	 monolayers	 have	 been	
documented	and	are	thought	to	be	due	to	heterogeneity	between	Caco-2	cell	 lines	
in	different	 laboratories.	 It	has	been	suggested	that	variability	between	Caco-2	cell	
lines	 is	 induced	 as	 a	 result	 of	 differing	 culture	 conditions,	 yielding	 varying	
compositions	of	sub-populations	(Walter	and	Kissel,	1995).	
	
Passive	
Transcellular	
Passive	
Paracellular	
Active	Carrier-
Mediated	
Active	
Transcytosis	 Apical	Side	
Basal	Side	
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6.2:	Results	
6.2.1:	Quantification	of	Uptake	of	Fluorophore-Conjugated	NT	in	Polarised	Caco-2	
Monolayers	
The	figures	in	this	section	(figures	6.2-6.9)	describe	internalisation	of	GFP-NT	and	F-
NT	 into	 polarised	 Caco-2	 monolayers	 at	 30-minute	 intervals	 for	 a	 total	 of	 150	
minutes.	Sample	solutions	were	made	using	serum-free	media	as	a	diluent.	Refer	to	
section	 2.2.30	 for	 detail	 of	 the	 methods	 used	 in	 this	 section.	 Briefly,	 samples	 of	
fluorophore	 at	 known	 concentrations	 (which	 are	 specified	 in	 each	 figure)	 were	
applied	 to	 the	 apical	 surface	 of	 each	 Caco-2	 monolayer	 and	 incubated	 for	 a	 set	
period	of	time	(30,	60,	90,	120	or	150	minutes).	After	incubation,	the	monolayer	was	
thoroughly	washed	with	cold	PBS	and	lysed	with	lysis	buffer	(composition	of	the	lysis	
buffer	 is	 stated	 in	 section	 2.2.30).	 Cellular	 debris	 was	 then	 removed	 and	 the	
remaining	 solution	 was	 analysed	 for	 fluorescence	 intensity.	 The	 intensity	 reading	
was	 then	 converted	 into	 intracellular	molar	 concentration	using	 the	 same	method	
stated	 in	 section	 5.2.1.	 TEER	measurements	 were	 also	 taken	 prior	 to	 use	 of	 each	
Caco-2	monolayer	to	ensure	monolayer	integrity.	Figure	6.2	shows	internalisation	of	
NT-GFP	 vs	 GFP	 over	 time	 in	 a	 polarised	 Caco-2	 monolayer	 to	 assess	 whether	
conjugation	 to	 NT	 affects	 uptake	 of	 the	 fluorophore.	 This	 experiment	 was	 also	
conducted	to	assess	how	internal	amounts	of	fluorophore	differs	over	time.	
	
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 6.2:	 Quantified	 uptake	 of	 GFP-NT	 in	 Polarised	 Caco-2	monolayers	 over	 time.	 Error	 bars	 are	
representative	of	±	SD.	Data	points	are	representative	of	the	mean	of	n=3.	The	y-axis	represents	the	
intracellular	 concentration	 of	 each	 fluorophore	 (GFP-NT	 or	 GFP)	 after	 incubation	 with	 100	 nM	
solutions	on	the	apical	side	of	the	monolayer.	Fluorescence	was	detected	as	stated	in	section	2.2.30	
and	converted	into	a	molar	concentration	as	stated	in	section	5.2.1.	
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Figure	 6.3:	 3D	 confocal	 microscope	 image	 of	 internalised	 GFP-NT	 in	 a	 section	 of	 polarised	 Caco-2	
monolayer	after	3	hours	of	incubation	with	100	nM	GFP-NT.	The	white	bar	is	representative	of	50	μm.	
	
Figure	 6.3	 shows	 the	 presence	 of	 intracellular	 GFP-NT	 in	 a	 section	 of	 Caco-2	
monolayer	 following	 incubation	 with	 a	 100	 nM	 solution	 of	 GFP-NT	 in	 HBSS.	 This	
image	was	constructed	using	 the	z-stack	 function	of	 the	Leica	confocal	microscope	
described	in	section	2.2.26,	from	25	individual	images	at	set	increments	between	the	
apical	 and	 basal	 side	 of	 the	 monolayer.	 Figures	 6.7	 and	 6.9	 in	 this	 section	 were	
constructed	 in	 that	 same	manner.	 GFP-NT	 does	 not	 appear	 to	 concentrate	 in	 any	
one	area	of	the	cell,	but	is	scattered	throughout.	Figure	6.4	shows	internalisation	of	
F-NT	 vs	 F	 alone	 into	 a	 polarised	 Caco-2	 monolayer	 over	 time	 –	 comparing	 this	
experiment	 to	 internalisation	 of	 GFP-NT	 (see	 figure	 6.2)	 in	 the	 same	 conditions	
allows	for	comparison	of	how	fluorophore	size	affects	internalisation.	
	
	
	
	
	
	
	
	
	
	
Figure	 6.4:	 Quantified	 uptake	 of	 F-NT	 in	 Polarised	 Caco-2	 monolayers	 over	 time.	 Error	 bars	 are	
representative	of	±	SD.	Data	points	are	representative	of	the	mean	of	n=3.	The	y-axis	represents	the	
intracellular	concentration	of	each	fluorophore	(F-NT	or	F)	after	incubation	with	100	nM	solutions	on	
the	apical	side	of	the	monolayer.	Fluorescence	was	detected	as	stated	in	section	2.2.30	and	converted	
into	a	molar	concentration	as	stated	in	section	5.2.1.	
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Figure	6.5:	Confocal	microscope	image	of	internalised	F-NT	in	a	section	of	polarised	Caco-2	monolayer	
after	 3	 hours	 of	 incubation	 with	 100	 nM	 F-NT.	 The	 white	 arrow	 indicates	 areas	 when	 F-NT	 has	
collected	around	the	cell	membrane	instead	of	internally.	The	white	bar	is	representative	of	50	μm.	
	
Figure	6.5	above	shows	a	2D	image	of	a	polarised	Caco-2	monolayer	after	incubation	
with	100	nm	F-NT	for	three	hours.	The	image	shows	F-NT	to	be	scattered	throughout	
the	 cytoplasm	 with	 no	 obvious	 areas	 of	 concentration	 of	 the	 fluorophore.	 Some	
areas	 (indicated	 by	 a	 white	 arrow)	 appear	 to	 have	 low	 levels	 of	 the	 fluorophore	
within	the	cytoplasm,	but	collections	of	it	around	the	membrane	itself.	This	could	be	
an	 indication	 of	 paracellular	 transport	 of	 F-NT.	 A	 2D	 image	 was	 selected	 for	 this	
figure	as	it	best	displays	collections	of	F-NT	around	the	outside	of	the	cell.	Figure	6.6	
shows	 internalisation	 of	 NT-GFP	 in	 uninhibited	 and	 inhibited	 conditions.	 This	
experiment	was	 conducted	 to	 ascertain	whether	 inhibition	of	NT	 receptors	 (all	NT	
receptors	in	this	case)	would	also	inhibit	uptake	of	the	NT-bound	fluorophore.		
Figure	 6.6:	 Quantified	 uptake	 of	 GFP-NT	 vs	 GFP-NT	 inhibited	 by	 100x	 free	 NT	 in	 Polarised	 Caco-2	
monolayers	over	 time.	 Error	bars	 are	 representative	of	 ±	 SD.	Data	points	 are	 representative	of	 the	
mean	of	 n=3.	 The	 y-axis	 represents	 the	 intracellular	 concentration	of	GFP-NT	 after	 incubation	with	
100	nM	solutions	of	either	GFP-NT	or	GFP-NT	with	100x	free	NT	on	the	apical	side	of	the	monolayer.	
Fluorescence	was	detected	as	 stated	 in	section	2.2.30	and	converted	 into	a	molar	concentration	as	
stated	in	section	5.2.1.	
0 30 60 90 120 150
0.00
0.05
0.10
Time (Mins)
C
on
ce
nt
ra
tio
n 
(nM
)
GFP-NT vs Inhibited GFP-NT internalisation in Polarised Caco-2
GFP-NT
GFP-NT + Free NT
Chapter	6	 Internalisation	and	Transport	of	NT-Conjugated	
	 		Fluorophores	in	Polarised	Caco-2	Monolayers	 	 	
	
90	
Figure	 6.7	 shows	 an	 image	 obtained	 by	 confocal	 microscopy	 of	 a	 polarised	
monolayer	of	differentiated	Caco-2	cells	following	incubation	with	GFP-NT	whilst	 in	
the	presence	of	excess	NT	receptor	inhibitor	(100x	free	NT).	This	image	was	taken	to	
display	GFP-NT	 localisation/relative	amount	of	GFP-NT	present	within	 the	cell.	This	
experiment	was	conducted	to	determine	whether	uptake	was	reduced	compared	to	
figure	6.3	(uninhibited	conditions)	due	to	inhibition	of	neurotensin	receptors.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 6.7:	 3D	 confocal	 microscope	 image	 of	 internalised	 GFP-NT	 in	 a	 section	 of	 polarised	 Caco-2	
monolayer	when	incubated	with	a	solution	of	100	nM	GFP-NT	and	100x	excess	free	NT	(10	μM)	for	3	
hours.	The	white	bar	is	representative	of	50	μm.	
	
Figure	 6.8	 shows	 F-NT	 uptake	 in	 uninhibited	 and	 inhibited	 (excess	 free	 NT)	
conditions.	This	experiment	was	conducted	to	determine	whether	inhibition	of	N	T	
receptors	would	also	inhibit	uptake	of	the	NT-bound	fluorophore.	
Figure	 6.8:	 Quantified	 uptake	 of	 F-NT	 vs	 F-NT	 inhibited	 by	 100x	 free	 NT	 in	 Polarised	 Caco-2	
monolayers	over	 time.	 Error	bars	 are	 representative	of	 ±	 SD.	Data	points	 are	 representative	of	 the	
mean	of	n=3.	The	y-axis	represents	the	intracellular	concentration	of	F-NT	after	incubation	with	a	100	
nM	solution	of	F-NT	or	100	nM	solution	of	F-NT	with	100x	free	NT	on	the	apical	side	of	the	monolayer.	
Fluorescence	was	detected	as	 stated	 in	section	2.2.30	and	converted	 into	a	molar	concentration	as	
stated	in	section	5.2.1.	
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Figure	 6.9	 shows	 an	 image	 obtained	 by	 confocal	 microscopy	 of	 a	 polarised	
monolayer	of	differentiated	Caco-2	cells	following	incubation	with	F-NT	whilst	in	the	
presence	 of	 excess	 NT	 receptor	 inhibitor	 (100x	 free	NT).	 This	 image	was	 taken	 to	
display	 F-NT	 localisation/relative	 amount	 of	 F-NT	 present	 within	 the	 cell.	 This	
experiment	was	conducted	to	determine	whether	uptake	was	reduced	compared	to	
figure	 6.5	 (uninhibited	 conditions)	 due	 to	 inhibition	 of	 neurotensin	 receptors.	
Imaging	 of	 F-NT	 uptake	 in	 inhibited	 and	 uninhibited	 comditions	 also	 allows	 for	
comparison	of	GFP-NT	under	the	same	conditions	to	see	 if	 fluorophore	size	affects	
localisation	of	uptaken	fluorophore	(see	figures	6.3	and	6.7).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 6.9:	 3D	 confocal	 microscope	 image	 of	 internalised	 GFP-NT	 in	 a	 section	 of	 polarised	 Caco-2	
monolayer	when	 incubated	with	a	 solution	of	100	nM	F-NT	and	100x	excess	 free	NT	 (10	μM)	 for	3	
hours.	The	white	bar	is	representative	of	50	μm.	
	
6.2.2:	Quantification	of	Transport	of	Fluorophore-Conjugated	NT	Across	Polarised	
Caco-2	Monolayers	
	The	figures	in	this	section	(figures	6.10-6.14)	describe	transport	of	GFP-NT	and	F-NT	
across	polarised	Caco-2	monolayers	(apical	à	basal	side)	at	30-minute	intervals	for	a	
total	 of	 180	 minutes.	 Sample	 solutions	 were	 made	 using	 serum-free	 media	 as	 a	
diluent.	Refer	to	section	2.2.29	for	detail	of	the	methods	used	in	this	section.	Briefly,	
samples	 of	 NT-fluorophore	 at	 known	 concentrations	 (which	 are	 specified	 in	 each	
figure)	were	applied	to	the	apical	surface	of	each	Caco-2	monolayer	and	incubated	
for	180	minutes.	100	μl	samples	were	taken	from	the	media	on	the	basal	side	of	the	
monolayer	every	30	minutes	for	each	well/monolayer	and	the	fluorescence	intensity	
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of	 the	 sample	 was	 read	 as	 described	 in	 section	 2.2.29.	 This	 reading	 was	 then	
converted	 into	 a	 molar	 concentration	 using	 a	 calibration	 curve	 constructed	 from	
known	dilutions	of	each	 fluorophore	 in	HBSS.	Samples	were	taken	at	 time	0	 for	all	
data	sets	in	this	chapter	to	ensure	the	integrity	of	the	cell	monolayer	and	ensure	that	
any	 transport	 was	mediated	 by	 the	 cells	 themselves	 and	 not	 through	 gaps	 in	 the	
monolayer.	 TEER	 measurements	 were	 also	 taken	 prior	 to	 use	 of	 each	 Caco-2	
monolayer	to	ensure	monolayer	integrity.	Figures	6.10	and	6.11	shows	transport	of	
GFP-NT	 at	 differing	 concentrations	 to	 assess	 whether	 transport	 is	 concentration	
dependent.	GFP	alone	was	used	as	a	control.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 6.10:	 Comparison	of	 transport	 of	GFP-NT	 across	 polarised	Caco-2	monolayers	 read	 every	 30	
minutes	after	application	of	either	20	nM	or	50	nM	GFP-NT	solutions	to	the	apical	side	of	monolayer.	
The	data	points	are	representative	of	the	concentration	of	GFP-NT	in	the	1.5	ml	volume	of	media	on	
the	basal	 side	of	 the	monolayer.	50	nM	GFP	alone	was	used	as	a	negative	control.	Data	points	are	
representative	of	the	mean	of	n	=	3	and	error	bars	are	representative	of	±	SD.	
	
	
	
	
	
	
	
	
	
	
Figure	 6.11:	 Comparison	of	 transport	 of	GFP-NT	 across	 polarised	Caco-2	monolayers	 read	 every	 30	
minutes	after	application	of	either	100	nM,	500	nM	or	1	μM	GFP-NT	solutions	 to	 the	apical	 side	of	
monolayer.	The	data	points	are	representative	of	the	concentration	of	GFP-NT	in	the	1.5	ml	volume	of	
media	 on	 the	 basal	 side	 of	 the	monolayer.	 1	 μM	GFP	 alone	was	 used	 as	 a	 negative	 control.	 Data	
points	are	representative	of	the	mean	of	n	=	3	and	error	bars	are	representative	of	±	SD.	
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Figure	 6.12	 shows	 transport	 of	 F-NT	 at	 differing	 concentrations,	with	 F	 alone	 as	 a	
control.	 This	 was	 done	 to	 assess	 whether	 transport	 of	 F-NT	 through	 a	 model	
epithelial	 monolayer	 is	 concentration	 dependent	 and	 compare	 transport	 to	 the	
fluorophore	alone.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	6.12:	Comparison	of	transport	of	F-NT	across	polarised	Caco-2	monolayers	read	every	30	
minutes	after	application	of	either	20	nM,	50	nM	or	100	nM	F-NT	solutions	to	the	apical	side	of	
monolayer.	The	data	points	are	representative	of	the	concentration	of	F-NT	in	the	1.5	ml	volume	of	
media	on	the	basal	side	of	the	monolayer.	100	nM	F	alone	was	used	as	a	negative	control.	Data	points	
are	representative	of	the	mean	of	n	=	3	and	error	bars	are	representative	of	±	SD.	
	
Figure	6.13	shows	transport	of	GFP-NT	under	uninhibited	and	inhibited	(100x	excess	
free	NT)	conditions	to	determine	whether	transport	can	be	inhibited	through	
inhibition	of	neurotensin	receptors.	GFP	alone	was	used	as	a	control.	
	
	
	
	
	
	
	
	
	
Figure	 6.13:	 Comparison	of	 transport	 of	GFP-NT	 across	 polarised	Caco-2	monolayers	 read	 every	 30	
minutes	after	application	of	either	100	nM	GFP-NT	or	100	nM	GFP-NT	+	100x	excess	free	NT	solution	
to	the	apical	side	of	monolayer.	The	data	points	are	representative	of	the	concentration	of	GFP-NT	in	
the	1.5	ml	 volume	of	media	on	 the	basal	 side	of	 the	monolayer.	 100	nM	GFP	alone	was	used	as	 a	
negative	 control.	 Data	 points	 are	 representative	 of	 the	 mean	 of	 n	 =	 3	 and	 error	 bars	 are	
representative	of	±	SD.	
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Figure	6.14	shows	transport	of	F-NT	in	inhibited	(100x	excess	free	NT)	and	
uninhibited	conditions	with	F-NT	at	differing	concentrations.	This	experiment	was	
conducted	to	evaluate	whether	transport	of	F-NT	can	be	inhibited	by	inhibiting	NT	
receptors	and	whether	this	effect	can	be	overcome	by	increasing	the	concentration	
of	F-NT	(keeping	the	ratio	of	F-NT	to	inhibitor	the	same).	
Figure	6.14:	Comparison	of	transport	of	F-NT	across	polarised	Caco-2	monolayers	read	every	30	
minutes	after	application	of	solutions	of	F-NT	+	100x	free	NT	(20	nM,	50	nM	and	100	nM)	to	the	apical	
side	of	monolayer.	The	data	points	are	representative	of	the	concentration	of	F-NT	in	the	1.5	ml	
volume	of	media	on	the	basal	side	of	the	monolayer.	100	nM	F-NT	alone	was	used	as	a	positive	
control.	Data	points	are	representative	of	the	mean	of	n	=	3	and	error	bars	are	representative	of	±	SD.	
	
Figures	 6.10	 and	 6.11	 show	 GFP-NT	 to	 be	 transported	 in	 a	 receptor-mediated	
manner	 due	 to	 observably	 greater	 transport	 than	 GFP	 alone,	 representing	 non-
specific	 transport.	 Furthermore,	 increasing	 levels	 of	 transport	 can	 be	 seen	 in	
proportion	with	concentration	of	GFP-NT	solutions	applied	to	the	apical	side	of	the	
monolayer.	 For	example,	 the	 transport	observed	with	1	μM	GFP-NT	solutions	with	
greater	than	that	observed	with	100	nM	GFP-NT	solutions.	The	same	trend	 is	seen	
with	 internalisation	 of	 F-NT,	 however	 a	 greater	 amount	 of	 F-NT	 appears	 to	 be	
transported	compared	to	the	corresponding	concentrations	of	GFP-NT.		
	
GFP-NT	 and	 F-NT	 transport	 is	 further	 confirmed	 as	 receptor-mediated	 by	 the	
apparent	inhibition	of	transport	caused	by	addition	of	100x	free	NT	in	each	sample	
concentration.	 This	 is	 observable	 in	 both	 GFP-NT	 and	 F-NT	 samples	 detailed	 in	
figures	 6.13	 and	 6.14	 respectively.	 In	 these	 inhibitory	 assays,	 transport	 of	 GFP-NT	
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and	 F-NT	 is	 comparable	 to	 (if	 not	 less)	 the	 amount	 of	 non-specific	 transport	
demonstrated	by	each	unconjugated	fluorophore.	
	
6.3:	Discussion	
The	main	aim	of	this	chapter	is	to	evaluate	the	potential	for	NT	conjugation	to	bio-
therapeutics	 (comparable	 in	 size	 to	 that	 of	 GFP)	 to	 allow	 for	 receptor-targeted	
internalisation	 and	 transport	 of	 the	 bio-therapeutic	 itself.	 The	 ability	 for	 bio-
theraputics	to	be	targeted	to	NT-R	overexpressing	cancerous	cells	would	reduce	the	
need	 for	 quantities	 of	 bio-therapeutics	 that	 elicit	 unnecessary	 toxicities	 for	 non-
cancerous	 cells,	 as	 neurotensin	 has	 a	 very	 high	 affinity	 for	 its	 receptor	 (~0.3	 nM	
affinity	 for	 NTS1).	 As	 previously	 mentioned,	 Caco-2	 cells	 closely	 resemble	 the	
morphological	 characteristics	 of	 mature	 enterocytes	 once	 differentiated	 and	 thus	
present	an	in	vitro	model	closer	to	in	vivo	conditions	that	conventional	tissue	culture	
of	Caco-2	cells	allows	for.	This	model	serves	as	an	effective	tool	to	mimic	the	uptake	
and	transport	of	NT-conjugated	fluorophores	in	mature	enterocytes.	Polarised	Caco-
2	 cells	 have	 been	 previously	 characterised	 to	 almost	 homogenously	 express	 high	
levels	of	NTS1	(see	chapter	3).	
	
Referring	to	figures	6.6	and	6.8,	inhibition	of	internalisation	of	NT	with	an	excess	of	
NT	suggests	that	uptake	of	NT	in	polarised	Caco-2	monolayers	is	receptor	mediated.	
Uptake	 of	 GFP-NT	 (figures	 6.2	 and	 6.6)	 and	 F-NT	 (figures	 6.4	 and	 6.8)	 appears	 to	
plateau,	 starting	 at	 around	 minute	 60.	 The	 plateau	 of	 GFP-NT	 uptake	 remains	
constant,	whereas	F-NT	levels	begin	to	decrease	towards	the	end	of	the	150-minute	
incubation.	As	large	cargo	size	is	known	to	have	a	negative	influence	on	the	rate	of	
transport	 through	 caco-2	 monolayers	 and	 the	 hydrophilic	 nature	 of	 the	 molecule	
determines	 that	 it	 cannot	 diffuse	 through	 the	 cell	 membrane.	 As	 previously	
discussed	in	chapter	5,	it	is	unclear	with	the	data	obtained	in	this	study	whether	NT	
is	 degraded	once	 it	 internalises	 into	 the	 cells.	 Therefore,	 it	 is	 unclear	whether	 the	
fluorophore	detected	within	the	cell	has	followed	the	same	trafficking	pattern	that	
would	 be	 elicited	 with	 NT	 alone.	 For	 future	 work,	 it	 is	 advised	 that	 stable	
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neurotensin	 analogues	 be	 used	 to	 repeat	 these	 findings	 and	 the	 trafficking	
mechanisms	of	NT	in	polarised	Caco-2	be	elucidated.		
	
Figures	 6.3,	 6.5,	 6.7	 and	 6.9	 can	 be	 used	 to	 speculate	 the	 locality	 of	 NT-bound	
fluorophores	 following	 internalisation.	 It	 should	 be	 noted	 that	 these	 images	were	
taken	three	hours	after	 initial	exposure	to	100	nM	solutions	of	both	NT-conjugates	
(as	 they	 were	 taken	 following	 on	 from	 transport	 studies)	 and	 so	 are	 not	 directly	
comparable	to	the	images	included	in	chapter	5.	Figure	6.3	displays	the	position	of	
GFP-NT	 after	 incubation	 and	 does	 not	 appear	 to	 be	 as	 localised	 to	 the	 nucleus	 as	
seen	 in	 figure	 5.6.	 This	 may	 be	 due	 to	 polarised	 Caco-2	 cells	 having	 a	 greater	
proteolytic	activity	than	HEK293	cells,	resulting	in	a	greater	amount	of	free	GFP	able	
to	readily	diffuse	throughout	the	cell	cytoplasm.	However,	the	monolayer	imaged	in	
figure	5.6	was	subjected	to	a	much	lower	concentration	of	GFP-NT	than	that	seen	in	
figure	 6.3,	 perhaps	 leading	 to	 increased	 uptake	 and	 increased	 scattering	 of	 the	
fluorophore.		
	
Since	 the	 discovery	 of	 neurotensin	 in	 1973,	 many	 studies	 that	 document	 cellular	
responses	to	the	neuropeptide	report	rapid	desensitisation	following	exposure.	This	
is	 characterised	 by	 a	 decrease	 in	 responsiveness	 to	 the	 peptide	 following	 long	
periods	of	exposure	or	lack	of	response	to	repeated	exposure	(Carraway	and	Leeman,	
1973;	 Hermans	 and	 Maloteaux,	 1998).	 In	 studies	 concerning	 the	 effects	 of	
neurotensin	 on	 the	 gastrointestinal	 system	 of	 rats,	 exposure	 to	 concentrations	 of	
neurotensin	 as	 low	 as	 5	 nM	 for	 prolonged	 periods	 of	 time	 induced	 a	 decrease	 in	
maximum	response	 (compared	to	at	 time	=	0	mins)	and	shifted	 the	dose-response	
curve	 to	 the	 right.	 However,	 thorough	 washing	 of	 neurotensin	 from	 the	 tissue	
allowed	 for	 time-dependant	 recovery	 (Mulè	et	 al.,	 1995).	 It	 is	 clear	 form	 the	 data	
presented	in	this	chapter	that	the	internalisation	and	transport	of	both	GFP-NT	and	
F-NT	reaches	a	plateau	after	around	60	minutes	(figures	6.2,	6.4,	6.6,	6.8-14)	and	in	
some	cases	begins	 to	decrease	 toward	 the	end	of	 the	 three-hour	exposure	 (figure	
6.10).	This	could	be	attributable	to	desensitisation	of	neurotensin	receptors.	
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The	 regulation	 of	 neurotransmitter	 desensitisation	 is	 thought	 to	 be	 entirely	
dependent	on	the	 individual	receptor	and	a	common	property	of	neurotransmitter	
receptors	 (Huganir	 and	 Greengardt,	 1990).	 The	 influence	 of	 receptor	
phosphorylation	on	desensitisation	has	been	investigated	into	using	the	β-adrenergic	
receptor;	concluding	that	it	is	possible	for	receptor	activated	kinases,	such	as	protein	
kinase	 A	 and	 C,	 to	 control	 desensitisation	 through	 receptor	 inactivation	 and	
uncoupling	 from	 intracellular	 second	 messengers	 (Premont	 et	 al.,	 1995).	
Desensitisation	of	the	neurotensin	receptor	may	be	regulated	in	the	same	manner.	
Turner	 et	 al.,	 (1990)	 used	 the	 HT-29	 human	 colonic	 adenocarcinoma	 cell	 line	 to	
question	 whether	 desensitisation	 of	 neurotensin	 receptors	 is	 mediated	 from	 this	
early	 uncoupling	 of	 receptor	 from	 second	 messenger,	 or	 from	 later	 phases	 of	
internalisation.	The	study	highlighted	that	protein	kinases	were	not	responsible	for	
the	regulation	of	receptors	induced	by	exposure	to	neurotensin	like	it	does	in	other	
receptor	systems.		
	
It	 has	 been	 proposed	 recently	 that	 the	 structure	 and	 composition	 of	 neurotensin	
itself	plays	a	part	in	regulation	of	its	corresponding	cell	surface	receptors.	Lee	et	al.,	
(2015)	documented	 the	 comparison	of	 contulakin-G	 (a	marine	glycopeptide	with	a	
similar	C-terminal	structure	to	NT,	and	therefore	with	an	ability	to	act	as	an	agonist	
to	 neurotensin	 receptors)	 to	 NT	 in	 their	 ability	 to	 desensitise	 receptors.	 The	 two	
molecules	 differ	 in	 the	 presence	 of	 the	 conserved	 Lys6	 residue	 in	 NT	 and	 an	
extended	 N-terminus	 in	 contulakin-G.	 Due	 to	 these	 structural	 differences,	
contulakin-G	 is	known	to	have	a	much	 lower	affinity	to	neurotensin	receptors	and,	
interestingly,	 not	 exert	 as	 greater	 a	 desensitising	 effect	 on	 cell	 surface	 receptors	
(Craig	 et	 al.,	 1999).	 The	 study	 by	 Lee	 et	 al.,	 (2015)	 employed	 structure	 related	
desensitisation	 assays	 with	 several	 NT	 analogues	 to	 ascertain	 the	 structural	
component	contributing	to	increased	desensitisation	–	they	concluded	that	removal	
of	the	negatively	charged	residue	at	position	4	did	not	affect	affinity	of	NT	to	NT-R,	
but	did	reduce	desensitisation	potency	five-fold.	
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Figures	 6.11	 and	 6.12	 show	 the	 comparison	 of	 maximum	 transport	 of	 each	 NT-
conjugate.	 Using	 100	 nM	 samples	 for	 comparison,	 GFP-NT	 transport	 plateaus	 at	
around	0.4	nM,	as	opposed	to	1.5	nM	for	F-NT.	This	may	be	due	to	the	small	size	of	
fluorescein	 allowing	 for	 a	 greater	 extent	 of	 transport.	 Inhibition	 of	 transport	 by	
excess	NT	(as	can	be	seen	in	figures	6.13	and	6.14)	suggests	that	receptor	mediated-
transport	 rather	 than	diffusion	 is	predominantly	 responsible	 for	F-NT	 translocation	
across	 the	 monolayers.	 Another	 factor	 responsible	 for	 this	 discrepancy	 between	
GFP-NT	 and	 F-NT	 transport	 is	 the	 macromolecular	 nature	 of	 GFP	 attenuating	 the	
efficiency	of	NT	receptor	mediated	 transport.	 	The	extent	of	 transport	of	each	NT-
conjugated	 fluorophore	 also	 appears	 to	 be	 concentration-dependant.	 Figure	 6.11	
displays	 transport	 of	 GFP-NT	 at	 concentrations	 of	 100	 nM,	 500	 nM	 and	 1	 μM,	
showing	 a	 correlation	 between	 the	 concentrations	 of	 fluorophore	 applied	 to	 the	
monolayer	 and	 the	maximum	 rate	 of	 transport	 of	GFP-NT	 taking	 place	 between	 0	
and	30	minutes.	As	the	majority	of	transport	is	documented	to	occur	within	the	first	
30	minutes	of	incubation,	further	work	to	elucidate	the	dynamics	of	transport	within	
this	time	range	is	recommended.	
	
Although	uptake	of	GFP-NT	and	F-NT	(100	nM	each)	is	relatively	similar	at	~0.1	nM	
(see	Figures	6.4	and	6.2),	transport	varies.	It	is	not	possible	to	compare	the	figure	for	
cellular	 uptake	 against	 the	 number	 of	 cells	 per	 Transwell®	 well	 as	 this	 was	 not	
characterised	after	21	days	of	growth,	but	the	data	sets	are	comparable	against	one	
another	as	each	well	was	cultured	and	seeded	identically.	Transport	of	GFP-NT	after	
incubation	with	a	concentration	of	100	nM	plateaus	at	around	0.2	nM	(this	value	is	
variable	in	proportion	with	the	incubation	concentration).	F-NT	however,	reaches	a	
transport	maximum	of	around	1.25	nM	at	a	concentration	of	100	nM	(this	value	 is	
also	variable	with	incubation	concentration).	Again,	this	could	be	due	to	an	increased	
transport	efficiency	with	the	smaller	fluorophore.		
	
6.4:	Conclusion	
Both	GFP-NT	and	F-NT	have	shown	to	be	internalised	and	transported	in	a	receptor-
mediated	fashion	in	polarised	Caco-2	monolayers.	A	relationship	between	the	nature	
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of	the	cargo	conjugated	to	NT,	in	this	case	fluorescein	versus	GFP,	is	also	apparent,	
influencing	the	efficiency	of	transport,	with	the	amount	F-NT	transported	being	over	
3x	greater	 than	that	of	GFP-NT	over	3	hours.	As	described	 in	chapter	5,	only	NTS1	
expression	 was	 characterised	 in	 this	 cell	 line	 so	 it	 is	 unclear	 which	 receptor	 is	
responsible	 for	 any	 transport	 or	 uptake	 observed.	 Further	 work	 is	 needed	 to	
elucidate	 whether	 NT	 is	 degraded	 within	 the	 cell	 following	 internalisation.	 As	 a	
response	 is	 observed	 in	 concentrations	 as	 low	 as	 20	 nM	 for	 transport	 and	
internalisation,	 neurotensin	 receptor-targeted	 delivery	 has	 been	 shown	 to	 be	 a	
promising	candidate	for	delivery	of	bio-therapeutics	to	NT	receptor	over-expressing	
tumours.
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General	Conclusion	
	
Firstly,	NTS1	expression	was	 characterised	by	 immunostaining	 in	 two	 separate	 cell	
lines	–	Caco-2	and	HEK293.	Concluding	a	 lack	of	expression	on	unpolarised	Caco-2,	
but	 moderate	 expression	 on	 wild	 type	 HEK293.	 In	 an	 attempt	 to	 mimic	 NTS1	
expression	 in	 NTS1	 over-expressing	 tumour	 cells,	 HEK293	 were	 transfected	 with	
NTS1.	 This	 procedure	 was	 optimised	 and	 found	 to	 induce	 a	 much	 higher	 level	 of	
expression	of	NTS1	than	that	seen	on	wild	type	HEK293.	Caco-2	cells	can	be	grown	
on	 polycarbonate	 membranes	 for	 an	 extended	 period	 of	 time	 after	 confluency	 is	
reached	 (21	 days),	 which	 causes	 them	 to	 differentiate	 into	 'polarised'	 Caco-2	
monolayers	 and	 acquire	 a	 similar	 structure	 to	 that	 of	 mature	 enterocytes.	
Characterisation	 of	 polarised	 Caco-2	 showed	 NTS1	 expression	 to	 be	 highly	 up	
regulated	and	membrane-localised	compared	to	that	of	wild-type	Caco-2.	
	
In	 chapter	 4,	 the	 optimised	 production	 of	 GFP-NT	 and	 GFP	 alone	 by	 recombinant	
protein	expression	is	also	documented	in	this	study.	Quikchange	mutagenesis	of	the	
original	 his-tagged	 GFP-NT	 (His-GFP-NT)	 containing	 plasmid	 was	 shown	 to	
successfully	 introduce	 an	 stop	 codon	 (TAA)	 before	 the	 sequence	 for	NT,	making	 a	
plasmid	that	recombinantly	expresses	GFP	alone.	Expression	of	each	plasmid	in	BL21	
E.coli	was	optimised	and	the	purification	of	the	respective	proteins	was	shown	to	be	
successful	with	UV-Vis	spectrophotometry	and	SDS-PAGE.	
	
In	 chapters	 5	 and	 6,	 the	 production,	 internalisation	 and	 transport	 of	 GFP-NT	 is	
documented	and	discussed,	and	compared	against	 the	elicited	 internalisation	of	F-
NT	,	a	smaller	fluorophore.	Both	GFP-NT	and	F-NT	were	shown	to	be	internalised	in	a	
receptor-mediated	 fashion	 in	 undifferentiated	 Caco-2	 and	 HEK293.	 Chapter	 6	
documented	 the	 interaction	 of	 GFP-NT	 and	 F-NT	 with	 differentiated	 Caco-2	
monolayers,	 showing	 cellular	 uptake	 to	 also	 be	 receptor	 mediated,	 as	 well	 as	
concentration	and	time	dependent.	A	ubiquitous	plateau	in	cellular	uptake	after	~	60	
minutes	 suggests	 desensitisation	 of	 the	 receptor.	 Localisation	 of	 each	 fluorophore	
within	 transfected	HEK293	 cells	 shows	 localisation	 around	 the	 nucleus,	 suggesting	
eventual	 and	 general	 trafficking	 to	 the	 trans-golgi	 network	 within	 the	 cell.
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Future	Work	
	
NTS1	 expression	 was	 characterised	 on	 the	 cell	 lines	 used	 in	 this	 study,	 however,	
characterisation	of	NTS2	and	NTS3	(the	other	membrane-bound	receptors	shown	to	
internalise	 upon	 interaction	 with	 NT)	 expression	 on	 the	 same	 cell	 lines	 was	 not	
performed.	Although	 literature	 suggests	 that	 the	majority	 of	 the	 effects	 of	NT	 are	
exhibited	 through	 interactions	 with	 NTS1,	 as	 this	 study	 documents	 internalisation	
rather	 than	 exhibited	 effects,	 the	 presence	 of	 these	 other	 receptors	 should	 be	
evaluated.	 Furthermore,	 the	 characterisation	 of	 NTS1	 expression	 in	 this	 study	 is	
purely	 qualitative.	 It	 is	 suggested	 that	 evaluation	 of	 expression	 be	 repeated	 in	 a	
quantitative	manner	with	techniques	such	as	 flow	cytometry	or	quantitative	 image	
evaluation	 software.	 Also,	 as	 transfection	 with	 lipofectamine	 yielded	 non-
homogenous	 expression	 of	 NTS1,	 further	 optimisation	 or	 a	 different	 method	 of	
transfection	is	advised	to	eliminate	this.	
	
The	precise	mechanism	of	internalisation	of	NT	is	variable	among	cell	lines	and	tissue	
types,	 as	previously	discussed	 in	 this	document.	 This	 study	visually	documents	 the	
location	 of	 NT-conjugated	 fluorophores,	 but	 does	 not	 elucidate	 the	 step-wise	
dynamics	 of	 NT	 internalisation	 into	 the	 cells.	 It	 is	 suggested	 that	 the	 specific	
mechanism	of	internalisation	in	HEK293	and	Caco-2	be	investigated	with	endosome	
staining	techniques.	Usually,	in	studies	such	as	this	that	document	cellular	uptake	of	
a	 protein	 conjugated	 to	 NT,	 stable	mutants	 analogues	 of	 NT	 are	 used	 to	 prevent	
internal	 degradation	 by	 peptidases.	 An	 analogue	of	NT	was	 not	 used	 in	 this	 study	
and	therefore	the	structural	integrity	of	the	NT	portion	of	GFP-NT	or	F-NT	cannot	be	
confirmed.	 It	 is	 suggested	 that	 this	 study	be	 repeated	with	 the	use	of	 a	 stable	NT	
analogue.		
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